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Abstract. 
 
Merkel cell Polyomavirus (MCPyV) is implicated in the pathogenesis of 
Merkel cell carcinoma (MCC), a rare and highly aggressive neuroendocrine 
skin cancer, through expression of two oncoproteins, small T antigen (sT) 
and large T antigen (LT). MCPyV sT expression is essential for cell 
transformation, however, the mechanisms by which sT may contribute 
towards MCC are poorly understood. Studies from our group identified that 
sT is an antagonist of NF-B signalling (Griffiths et al., 2013).  This thesis 
focuses on dissecting the molecular basis of inhibition.  
Co-immunoprecipitation and co-immunofluorescence studies demonstrate an 
interaction between sT and the critical adaptor protein NF-B essential 
modulator (IKKγ, NEMO) that is necessary for inhibiting NF-B activation. A 
comprehensive mapping exercise identified the regions in each protein 
necessary for mediating this interaction. Mechanistically, we reveal that 
NEMO does not interact with sT directly, rather it forms part of a larger 
protein complex. Using proteomic data, we establish interactions between sT 
and novel protein phosphatase proteins including PP4C. In comprehensive 
studies, we show that a complex of PP4C and the PP4 targeting sub-unit 
PP4R1 are necessary for bridging sT to NEMO in vitro.  In cells, depletion of 
PP4R1 prevents formation of the sT-NEMO complex and point mutations in 
sT that prevent binding to these host proteins reduce the ability of sT to 
impair NF-B driven transcription. Finally, we demonstrate that interactions 
with PP4R1 and NEMO are not shared with sT proteins from other 
polyomaviruses tested, implicating potential unique functions for MCPyV sT 
amongst the Polyomaviridae.  
This study provides convincing evidence for the molecular mechanisms that 
MCPyV sT utilises to evade the innate immune system and may help to 
explain the chronic nature of this virus.  
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DTT 
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Gaussia luciferase 
Ganglioside  
h  
H1 
hour(s) 
histone 1 
HA  haemagglutinin  
HCMV 
HCV 
HDAC3 
human cytomegalovirus  
Hepatitis C Virus 
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Chapter 1. Introduction 
 
1.1 Merkel Ranvier cells  
Merkel Ranvier cells, also known as Merkel cells, are receptor cells first 
identified by Fredrich Sigmund Merkel, a German anatomist and pathologist, 
in 1875 (Merkel, 1875). Although first identified by Merkel in the skin of birds 
and mammals, Merkel cells have since been found to be common to all 
vertebrates (Fox et al., 1980, Tweedle, 1978, Saxod, 1978). In mammals, 
Merkel cells are commonly found in the Stratum basale, in particular, the 
epidermal invaginations of the palmar (Halata et al., 2003) and plantar 
surfaces (Johnson et al., 2000). They are also found co-localised with 
Langerhans cells in the bulge of hair follicles (Taira et al., 2002), as well as 
mucous membranes, such as the oral mucosa (Righi et al., 2006), although 
in varying density and distribution. Merkel cells are commonly located at the 
end of sensory nerves and in such cases these are termed Merkel nerve 
endings (Figure 1.1). Merkel cells are oval in shape and transparent, making 
them difficult to examine by light microscopy, due to their absence of 
tonofilament in the cell cytoplasm. Although this makes them easy to 
differentiate from keratinocytes, they can be difficult to distinguish from 
Langerhans cells, Melanocytes and Lymphocytes (Merot et al., 1987).  
In addition to the common cell organelles such as mitochondria, free 
ribosomes, lysosomes, microfilaments, vacuoles and lobulated nucleus, the 
cytoplasm of Merkel cells also contains membrane bound melanosomes; 
melanin granules; dense core neurosecretery granules; cytokeratin (K); and 
desmosomal proteins (Saurat et al., 1984, Moll et al., 1984).  
Despite being first identified over 100 years ago, the developmental origin of 
Merkel cells is still unclear and a subject of debate. Some consider the 
presence of Merkel cells in the dermis of foetal and newborn mammalian 
skin an indication that Merkel cells originate from the neural crest, whilst 
others  
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believe the source of Merkel cells to be ectoderm at stem cells (Halata et al., 
2003, Halata et al., 1999, Lane and Whitear, 1977).  
Similarly, a consensus is lacking as to the function of Merkel cells. The 
accumulation of neuropeptides observed at the nerve fibre junction in these 
cells may indicate these cells play a role in the expression of voltage gated 
ion channels (essential for synaptic transmission) (Piskorowski et al., 2008). 
Others believe, based on histochemical composition, that Merkel cells belong 
to a group of cells that secrete low molecular weight polypeptide hormones 
called the Amine Precursor Uptake and Decarboxylation (APUD) and have a 
neuroendocrine function (Pearse, 1980, Pearse, 1986). In addition, Merkel 
cells can be found in hair follicles, attached to Langerhan cells and it may be 
they have a distinct function in this location (Taira et al., 2002).  
It is important to note that Merkel cells found independently of neurones in 
the skin and mucosa are believed to have a neuroendocrine, as opposed 
sensory receptor, role. It is these cells that are believed to be the origin of the 
unusual but highly malignant skin cancer Merkel cell carcinoma (Gould et al., 
1985). 
  
1.2 Merkel cell carcinoma  
Merkel cell carcinoma (MCC) is a primary cutaneous neuroendocrine 
carcinoma first identified by Toker in 1972, who conceived the term 
trabecular carcinoma, on account of the solid trabeculae (solid projections 
within the skin) present on the tumours of the patients he diagnosed with the 
disease. MCCs usually appear as solid bumps purplish-reddish in colour and 
usually painless, on the surface of the skin. They are highly metastatic and 
sometimes form ulcers (Toker, 1972). 
The tumours are present on various parts of the patient's bodies such as; 
leg, lip, forearm, buttock and face, and are painless, bluish-red or flesh toned 
in colour (Toker, 1972). In the 1980's the cancer was renamed Merkel cell 
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carcinoma as techniques including immunohistochemisty and electron 
microscopy were utilised and revealed the role of Merkel cells in these 
tumours (Wolf‐Peeters et al., 1980).  
Immunohistochemistry techniques revealed the presence of neuropeptides 
synaptophysin, chromogranin and others as well as the detection of 
cytokeratins 8, 18, 19, 20 and their prenuclear distribution (Pilloni et al., 
2009, Jensen et al., 2000, Leech et al., 2001). Tang and Toker also used 
electron microscopy to study MCC tumour and found they contained dense-
core neuroendocrine granules, were subject to plasma cell infiltration (as 
indicated by the presence of peripheral lymphocytes) and contained 
peritumoural connective tissue (Tang and Toker, 1978).  
Later, immunohistochemical assays were employed in the diagnosis of MCC 
with the presence of cytokeratins, thyroid transcription factor, leukocyte 
common antigen, chromogranin and synaptophysin considered indicative of 
MCC (Sidiropoulos et al., 2011). 
A detailed morphology of MCC tumour cells is available due to advances in 
electron microscopy. Focal trabecular pattern are common in the vast 
majority of MCCs. The cells are enlarged with spike like appendages 
protruding from the membrane thought to be involved in cell-to-cell 
connection. The cytoplasm contains hemidesmosomes with rosette like 
attachments, densosomes, fine cytofilaments and dense granules (Figure 
1.1) (Kontochristopoulos et al., 2000).  
Genetic screening has found genetic abnormalities in most MCC cases with 
abnormalities commonly found on chromosomes 1, 6, 11 and 16. These 
abnormalities may play a role in the aetiology of the cancer although the 
cause of MCC may be complex and several hypotheses have been put 
forward (Van Gele et al., 1998, Frigerio et al., 1983).  
Ultra violet radiation exposure is considered a risk factor in the development 
of MCC as tumours develop more prevalently in areas of the body exposed 
to the sun (50% head and neck area, 40% extremities, <10% trunk and 
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genitals) (Agelli and Clegg, 2003, Tennvall et al., 1989, Chen, 1994, 
Goepfert et al., 1984, Gillenwater et al., 2001, Brissett et al., 2002).  
A significant finding in the aetiology of this cancer came with the identification 
of Merkel Cell Polyomavirus (MCPyV). MCPyV is a small, non-enveloped, 
double stranded DNA virus, which has been found to be present in the 
majority of MCC tumours (Feng et al., 2008). Whilst both infected and non-
infected tumours have high mitotic activity, immunohistochemical techniques 
have identified morphological differences in the MCPyV associated and non 
MCPyV associated MCC tumour cells, with MCPyV infected tumours having 
round nuclei and a scant cytoplasm and non MCPyV infected tumours having 
an irregular shaped nuclei and abundant cytoplasm (Kuwamoto et al., 2011).  
A further breakthrough came when Tolstov and colleagues developed an 
enzyme linked immunosorbent assay (ELISA) for the detection of MCPyV 
VP1 and VP2 proteins in blood samples, allowing for rapid diagnosis of 
MCPyV infection. The success of this ELISA was largely due to the low cross 
reactivity of the anti-VP1 antibody to other similar viruses, avoiding false 
positive results (Tolstov et al., 2009).  
Further research has shown that MCPyV is highly oncogenic and metastatic. 
Aided by its ability to travel through the lymphatic drainage of the body, 
MCPyV can cause MCC to develop at other organ sites. These sites include; 
lymph node, pancreas, breast, duodenum and colon epithelium, and lip and 
palatine tonsil (Mehrany et al., 2002, Bachmann et al., 2005, Cusick and 
Refsum, 2004, Senda et al., 1999, Nagy et al., 2005, Howard et al., 2006).  
 
1.2.1 Epidemiology of MCC 
Epidemiological studies have indicated that more than 74% of MCC cases 
occur in people over 65 and most of them in whites of both men and women 
but men have a significantly higher incidence (Agelli and Clegg, 2003). 
Worryingly the incidence has increased and the prognosis is poor with 4.4 
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cases per million in 15 years rising to 2.2 per million in one year. More than 
50% of infected patients die within one year of diagnosis, in line with 
mortality rates for other skin cancers (Hodgson, 2005, Agelli and Clegg, 
2003, Bichakjian et al., 2007). MCC can manifest as a secondary 
complication in other conditions such as chronic lymphocytic leukaemia, 
malignancies of the biliary tract, multiple myeloma and other malignancies 
(Craig et al., 2009, Howard et al., 2006, Kressin and Kim, 2012).  
MCC is most likely to infect people with a lighter skin tone as well as people 
who have undergone organ transplant or who have human 
immunodeficiency virus (HIV) or acquired immune deficiency syndrome 
(AIDS) infection, the auto-immune diseases or/and lymphoproliferative 
disorder like chronic lymphocytic leukaemia (Lanoy et al., 2010, Engels et 
al., 2002, Dworkin et al., 2009, Tadmor et al., 2011). In the US, the annual 
number of individuals receiving an MCC diagnosis is 950-2300. Due to 
factors such as population ageing, the increasing prevalence of adverse 
effects of sun exposure, and the growing number of immunocompromised 
cases, this figure is on the rise (Albores‐Saavedra et al., 2010, Iyer et al., 
2014). Usually found on the sun-exposed skin of white individuals of over 
fifty years of age, MCC is a rare malignancy of the skin that displays age-
dependent incidence rates of 0.18-0.41 for every 100000 white individuals 
(Eng et al., 2007, Miller and Rabkin, 1999). 
Research revealed that, of 3870 MCC cases, female and male individuals 
accounted for 1490 (38.5%) and 2380 (61.5%) cases, respectively. 
Individuals’ age was in the range 60-85 years and 94.9% of them were 
Caucasian. By contrast, individuals of African origin were not usually 
affected. The salivary glands, nasal cavity, lip, lymph nodes, vulva, vagina 
and oesophagus, cervical squamous cell carcinomas and adenocarcinomas 
were the main sites of MCC (Albores‐Saavedra et al., 2010). 
Furthermore, it was observed that, compared to men, women were more 
likely to survive over a ten-year period (Albores‐Saavedra et al., 2010). In a 
different study, 6700 individuals suffered from local, nodal and distant 
metastatic diseases in a proportion of 66%, 27% and 7%, respectively, with 
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a five-year survival rate of 64%, 39% and 18%, respectively (Lemos et al., 
2010). Additionally, severely immunosuppressed individuals, such as those 
who received organ transplant or had lymphoma or HIV infection, displayed 
a higher incidence rate of MCC (Lanoy et al., 2010).  
Immunosuppression has been associated with a range of cancers with an 
infection-based aetiology, including Kaposi’s sarcoma-associated herpes 
virus (KSHV), lymphomas, cervical, oropharyngeal, and penile cancers in 
individuals with HIV, and non-melanoma skin cancers, lymphomas, and 
cancers of the oral cavity, vulva, and vagina in individuals who had 
undergone organ transplant. The prevalence of MCC in 
immunocompromised people served to reinforce the notion regarding the 
infectious aetiology of MCC (Engels et al., 2008, Palella Jr et al., 1998).  
1.2.2 MCC and UV Light Exposure 
Sun-exposed skin surfaces are conducive to tumour development, meaning 
that a major risk factor for MCC is exposure to ultraviolet (UV) light. The 
correlation between MCC and UV exposure has been supported by 
epidemiological findings, but there is currently insufficient proof for how UV 
causes the condition to develop (Schwarz and Schwarz, 2011). 
Inhibition of immune surveillance is one mechanism through which UV light 
has been proposed to trigger MCC pathogenesis (Feng et al., 2008, 
Schwarz and Schwarz, 2011, Schneider et al., 2013). As previously 
mentioned, individuals older than fifty years of age are most susceptible to 
MCC, this might be as a result of their tendency to exposure to the sun 
(Syrigos et al., 2005).  
Furthermore, by comparison to primary malignant melanomas on body 
surfaces that are not exposed to the sun, those on sun-exposed surfaces 
often induces reactivation of herpes simplex virus (Lundberg et al., 2006, 
Sadowska et al., 2003) Viral pathogenesis may be better understood based 
on the correlation between MCPyV and UV exposure. For example, it was 
reported that UV exposure triggered the in vitro activation of the MCPyV 
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Non-Coding Regulatory Region (NCRR), while sT transcript levels rose in a 
dose-dependent manner upon skin exposure to solar simulated radiation 
(Mogha et al., 2010).  
Furthermore, normal repair mechanisms in UV-exposed cells are likely to be 
affected by viral presence, because UV radiation exposure was noted to 
suppress cell cycle and hinder complete DNA damage repair, which was 
associated with LT, in an MCC cell line infected with MCPyV (Demetriou et 
al., 2012, Purdie et al., 1999). By contrast, in vivo irradiation of skin exposed 
to UV led to an increase in sT, implying a UV-based regulation of the activity 
of the MCPyV early promoter (Mogha et al., 2010) 
 
8 
 
  
St
ra
tu
m
 c
o
rn
eu
m
 
St
ra
tu
m
 lu
ci
d
u
m
 
St
ra
tu
m
 b
as
al
e
 
St
ra
tu
m
 s
p
in
o
su
m
 
St
ra
tu
m
 g
ra
n
u
lo
su
m
 
D
er
m
is
 
Epidermis 
M
er
ke
l c
el
l c
ar
ci
n
o
m
a 
 
M
er
ke
l c
el
l  
M
el
an
o
cy
te
 c
el
l  
Ta
ct
ile
 d
is
c 
Se
n
so
ry
 n
eu
ro
n
  
La
n
ge
rh
an
s 
ce
ll 
B
u
m
p
 
Tr
ab
ec
u
la
e
 
F
ig
u
re
 1
.1
 S
k
in
 c
ro
s
s
 s
e
c
ti
o
n
 i
llu
s
tr
a
ti
n
g
 d
if
fe
re
n
t 
ty
p
e
 o
f 
c
e
lls
 i
n
 b
o
th
 e
p
id
e
rm
is
 a
n
d
 d
e
rm
is
. 
S
ix
 s
tr
a
tu
m
s
 i
n
 t
h
e
 e
p
id
e
rm
 i
s
 
s
ta
rt
in
g
 f
ro
m
 u
p
 t
o
 d
o
w
n
, 
S
tr
a
tu
m
 c
o
rn
e
u
m
 w
h
ic
h
 s
h
o
w
e
d
 b
u
m
p
 i
n
 t
h
e
 r
ig
h
t 
s
id
e
, 
S
tr
a
tu
m
 l
u
c
id
u
m
; 
s
tr
a
tu
m
 g
ra
n
u
lo
s
u
m
; 
s
tr
a
tu
m
 s
p
in
o
s
u
m
 i
n
 w
h
ic
h
 L
a
n
g
e
rh
a
n
s
 c
e
lls
 l
ie
; 
s
tr
a
tu
m
 b
a
s
a
le
 c
o
n
ta
in
s
 M
e
rk
e
l 
c
e
ll 
a
n
d
 M
e
la
n
o
c
y
te
 c
e
ll.
 D
e
rm
is
 l
a
y
e
r 
s
h
o
w
e
d
 s
e
n
s
o
ry
 n
e
u
ro
n
 a
n
d
 t
a
c
ti
le
 d
is
c
. 
D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 n
o
rm
a
l 
M
e
rk
e
l 
c
e
ll 
a
n
d
 M
e
rk
e
l 
C
e
ll 
c
a
rc
in
o
m
a
 w
h
ic
h
 a
re
 
b
ig
g
e
r 
w
it
h
 a
b
n
o
rm
a
l 
n
u
c
le
u
s
. 
9 
 
1.3 Human Polyomaviruses 
The first polyomavirus discovered was a mouse species identified in 1952 by 
Kilham (Kilham and Murphy, 1953) and quickly verified by an independent 
identification of the virus by Gross in 1953, who isolated the virus from a 
murine salivary gland cancer sample (Gross, 1953). The oncogenic role of 
this virus was confirmed four years later by Stewart who experimentally 
infected mice with the virus resulting in the development of multiple tumours 
within the host animals (Stewart et al., 1958). 
Hence the virus name derived from the Greek word poly for many and oma 
for tumours. An in vitro cell culture system helped to further identify 
polyomavirus species and led to the identification of the first primate 
polyomavirus, named simian Vacuolating virus 40 (SV40), although this was 
discovered serendipitously in a polio virus vaccine study using rhesus 
monkey kidney cells (Sweet and Hilleman, 1960, Eddy et al., 1962). 
Subsequently, human tumours were screened for the presence of SV40 and 
traces of the virus were identified in a limited number of cancers such as 
pleural mesothelioma and osteosarcoma. However, evidence of SV40 as a 
causative agent in these tumours or even as a human pathogen remains 
lacking, as indicated (Poulin and DeCaprio, 2006). 
Since 2007, with the help by new molecular techniques, particularly unbiased 
deep sequencing, rolling circle amplification (RCA), generic polymerase 
chain reaction (PCR), pyrosequencing, multiple displacement amplification 
(MDA), and complementary DNA library screening, the number of known 
human members of the Polyomaviridae family has grown by the discovery of 
13 species isolated from humans and use of such advanced molecular 
analysis of viral genomes is likely to yield additional novel human 
polyomavirus (Table 1.1). 
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Table 1.1 list of Human polyomaviruses and their references.  
 
Human 
Polyomavirus 
Clinical aspects Sample 
Identification 
method 
Reference
s 
BKPyV 
polyomavirus-
associated 
nephropathy 
(PVAN) 
urine sample of a 
Sudanese kidney 
transplant 
recipient 
-Electron 
microscopy 
-Serologic testing 
(Gardner 
et al., 
1971) 
 
 
JCPyV 
Progressive 
multifocal 
leukoenceph-
alopath 
extracts isolated 
from brain which 
obtained at 
necropsy 
-Electron-
microscopy 
-Serologic testing 
(Padgett 
et al., 
1971) 
 
Karolinska 
Institute 
polyomavirus 
(KIPyV) 
respiratory tract 
infection 
paediatric 
nasopharyngeal 
aspirates 
unbiased deep 
sequencing 
(Allander 
et al., 
2007) 
Washington 
University 
Polyomavirus 
(WUPyV) 
respiratory tract 
infection 
paediatric 
nasoph-aryngeal 
aspirates 
high throughput 
sequencing 
strategy 
(Gaynor et 
al., 2007) 
Merkel cell 
polyomavirus 
MCPyV 
MCC tumour 
mRNA samples 
Most  MCC 
digital 
subscription 
subtraction 
(Feng et 
al., 2008) 
 
 
 
Human 
polyomavirus 
6 (HPyV 6) 
skin swab 
specimens 
Normal skin flora 
and has not been 
associated with a 
specific clinical 
aspect 
Rolling circle 
amplification 
(RCA) 
(Schowalt
er et al., 
2010) 
Human 
polyomavirus 
7 (HPyV 7) 
 
skin swab 
specimens 
Normal skin flora 
and has not been 
associated with a 
specific clinical 
aspect 
Rolling circle 
amplification 
(Schowalt
er et al., 
2010) 
Human 
polyomavirus 
8 (HPyV8) 
trichodysplasia 
spinulosa skin 
lesions 
Trichodysplasia 
spinulosa-
associated PyV 
(TSPyV) disease. 
Rolling-circle 
amplification 
(van der 
Meijden et 
al., 2010) 
 
 
 
human 
polyomavirus 
serum of a 
kidney 
there is a 
suspicion of its 
high-throughput 
nucleotide 
(Sauvage 
et al., 
11 
 
9 (HPyV9) 
 
transplant 
patient 
correlated with 
renal infection 
sequencing 2011) 
 
 
 
 
human 
polyomavirus 
10 (HPyV10) 
 
condyloma 
sample from a 
patient with 
Hypogamma-
globulinemia, 
wart and 
Myelokathexis 
Syndrome 
(WHIMS) 
there is a 
suspicion of its 
correlated with 
Hypogamma-
globulinemia, 
wart and 
Myelokathexis 
Syndrome 
(WHIMS) 
Rolling circle 
amplification 
 (Buck et 
al., 2012). 
Mexican 
polyomavirus 
(MXPyV) 
stool samples 
Is not yet been 
associated with 
disease 
Unbiased deep 
sequencing 
(Yu et al., 
2012). 
Malawai 
polyomavirus 
(MWPyV) 
stool sample 
Is not yet been 
associated with 
disease 
Real-Time PCR & 
Pyrosequencing 
Strategy 
(Siebrasse 
et al., 
2012). 
Saint Louis 
polyomavirus 
(STLPyV) 
stool sample 
Is not yet been 
associated with 
disease 
Multiple 
displacement 
amplification 
(MDA) 
(Lim et al., 
2013) 
 
 
 
human 
polyomavirus 
12 (HPyV12) 
liver, colon and 
rectum biopsies 
and feces 
Is not yet been 
associated with 
disease 
-Generic PCR 
-Real-time PCR 
-Conventional 
nested PCR 
(Korup et 
al., 2013). 
 
 
 
New Jersey 
polyomavirus 
(HPyV13-
NJPyV-2013) 
muscle biopsy 
of pancreatic 
transplant 
patient 
may contributed 
to muscle and 
ocular damage 
Electron micros-
copy and high-
throughput 
nucleotide 
sequencing 
 
 
(Mishra et 
al., 2014). 
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1.4 Merkel Cell Polyomavirus (MCPyV) 
1.4.1 The Isolation of the Merkel Cell Polyomavirus 
The Chang-Moore research group at the University of Pittsburgh 
revolutionised the principles of representation difference analysis (RDA) 
(Lisitsyn and Wigler, 1993). This assisted with their earlier finding of KSHV 
(Chang et al., 1994). By combining RDA with the available sequences of the 
complete human genome a new method, digital transcriptome subtraction 
(DTS), was devised. In 2008, the group used this new method to discover a 
viral agent in MCC called Merkel Cell Polyomavirus (MCPyV) (Feng et al., 
2008). DTS combines high-throughput cDNA sequencing with in silico 
methods to exclude human sequences from tissue samples. cDNA libraries 
are created from each normal and diseased tissue sample by subjecting the 
sample to sequencing and then matching the results against human 
sequence databases (Feng et al., 2007). By scrutinising hundreds of 
thousands of cDNA sequences from four MCC tumours, the Chang-Moore 
research group identified a cDNA sequence that bore significant similarity to 
the large T antigens of lymphotropic polyomavirus that is known to initiate 
cancer in animal model system (Feng et al., 2008). 
Using PCR walking method and primers derived from the DTS viral 
transcript, the complete closed circular genome of MCPyV 350 (5387 base 
pairs (bp)) and MCPyV 339 (5201 bp) were sequenced. In samples collect 
from ten MCC patients, MCPyV DNA was detectable by Southern blot and 
polymerase chain reaction products of 8 samples, leaving a small subgroup 
of MCC tumours in which the virus was absent (Feng et al., 2008).  
Such findings were corroborated by subsequent studies, with MCPyV 
sequences isolated from the majority of MCC patients (80-97%) (Becker et 
al., 2009, Rodig et al., 2012, Bhatia et al., 2010). An important observation 
made by different studies is that most patients acquire the MCPyV infection 
by adulthood, as is the case with other human polyomaviruses (Nicol et al., 
2013, Carter et al., 2009). 
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1.4.2 The Life Cycle of MCPyV and tissue tropism. 
Due to the discovery of MCPyV within a malignancy instead of its natural 
host cell, its cellular tropism is yet to be determined. Nonetheless, the host 
cell is likely to derive from an epidermal source, as indicated by the origin of 
the Merkel cell carcinoma and the observation regarding the skin shedding 
of MCPyV at regular intervals (Schowalter et al., 2010).  
Whilst tissue tropism and the natural reservoir of MCPyV infection remain 
unknown, there has been a concerted effort to find an appropriate cell 
culture system for MCPyV to determine the oncogenic activity of the virus. 
Aiming to study MCPyV tissue tropism, Buck and colleagues used MCPyV-
based vectors encapsidating a secreted Gaussia luciferase (Gluc) reporter 
plasmid (Pastrana et al., 2009). They expanded their study by using in 
addition to MCC tumour originating cell lines (WaGa, MaTi, UISO, and MKL-
1), the NCI-60 panel of human cancer cell lines. The sixty different cell lines 
that comprise the NCI-60 panel are derived from brain, breast, colon, 
kidney, lung, ovary, and prostate tumours, as well as leukaemia and 
melanoma cell lines. In contrast to ovarian cancer cell line (NCI/ADR-RES), 
which produced the greatest MCPyV titre, leukaemia and colon cancer cell 
lines have been shown to be resistant to MCPyV transduction. The titre of 
the NCI/ADR-RES cell line was more than twice that of the MALME-3M 
melanoma cell line, which was the second most transducible cell line. The 
data reveals that MCPyV is able to transduce a wide range of solid tumours, 
but this finding is not duplicated in cultured cell lines, where MCPyV 
replication is weak (Schowalter et al., 2012). Spurgeon and colleagues tried 
to study the oncogenic activity of MCPyV LT by developing a tissue-specific 
mouse model. Expression of MCPyV LT and sT antigens in epidermal 
stratified squamous epithelial cells of mice and Merkel cells was induced by 
the expression of Human keratin 14-mediated Cre recombinase (Cyclization 
recombination enzymes). In response to expressing MCPyV T antigens, the 
mice developed different skin disorders including hyperkeratosis, 
hyperplasia, and thickened patches of skin called acanthosis. Further 
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abnormalities were observed in the eyes, footpads, and whisker pads. 
Almost 50% of the mice developed skin papillomas (Spurgeon et al., 2015).  
Recently, Li and colleagues tried to develop a new cell culture systems to 
help in MCPyV genome replication and production of infectious particles. 
They used BTL-Tn 5B1–4 (also known as High Five, Tn5) cell line derived 
from the Trichoplusia ni moth and it appeared to be an effective generator of 
MCPyV-like particles. Yet the yield of viral particles created by the 
replication systems have not been employed for structural analysis, 
probably because of the low volume of virions generated (Li et al., 2015a) . 
 
1.4.3 MCPyV Binding, Entry and Replication 
For binding and entering cells, viruses utilise on interactions with particular 
receptor molecules on the host cells. Hence, a viral entry pathway is made 
up of a series of coordinated attachments between viral proteins and cellular 
receptors such as proteins or other biomolecules (Neu et al., 2012). MCPyV 
entry is initiated by the major capsid protein VP1, which attaches to cellular 
receptors to promote internalization and transport of the viral genome into 
the nucleus for replication. Unlike other polyomaviruses, including MPyV, 
SV40, BKPyV and JCPyV, which undertake cell binding and internalisation 
solely with carbohydrates containing sialic acid, MCPyV VP1 detects the 
disaccharide N-acetylneuraminic acid galactose motif (Neu5Ac-a2, 3-Gal) 
(Figure 1.2), through a shallow binding site on its apical surface (Neu et al., 
2012, Tsai et al., 2003, Neu et al., 2013, Maginnis et al., 2014). 
The crystal structure of VP1 identified that five VP1 monomers arranged 
around a central five-fold axis to form a symmetric ring shape of 
homopentamer. Each of VP1 monomer is consist of two β-sheets which form 
a β-sandwich with jelly-roll topology. This unique structure looks to be  
important for virus to interact with cell surfaces (Neu et al., 2012).  
The singular character of MCPyV among members of the Polyomaviridae 
family is further reinforced by the fact that VP1 mutations do not prevent 
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MCPyV pseudovirions from binding to cells (Neu et al., 2012, Schowalter and 
Buck, 2013). 
VP1 mediates MCPyV entry by binding initially to sulphated carbohydrates 
called glycosaminoglycans (GAGs) (e.g. heparin sulphate and chondroitin 
sulphate). Post-attachment of VP1 with Sialic acid is crucial for a post-
attachment step of MCPyV infection (Neu et al., 2012, Sapp and Day, 2009).  
Following the interaction between VP1 and GT1b, the virus is transferred in a 
retrograde way to the endoplasmic reticulum (ER) lumen and the caveolin-
free membrane structures. Endocytosis mediated by caveolae leads to 
internalisation of MCPyV, which is then transferred through the cytoplasm of 
the host cell to the ER. At the ER, MCPyV is uncoated during infection, while 
endosomal and lysosomal trafficking enable viral genomes to migrate from 
the cell membrane to the nucleus, where they are imported by the nuclear 
import mechanism of the host (Schowalter and Buck, 2013). 
Right after uncoating and transfer of the episomal viral genome to the 
nucleus, the transcription of the early region is initiated at the early promoter. 
This process relies on T antigens and therefore their transcription occurs 
immediately after enters the cell nucleus. Under the action of these genes, 
the cells enter the S-phase, the cellular environment being modified to 
enable viral replication (Puntener and Greber, 2009). When T antigen 
expression reaches adequate levels, the MCPyV genome-encoded miRNA is 
likely to suppress further early gene transcription in order to ‘’ prioritise ’’ viral 
replication and transcription of late region capsid gene (Theiss et al., 2015). 
MCPyV is similar to other polyomaviruses in its necessity for T antigens to 
start genome replication. The oligomerisation of LT gives rise to hexameric 
molecules, two of which attach to the replication origin in a head-to-head 
orientation. Subsequently, viral DNA is unwound by the LT helicase and 
replication proceeds in a bidirectional way (i.e. hexamer movement in 
opposite directions) ( Wessel and Schweizer, 1992, Kwun et al., 2009).  
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Figure 1.2: Schematic illustrates attachment of MCPyV to the plasma  
membrane. VP1 binds GTb1 which contains Neu5Ac, Galactose, Glucose and 
N-acetyl-D-galactosamine and all these may allow the virus to enter the cell 
through ceramide which diffuses within the cell membrane.  
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.4 Transmission of the Virus  
MCPyV is part of the normal skin flora and therefore it can be found on all 
skin surfaces, similar to HPyV6 and HPyV7. It is believed that MCPyV 
causes a persistent skin infection, since the DNA sequence was observed 
to be the same on different skin surfaces of the same patient (Wieland et 
al., 2009, Schowalter et al., 2010, Duncavage and Pfeifer, 2011).  
As highlighted by many studies, the prevalence of the infection among 
adults suggests that individuals become infected with MCPyV at a young 
age and this primary infection lacks symptoms (Martel-Jantin et al., 2013, 
Tolstov et al., 2009). However, no in-depth study has so far been conducted 
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on how the primary MCPyV infection is disseminated and transmitted or on 
the occurrence of a latent phase (Foulongne et al., 2010).  
It has been reported that a proportion of 60-70% of individuals acquired 
primary MCPyV infections when they were younger than six years of age 
(Martel-Jantin et al., 2013). Although, it is unlikely that the virus is 
transmitted from mother to child because foetal autopsy samples were not 
found to contain MCPyV, perinatal transmission during birth might still 
occur. Nevertheless, the most probable mode of transmission of MCPyV is 
via saliva and/or skin contact, especially among young siblings and between 
mother and child, as indicated by correlations in MCPyV infection and 
serological status (Sadeghi et al., 2010). 
Nasopharyngeal aspirates from children and adults were found to contain 
MCPyV DNA in a proportion of 0.6-1.3% and 2.1-8.5%, respectively (Carter 
et al., 2009, Bialasiewicz et al., 2009, Gaynor et al., 2007). Meanwhile, 
tonsils, lung tissues, and bronchoalveolar and bronchoaspirates displayed 
MCPyV in proportions of 3.5%, 6.7% and 17.2%, respectively. Therefore, an 
aerodigestive transmission mode is implied by the occurrence of MCPyV in 
both upper and lower respiratory tract (Saláková et al., 2015, Babakir‐Mina 
et al., 2010). 
On the other hand, cerebrospinal fluid, peripheral blood mononuclear cells, 
plasma/blood, brain or prostate tissue samples, or frozen autopsy samples 
from immunocompetent as well as immunosuppressed individuals did not 
exhibit MCPyV (Kassem et al., 2008, Gustafsson et al., 2013, Laude et al., 
2010, Sadeghi et al., 2010). However, urine and serum samples were 
reported to contain MCPyV DNA sequences in a proportion of 15-25% and 
0.1-12%, respectively (Husseiny et al., 2010, Bofill-Mas et al., 2010).    
MCPyV may also be transmitted via blood as its presence in serum was 
detected by some studies. However, given that the majority of adults 
possess MCPyV antibodies, this transmission mode is unlikely to have 
subsequent involvement (Carter et al., 2009). Furthermore, contamination of 
urethral openings during urine sample collection may explain the low 
MCPyV copy number in urine (Husseiny et al., 2010). Everything coming 
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into contact with people may display viral DNA presence, as 85% of 
environmental surfaces that were examined, including urban waste and 
river water, were found to contain MCPyV (Calgua et al., 2013, Bofill-Mas et 
al., 2010). The fact that the encapsulated DNA originated from possibly 
infectious viruses was suggested by the detection of viral MCPyV DNA in 
environmental surface samples following DNase treatment conducted prior 
to nucleic acid extraction (Foulongne et al., 2011). Another study 
corroborated this finding, therefore implying that individuals may also 
acquire MCPyV infection from environmental sources (Schowalter et al., 
2010). 
 
1.4.5 Virus epidemiology 
A number of independent researchers have produced compelling evidence 
that MCC tumours sampled from various countries contained the MCPyV 
genome. Corroborating the initial findings of Feng and colleagues, the 
majority of studies detected MCPyV in a proportion of 80% of MCC tumours 
(Feng et al., 2008, Garneski et al., 2009, Ridd et al., 2009, Paulson et al., 
2009, Loyo et al., 2010, Martel-Jantin et al., 2014). Healthy human skin is 
highly susceptible to MCPyV infection, which can occur throughout the 
surface of the body (Schowalter et al., 2010, Foulongne et al., 2010). In spite 
of this, MCPV viral loads are over 60 times higher in MCC tumours than in 
other skin sites. The geographical location of the research population, the 
conditions under which tissue samples are stored, PCR type and primer set 
are the major factors that determine the extent to which MCPyV DNA can be 
detected in tissue samples. In the populations that have been investigated, 
measurements based on ELISA or Luminex assays designed to identify 
MCPyV-specific IgG antibodies revealed a consistently high MCPyV 
seroprevalence, in the range of 46-88% (Touzé et al., 2010).  
The results of a MCPyV epidemiological research conducted on a healthy 
population from China indicated that females exhibited lower seropositivity 
than males (57.7% vs 64.5%); nonetheless, seropositivity increased with age 
in both males and females. By contrast, sexual behaviour and MCPyV 
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seropositivity were not found to be correlated (Zhang et al., 2014). The 
relation between age and seroposivity was highlighted by Viscidi and 
colleagues as well, observing that children younger than 10 years old had a 
45% seroprevalence, which rose to 60% in the following ten years and 
reached the highest percentage at 60-69 years of age (81%) (Viscidi et al., 
2011). 
MCPyV seroprevalence was confirmed in around one-fourth of tested 
children. Investigating children 1-5 years old, Kean and colleagues obtained 
a seroprevalence of 20.5%, while children 2-5 years old were found to hold 
seroprevalence in a proportion of 43% (Kean et al., 2009).  
In a more recent study on 1-12 year-old children from Sweden, Faust and 
colleagues documented a seroprevalence of 32%. Moreover, among children 
younger than 3 years old who were found to be MCPyV-seronegative, 33% 
seroconverted when subjected to new testing 5-8 years after initial testing. 
Meanwhile, 9% and 35% seroprevalence was detected in children 1-4 years 
old and 4-13 years old, respectively (Faust and Dillner, 2014, Chen et al., 
2011). 
 
1.4.6 The Genome Structure of MCPyV 
MCPyV does not differ significantly from other polyomaviruses in terms of 
genetic composition (Feng et al., 2008). A circular DNA genome with double 
strands and 5387 base-pairs is displayed by the prototype virus MCV350 
(Figure 1.3). Since MCPyV is a polyomavirus, its genome presents 
bidirectional early and late coding regions between which is the non-coding 
regulatory region (NCRR) containing the regulator of viral replication. 
Although they are similarly long, early and late transcripts are encoded on 
parallel strands of the viral genome (Feng et al., 2008, Shuda et al., 2008). 
The MCPyV genome shows the greatest similarity with the African Green 
Monkey lymphotropic polyomavirus (Dalianis et al., 2009). 
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A temporally-modulated cascade of gene expression is enabled by the 
separation of the early and late transcriptional units and is associated with 
the beginning of viral DNA replication, which is similar to that of other DNA 
viruses (Feng et al., 2011). Infection is immediately followed by expression of 
the early genes related to the T antigen locus, which take part in viral 
genome replication. DNA replication is followed by the transcriptional 
activation of the late region for expression of the gene products constituting 
the structural elements of the viral capsid and participating in the production 
of progeny virion in the late infection phase (Cole, 2001). However, although 
it shares these features with other polyomaviruses, the MCPyV viral genome 
also presents a number of singular features. For instance, Merkel cell 
polyomavirus is more similar to murine polyomaviruses than to other human 
polyomaviruses with regard to the gene products of early (large and small T 
antigens) as well as late regions (VP1 and VP2) (Feng et al., 2008). 
As in the case of other polyomaviruses, a 71-base pair minimum replication 
origin is incorporated within the NCRR of MCPyV, possessing an AT-rich 
tract which participates in DNA melting, a region comprising 8 G(A/G)GGC 
pentanucleotide sequences that are responsible for attaching the origin-
binding domain (OBD) in the LT core in order to regulate the aggregation of 
LT proteins on the DNA. However, unlike other polyomaviruses, a greater 
number of pentanucleotide sequences are present within the MCPyV origin, 
they are more closely associated and four of them play a crucial role in virus 
replication (Feng et al., 2008, Johnson, 2010). 
Recent studies detected the association between the OBD of MCPyV LT and 
a segment of the MCPyV replication origin, which confirmed that LT proteins 
attached to the replication origin are the sites of OBD-OBD intermolecular 
interactions. Moreover, the singular combination of pentanucleotide 
sequences necessary for successful MCPyV replication was described and 
validated by the crystal structure (Kwun et al., 2009). However, due to the 
greater spatial division between OBD-binding pentanucleotide sequences, 
the SV40 origin does not exhibit these intermolecular interactions (VanLoock 
et al., 2002, Wessel et al., 1992). 
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However the NCRR also contains bidirectional transcriptional promoters and 
regulatory elements for early and late viral gene expression. (Harrison et al., 
2011, Shuda et al., 2008). Four of these pentanucleotide sequences sites 
are absolutely required for virus replication (Kwun et al., 2009). 
 
1.4.6.1 The Early Region 
The early coding region of the MCPyV genome produces four proteins 
translated from transcripts that result from differential splicing. Known as 
tumour antigens or T antigens, these proteins led to the labelling of the early 
region as the “T antigen locus”, comprising Large and Small T antigens (LT 
and sT), 57kT (Feng et al., 2008, Shuda et al., 2008), as well as alternative 
Large T open reading frame (ALTO) that was most recently identified (Carter 
et al., 2013). The first three have the same N-terminal 78 amino acids but 
terminate at different C-terminal residues. The 57kT and LT are identical 
except for a deletion in the C terminal region of the protein (Figure 1.4). In 
addition, The ALTO results from a +1 frameshift relative to the second exon 
of LT. The function of 57kT and ALTO in MCPyV genome replication is 
currently unclear (Carter et al., 2013). 
 
1.4.6.1.1 Large T Antigen  
The MCPyV LT antigen is composed of two exons that are responsible for 
encoding 816 amino acids. It shares many functionally important roles with 
LTs of other polyomaviruses, for example regions implicated in viral 
replication. MCPyV LT shares about 30% amino acid identity with other 
human polyomaviruses. They share the same LXXLL sequence, known as 
conserved region 1 (CR1) and LXCXE sequence, called the retinoblastoma 
protein (pRB) binding motif (except for HPyV12, which lacks a recognisable 
pRB binding domain) (Korup et al., 2013). Similar effect of LXCXE domain of 
DNA tumour viruses, including E7 from human papillomavirus (HPV) and 
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E1A from adenovirus showed to be required for inhibiting retinoblastoma 
tumour suppressor and antagonizing with DNA sensing (Lau et al, 2015).  
 
Figure 1.3 Genome organisation of MCPyV. MCPyV strain 350 composed 5387bp 
and organised into three regions: early region, late region and non-coding control 
region (NCCR). Proteins illustrated as coloured arrows. Early region contains Larg T 
antigen (LT, Red); Small T (sT, Green); 57KT protein (Light Blue), ALTO (Gray) and 
miRNA (Dark Blue). The structural proteins VP1, VP2 and VP3 are shown in yellow 
colour. 
 
In addition, the conserved DNA binding domain and helicase domain 
constitute the components of the C-terminus. The majority of the domains 
that participate in viral DNA replication, such as OBD, ATPase domain, and 
helicase domains, are found in the carboxyterminal half of LT, which is also 
where tumour-specific mutations occur (Figure 1.5) (Shuda et al., 2008, 
Nakamura et al., 2010). After MCPyV LT translation, it recognizes and 
interacts with GAGGC pentanucleotide repeats within the viral origin.  
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In turn, this interaction is responsible for triggering core origin melting and 
unwinding, after which host replication factors like polymerase α primase 
bind and are required for initiation of viral and replication (Kwun et al., 2009). 
The full-length LT sequence can integrate into the host cell genome and 
initiate its DNA replication. However, integration of this full length LT may 
lead to replication fork collision and cause DNA breakage leading to cell 
death (Tsang et al., 2014).  
Moreover, it was observed that MCPyV DNA integration in the MCC genome 
exhibited mutation in the C terminus of LT, resulting in truncated LT 
expression. In addition, transcription is also modulated by LT, which is of 
significance during infection, as it inhibits early transcription and at the same 
time it promotes late viral gene expression. The capacity of LT to activate 
viral origin DNA replication was significantly affected by LT phosphorylation 
at amino acids T297 and T299 (Diaz et al., 2014). 
The interaction between LT and the RB family (pRB, p107 and p130) led to 
the discovery that LT is involved in cell transformation. Underpinning the LT-
pRB interaction, pRB negatively modulates cell transformation by 
preferentially interacting with the E2F transcription factor. The expression of 
genes involved in cell progression is controlled by E2F in an inactive state 
when attached to pRB (Borchert et al., 2014). The E2F-pRB interplay is 
interrupted by particular cyclin-dependent kinases that phosphorylate pRB, 
leading to the regulation of the expression of genes necessary for cell cycle 
progression. Studies on the correlation between the MCPyV DNA level and 
pRB expression level in MCC provided evidence that, in MCC, the level of 
MCPyV DNA and the level of pRB were directly proportional (Bhatia et al., 
2010). 
A chaperone DnaJ domain (HPDKGG), which recognize heat shock protein 
40,  (Hsp40) is another key domain in the LT C-terminal whose interaction 
with the heat-shock protein cognate 70 (Hsc 70) is considered to be essential 
for viral replication (Whalen et al., 2005). This interaction is also responsible 
for interrupting the interaction between pRB and E2F, leading to E2F release 
(Kwun et al., 2009).  
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Figure 1.4 Schematic illustration early region proteins of MCPyV. LT, sT, 
57KT and ALTO protein. LT, sT and 57KT have conserve of N-terminal 
domains, each has conserved region 1 (CRI) and DnaJ domains.  At the 
C-terminus of LT and 57KT there are conserve of vam6p, pRB and MUR 
domains. The sT contains unique domains near to the C-terminus, a 
domain of 5 amino acids (91-95) called the LSD required for stability of LT, 
different domains for interaction with NEMO, PP4C, PP2A Aβ lie between 
residues (95-111) and two motifs for binding PP2A Aα (R7 and L142). LT 
has conserved  unique C-terminal regions, OBD, zinc fingers and leucine 
zipper, ATPase-Helicase. 
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Unlike the case of SV40 LT, MCPyV LT has not been confirmed to bind the 
tumour suppressor protein p53 directly, but MCPyV-positive MCC cells were 
observed to contain a low level of p53. Furthermore, compared to full-length 
LT, truncated LT derived from an MCC tumour was not reported to have any 
impact on p53 expression, due to the fact that no p53 binding domain is 
possessed by the tumour-related T antigen deletion mutations occurring in 
the LTs of MCC-related MCPyV genome (Shuda et al., 2008, Borchert et al., 
2014).  
Clearly, SV40 and MCPyV LTs must have different mechanisms to modulate 
p53. In SV40,  LT induces DNA damage stimulated kinases that 
phosphorylate and activate p53, whereas MCPyV LT stimulates the kinases 
to activate p53 leading to an induction cell of cycle arrest and inhibition cell of 
proliferation (Li et al., 2007b).    
Belonging to the group of apoptosis inhibitors (IAP), Survivin or baculoviral 
inhibitor of apoptosis repeat-containing 5 (BIRC5) is an oncoprotein recruited 
by MCPyV LT to prevent infected cells from dying. The findings indicated 
that, in contrast to MCC without MCPyV association, MCC associated with 
MCPyV exhibited a sevenfold increase in Survivin expression. The Survivin 
expression level declined as a result of LT knockdown, and this provided 
evidence not only for the relationship between LT and Survivin but also for 
the key role played by Survivin in cell survival (Arora et al., 2012). 
Another feature that distinguishes MCPyV LT from other polyomaviruses is 
that it includes a 200 amino acid region known as MCPyV-Unique Region 
(MUR). The significance of this region arises from its interaction with the 
vesicle-associated membrane protein (Vam6p), which, after it is expressed in 
transfected cells, exhibits a cytosolic distribution and induced perinuclear 
lysosome clustering. Furthermore, Vam6p is relocated to the nucleus as a 
result of being co-expressed with MCPyV LT during interaction with LT and 
lysosome clustering suppression (Figure 1.5) (Liu et al., 2011).  
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Figure 1.5 Schematic illustration binding domains of MCPyV LT which contains 
2884 pb. In N-terminal there are conservative region 1 (CR1, Yellow) and DnaJ 
(Black Red), in early C-terminal there is MCPyV-unique region (MUR, Black) and 
in C-terminal there are vesicle-associated membrane protein (Vam6p, Red), 
Protein Retinoblastoma (PRB, Blue), Origin Binding Domain(OBD, strips) and in 
the end of C-terminal there are Znic finger domain (ZF, Green), Leucine Zipper 
(LZ, light blue), ATPase domain (dotes) and at the extreme is Helicase domain 
(Purple).    
 
 
 
 
1.4.6.1.2 The 57kT protein. 
The 57 kDa protein (57kT) is encoded by the MCPyV early region. Its initial 
expression follows co-transfection with LT and is succeeded by expression of 
other viral proteins. The protein comprises 432 amino acids divided into three 
exons. Aside from the CR1 and DnaJ domains, the same 78 amino acids at 
the N-terminus are contained by the first exon of LT as well as sT (Feng et 
al., 2008). Similarly, the LT binding domains in the second exon are the 
same as those of pRB, nuclear localisation signal (NLS) and OBD, whilst 
also possessing the same 200 amino acids of MUR in LT. The third exon has 
the same 100 amino acids as the C-terminus of LT. However, the role played 
by 57kT in the life cycle of MCPyV remains unknown. Furthermore, viral 
replication has not been observed to be affected by the interaction of 57kT 
with LT or sT (Feng et al., 2008, Shuda et al., 2008). Interestingly, SV40 was 
noted to generate an analogous protein, termed the 17kT antigen (135aa), 
which was reported to have some effect on the phenotype of rat fibroblast 
cells (Zerrahn et al., 1993). 
 
1.4.6.1.3 ALTO protein. 
The discovery in the early region of the alternative large T open reading 
frame (ALTO) as the outcome of overprinting of the LT second exon was 
made during studies of the replication of the MCPyV genome. Just like LT, 
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the C-terminus of ALTO contains the residues 880-1624. Further research 
has demonstrated that only MCPyV and three hominoid polyomaviruses 
(ChimpPyV1, ChimpPyV2, and GorillaPyV1) encode this protein. 
Furthermore, ALTO shares similarities with the Middle T antigen (MT) of 
murine polyomavirus (MPyV), as they are both the result of LT overprinting, 
whilst also displaying a correlation with the transforming protein of MPyV MT 
via a conserved hydrophobic C-terminus (Carter et al., 2013). 
It thus describes a previously unknown group of mammalian polyomaviruses, 
encompassing PyVs from mouse, hamster, raccoon, bat gorilla, chimp and 
human, and spanning the same C-terminal region of both MCPyV and MPyV 
(Fluck and Schaffhausen, 2009). However, in comparison to MT, the 
transformating activity of ALTO on MCPyV genome replication has not been 
established so far. Empirical studies have pointed to the fact that viral DNA 
replication is not influenced by whether or not ALTO is present (Carter et al., 
2013).  
In unpublished data, Carter and colleague shed new light on ALTO. In 
particular, they highlighted two regions with homologous sequences between 
MCPyV and MPyV, namely, the C-terminal hydrophobic domain involved in 
MPyV subcellular localisation and transformation activity, and a region 
circumscribing a tyrosine subjected to MT phosphorylation (Y322) and in 
charge of activating Phospholipase C gamma 1 (PLCG1). Activation of 
PLCG1, which required is to activate a family of non-receptor tyrosine 
kinases called (SFKs), was associated with overexpression of ALTO as a 
result of ALTO Y114 phosphorylation. Moreover, MT interacted with 
members of SFKs like (Src, Fyn and Yes). Phosphorylation of Y114 in ALTO 
was enhanced when ALTO and SFKs were co-expressed. Since SFKs 
exhibit a number of identical biological features, they may help to improve 
understanding of how ALTO is involved in MCPyV replication(Carter et al. 
personal communication).  
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1.4.6.1.4 Small T Antigen (sT) 
MCPyV sT contains 186 amino acids. In the N-terminus, it shares 78 amino 
acids with LT and 57KT. It has the same conserved region 1 (CR1, LXXLL) 
and heat shock protein binding DnaJ motifs (HPDKGG). In contrast to LT, 
the role of CR1 and DnaJ domains in sT is not clear. However, the C-
terminus of sT (80-186) is not conserved in LT or 57KT. This unique region 
contains essential binding domains for interactions with a number of cellular 
proteins (Figure 1.6) (Feng et al., 2008, Shuda et al., 2008). 
Mutagenesis screening studies have emphasized MCPyV sT, like other 
polyomaviruses, possesses a capability to target protein phosphatase 2A 
(PP2A) which will be discussed in detail in section 1.8.1 (Pallas et al., 1990, 
Kumar and Rangarajan, 2009, Bollag et al., 2010, Berrios et al., 2014). With 
the fact that the role of sT of these viruses is different, SV40 and JCPyV use 
their sT to bind PP2A to influence cell transformation and cell cycle 
progression whereas targeting of MCPyV sT to PP2A is not critical for 
transformation properties. Mapping studies showed that the interaction 
between MCPyV sT and the structural sub-unit A isoform α of PP2A was 
dependent upon residues R7 and L142 in sT. Substitutions in R7 and L142 
disrupted the sT/PP2A binding interaction but retained their ability to 
transform rodent fibroblasts (Shuda et al., 2011, Rodriguez-Viciana et al., 
2006). In contrast, the sT-PP2A complex is essential for SV40 infection 
(Guergnon et al., 2011, Hahn et al., 2002). 
With roles in LT stabilisation and viral replication, the LT-stabilisation domain 
(LSD) is an additional sT binding site that was recently delineated within 
residues 91-95. This is an important region for targeting the complex of 
Skp1, Cul1, and F box protein ubiquitin ligase protein complex, SCFFbw7, 
which is known as the Cellular Ubiquitin Ligase (Kwun et al., 2013). The 
function of SCFFbw7 is to suppress MCC viral replication by targeting LT and 
breaking it down by the proteasome. In turn, SCFFbw7 is targeted by sT with 
the purpose of hindering proteasomal degradation of LT, hence activating 
cell transformation. This clearly illustrates how MCPyV sT and LT cooperate 
to benefit the development of MCC. What is more, research on rodents 
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Figure1.6 Schematic illustration multiply spliced of MCPyV sT domains. CR1 
form sequences (LXXLL) domains in C-terminus (Dark red), DnaJ-Hsc70 
(HPDKGG) (Yellow), and LSD (light blue) refers to LT stabilization domain 
(LKDYM). Domains of three cellular proteins PP4C, NEMO PP2A Aβ and PP2A 
Aα located within residues 95-111 and coloured as red, green black respectively. 
Two binding sites of PP2A Aα (R7 and L142) (Brown). 
revealed that the recently delineated LSD domain of MCPyV sT might alone 
be involved in cell transformation, in addition to LT stabilisation and viral 
replication. Meanwhile, LSD domain mutations make sT unable to trigger 
transformation. However, unlike other polyomaviruses, this capability of sT 
has no connection to PP2A, as demonstrated by the fact that sT continues to 
bind PP2A after mutations impair its ability to trigger transformation (Kwun et 
al., 2013).  
Another interaction partner for MCPyV sT was identified by Griffith and 
colleagues which observed the existence of a key sT binding domain in the 
proximity of its C-terminus in residues 96-111, which was associated with 
NEMO and two protein phosphatases, namely, protein phosphatase 4 
(PP4C) and a sub-unit of β isoform of protein phosphatase 2A (PP2A Aβ). 
The immune response of the host is disrupted by the interplay between sT 
and these cellular proteins. The cause of this disruption is the fact that the 
interaction of MCPyV sT with NEMO interferes with the immune signalling 
pathway of Nuclear Factor kappa-light-chain-enhancer of activated B cells 
(NF-B) (Griffiths et al., 2013). It is worth noting that the upregulation of NF-
B activation by SV40 sT is dependent on PP2A (Moreno et al., 2004). 
 
 
 
1.4.6.1.5 MicroRNA.  
It is 
hypothesised that genes involved in fostering immune evasion and regulation 
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of viral DNA replication are targeted by a virus-encoded microRNA (miRNA). 
A 22-nucleotide viral miRNA expressed by the MCPyV genome to form two 
mature miRNA (MCPyV-miR-M1-5p) and (MCPyV-miR-M1-3p) (Seo et al., 
2009). Evidence confirms that the miRNA-M1 of MCPyV possesses an ability 
to decrease the expression level of viral genes which are essential for viral 
DNA replication (Theiss et al., 2015). The complete reverse complement of 
miRNA to MCPyV LT sequence near the LXCXE motif suggests that this 
early protein is targeted by miRNA which induces LT gene silencing by 
binding the target site of mRNA and subsequently preventing LT production 
either by suppressing protein synthesis or by initiating mRNA degradation 
(Seo et al., 2009).  
The role of miRNA on DNA replication of SV40, murine PyV, and BKPyV and 
their LT expression level was illustrated by knock down of their miRNAs 
which showed that the lack of miRNA increased the level of LT and DNA 
replication in these viruses (Zhang et al., 2014, Sullivan et al., 2005, 
Broekema et al., 2013). Additionally, various cellular targets with roles in 
transformation may also be affected by the miRNA (Houben et al., 2010, Seo 
et al., 2009, Scaria and Jadhav, 2007). The findings of one study revealed 
that around half of MCPyV-positive MCC tumours had conserved miRNA 
expression, the level of which was dependent on the viral genome copy 
number (Lee et al., 2011). Further research is needed to elucidate the 
function of MCPyV miRNA in MCC tumours. A close correlation between 
miRNA overexpression and MCC metastases, as opposed to normal MCC, 
was reported and may provide an indication regarding miRNA function (Xie 
et al., 2014). 
1.4.6.2 Structural Proteins encoded by the Late Region 
The late region of viral DNA expresses the structural proteins consisting of 
VP1, VP2, VP3 and in some polyomaviruses VP4. These proteins are 
required for the initial interaction between the virus and the target host cell. 
Like other polyomaviruses, MCPyV is non-enveloped and its capsid consists 
of 360 capsomers of the major capsid protein VP1. VP1 is arranged in 72 
pentamers in the outer side of the capsid and each of the 72 pentamers is 
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linked with one copy of either VP2 or VP3. This structure provides the 
icosahedral form of the virus capsid (Campanero-Rhodes et al., 2007, Low et 
al., 2006, Erickson et al., 2009, Schowalter and Buck, 2013). By contrast to 
other polyomaviruses, the third capsid gene, VP3, cannot be detected in 
MCPyV-infected cells. This is consistent with the fact that MCPyV was less 
affected by VP3 knockdown than by VP2 knockdown, which reduces native 
MCPyV infectivity by 100 times. Unlike VP1 and VP2, a functional VP3 
protein is not encoded by MCPyV, as the conserved M, A and L motif 
underlying the amino-terminus of other polyomavirus VP3 proteins is absent 
in MCPyV (Schowalter and Buck, 2013). 
 
1.5 MCPyV sT Involvement in Viral Replication and Cell 
transformation 
Despite the lack of clarity surrounding the processes through which MCPyV 
triggers transformation, a number of findings have indicated that MCPyV 
tumour antigens mediate cellular transformation and replication.  
It has been suggested that MCPyV LT is the primary viral oncoprotein 
underpinning MCC transformation, while sT has merely a secondary role; 
however, sT is capable of triggering serum-free human cell proliferation, 
something which LT cannot do (Feng et al., 2008). By contrast to SV40 sT 
antigen, MCPyV sT can not only mediate transformation by LT, but also 
trigger it on its own (Saenz-Robles et al., 2001). This has been confirmed by 
the fact that MCC cell development and replication were retarded by sT 
knockdown (Kwun et al., 2009, Shuda et al., 2011). 
Transformation of rodent fibroblasts and serum-free growth of human 
fibroblasts were not promoted by MCPyV LT expression, but by sT 
expression. This conclusion was derived from experimental work involving 
the cloning of codon-optimised cDNAs for MCPyV sT and LT into lentivirus 
vectors followed  
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by expression in Rat-1 fibroblast cells. Dense foci were observed to be 
formed solely in cells with sT expression and not by the empty vector (Shuda 
et al., 2011). 
Stimulation of the hyperphosphorylation of Eukaryotic initiation factor 4E 
(eIF4E) binding protein (4E-BP1), an important protein translation regulator, 
is one potential mechanism through which cell transformation is regulated by 
sT. In eukaryotes, translation initiation is enabled at the mRNA 5’ cap to 
which the eIF4F multi-subunit translation factor promotes ribosomal binding 
to mRNAs that have a 5’7-methylguanosine cap (Buchkovich et al., 2008). 
The 4E-BP1 is an important regulator of this process. 4E-BP1 isolates eIF4E, 
preventing the association of ribosomal subunits with the capped mRNA. 
Studies have emphasised the significance to tumorigenesis of cap-
dependent translation controlled by the phosphatidylinositol 3-kinase (PI3K) 
in the PI3K-AKT-mTOR signalling pathway (Fukuglta et al., 1994, Polivka 
and Janku, 2014, Musa and Schneider, 2015). Induction of cap-dependent 
translation may be a factor in tumour cell growth, as demonstrated by rodent 
cell transformation detected in response to overexpression of eIF4E (Avdulov 
et al., 2004, Truitt et al., 2015). Manipulating cell transformation in this 
manner can make the pathway attractive for viruses to exploit. For example, 
poliovirus cleaves eIF4F, inactivating the complex, and preventing cap-
dependent translation and activates the translational repressor 4E-BP1 
(Gingras et al., 1996). Adenovirus stimulates PI3K-AKT-mTOR signalling to 
activate phosphorylation of 4E-BP1 early on during infection (Arias et al., 
2009). Similar to that, respiratory syncytial virus (RSV) by unknown 
mechanism able to enhance 4E-BP1 phosphorylation to activate viral 
replication (Pérez-Gil et al., 2015).  
SV40 also showed capable to activate eIF4E through interaction of SV40 sT 
to PP2A and prevent dephosphorylation of protein kinase B (AKT) and as a 
result prevent 4E-BP1 dephosphorylation which relases elF4E and promots 
cell transformation (Yu et al., 2005, Hahn et al., 2002, Rodriguez-Viciana et 
al., 2006). In contrast to SV40 sT, the interaction between MCPyV sT and 
PP2A Aα did not induce the activation of AKT (Shuda et al., 2011).  
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MCPyV sT was noted to act downstream, thus preserving 4E-BP1 
hyperphosphorylation; this resulted in impaired cap-dependent translation. 
Shuda and colleagues found that the MCPyV sT-initiated inhibition of 4E-
BP1 dephosphorylation or turnover resulted in elevated steady-state levels of 
hyperphosphorylated 4E-BP1 leading to dysregulated cap-dependent 
translation (Beretta et al., 1996). It is reasonable to conclude that the 
phenomenon is not a result of sT interaction with PP2A Aα; the sT mutants 
(R7A and L142A), which prevent sT binding to PP2A, demonstrated the 
same behaviour as wild type sT, preserving their ability to 
hyperphosphorylate 4E-BP1 and not influencing 4E-BP1 levels stimulated by 
MCPyV sT (Shuda et al., 2011). 
MCC is highly metastatic and has the potential to spread to a number of sites 
including the pancreas, stomach, breast, lymph node and others, in some 
cases it may lead to death (Bernstein et al., 2014, Vernadakis et al., 2013). 
Knight and colleagues confirmed that cells expressing MCPyV sT increased 
their motility and migration (Knight et al., 2015). Expression levels of proteins 
related to microtubule assembly were increased in the presence of MCPyV 
sT in contrast to non-transfected cells (Knight et al., 2015). Furthermore, by 
using scratch and Transwell migration assays, expression of sT was shown 
to up-regulate cell migration. Stathmin, also named Oncoprotein 18 (Op18), 
is a microtubule-binding protein, which regulates polymerization of the 
microtubule network. Phosphorylation of stathmin leads to a release of 
tubulin and helps microtubule network assembly. MCPyV sT interacts with 
stathmin and reduces its phosphorylation (Griffith et al., 2013). The effects of 
the PP2A Aα, PP2A Aβ and PP4C phosphatases on stathmin 
phosphorylation in presence of MCPyV sT were analysed and showed that 
PP2A Aα effects the stabilization of microtubules in control as well as the 
MCPyV sT transfected cells. In addition the mutant sT-R7A, which stops 
binding of PP2A Aα (Shuda et al., 2011, Griffith et al., 2013) conserved its 
ability to destabilize microtubules. The other phosphatases PP4C and PP2A 
Aβ caused stabilization in infected cells and the mutant sT- Δ95-111, which 
diminished the interaction with PP4C and PP2A Aβ (Griffith et al., 2013), 
caused microtubule stabilization. These data suggest that MCPyV sT recruits 
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PP4C and/or PP2A Aβ to mediate stathmin dephosphorylation and this may 
affect microtubule assembly and allow increased cell migration. This 
suggests a possible molecular mechanism for the highly metastatic 
phenotype associated with MCC (Knight et al., 2015).     An observation on 
microtubule stabilization during viral infection suggested that viruses recruit 
their proteins to cause microtubule instability to help dissemination. For 
example, the core protein of Hepatitis C Virus (HCV) plays an essential role 
in viral entry by its interaction with microtubules and this leads to microtubule 
polymerization (Roohvand et al., 2009).  
 
1.6 MCPyV Avoidance of the Immune System 
The vital role played by the immune system is highlighted by the increasing 
amount of evidence pointing to the fact that the risk of MCC development is 
five to fifty times greater among individuals with dysfunctional T cells (Bhatia 
et al., 2011, Iyer et al., 2011, Afanasiev et al., 2013). Nevertheless, MCPyV-
positive MCC may also occur in individuals whose immune system has not 
been compromised, implying that the immune system is not completely 
effective in targeting the virus and infected cells. As in the case of other 
chronic viral diseases, the immune response can be evaded by MCPyV by 
impairing the innate defence mechanism.  
To detect viral dsDNA in epithelial and MCC cells, the immune system relies 
on the Toll-like receptor 9 (TLR9) which is suppressed by the MCPyV 
oncoproteins LT and sT (Shahzad et al., 2013). TLR9 is one of the primary 
sensors that detect a wide variety of microbial components and elicits innate 
immune responses through activation of NF-kB, which regulates the 
expression of inflammatory cytokine genes. MCPyV LT mediates 
suppression of TLR9 through reduction in the mRNA levels of the 
transcription factor CCAAT-enhancer-binding protein (C/EBPβ) which 
interacts with the CCAAT motif that is contained in a number of gene 
promoters (Kawai and Akira, 2007). The involvement of sT alongside LT in 
TLR9 suppression is suggested by the fact that the mRNA levels of TLR9 
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rise slightly when sT is inhibited (Shahzad et al., 2013). Aside from MCPyV 
LT, BKPyV LT can also suppress TLR9, whereas the LTs of JCPyV, KIPyV 
and WUPyV cannot (Koralnik et al., 2001, Shahzad et al., 2013).  
It is worth noting that C/EBPβ is actively involved in the regulation of IL-6, IL-
8 and tumour necrosis factor alpha (TNF-α) cytokine transcription (Li et al., 
2007a). Furthermore, through down-regulation of cyclin-dependent kinase 
(CDK2 and CDK4) and E2F complex activity (Johnson, 2005), C/EBPβ also 
has an inhibitory effect on tumours. Hence, the immune response may be 
disrupted and cell proliferation promoted through C/EBPβ inhibition mediated 
by MCPyV LT (Shahzad et al., 2013). A comparative analysis of MCPyV-
positive and MCPyV-negative tumours revealed that the former had a greater 
count of infiltrating CD8+ T-cells (Lauttia et al., 2014).  
The NF-B signalling pathway has also highlighted the impact of MCPyV on 
the immune response. MCPyV has been shown to downregulate NF-B 
which is involved in regulating several proinflammatory and antiviral 
response genes. By interacting with cellular proteins, including NEMO and 
cellular protein phosphatases, MCPyV sT induced down-regulation of the 
NF-B pathway. This was identified by detection of a reduced level of p50 
and RelA in the nucleus of MCC when stimulated with TNF-α in the presence 
of MCPyV sT. In addition, the phosphorylated form of IKKα and IKKβ was 
decreased following transfection of MCPyV sT (Griffiths et al., 2013). The 
importance of MCPyV sT in targetting NF-B is still unclear. Some strategies 
of other viruses may explain the benefits to the virus in targetting the NF-B 
pathway. Some viruses activate NF-B to block apoptosis like HIV, whereas 
other viruses such as adenovirus inhibit the pathway to enhance viral 
replication (Zhang et al., 2012, Heimberg et al., 2001). 
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1.7 Modification of the NF-B pathway by MCPyV sT. 
1.7.1 Composition of NF-B. 
A range of biological processes, including inflammatory reaction, 
proliferation, cell apoptosis, embryonic and tissue development, as well as 
tumour development, are dependent on the transcription factor nuclear 
factor-kappa B (NF-B) (Ghosh et al., 1995). However, of all of these 
processes, the role of NF-B in regulating the innate immune response is 
best understood. It was over twenty years ago that this transcription factor 
was discovered in the laboratory of David Baltimore and was observed to 
have inducible activity with selective attachment to particular DNA motifs of 
around 10 bp called κB sites, whilst at the same time it was capable of 
regulating target gene transcription (Gilmore and Temin, 1986, Baeuerle and 
Baltimore, 1988).  
1.7.1.1 NF-B dimers  
The NF-B family is comprised of five polypeptide sub-units, which are 
classified in two sub-families (NF-B and Rel). NF-B can be composed of 
NF-B1 (p105/p50) and NF-B2 (p100/p52), encoded by NFKB1 and NFKB2 
genes respectively. The Rel subfamily contains RelA (also known as p65), 
RelB and c-Rel are encoded by RELA, RELB and REL respectively (Ghosh 
et al., 1998). 
By interacting with one another, these factors create homo- and 
heterodimeric complexes with distinct transcriptional activity. Up to fifteen 
distinct dimers can be produced by the members of the NF-B protein family 
by associating in different ways. Nonetheless, no validation has been 
extended so far regarding the physiological existence and relevance for 
every potential dimeric complex (Ryseck et al., 1992). Among all the Rel 
dimers, the one present in nearly every type of cell is the p50/p65 
heterodimer. Characterisations have also been made of the dimeric 
complexes p65/p65, p65/c-Rel, p65/p52, c-Rel/c-Rel, p52/c-Rel, p50/c-Rel, 
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p50/p50, RelB/p50, and RelB/p52, of which some occur solely in certain cell 
subsets (Dobrzanski et al., 1994) . 
Furthermore, they have the same conserved amino-terminal Rel homology 
domain (RHD) of 300 amino acids (Müller et al., 1995). A number of 
processes require RHD sequences, including dimerization, DNA binding, 
interaction with nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitors (IBs), and nuclear translocation (Figure 1.7).  
Specific DNA attachment to the NF-B consensus sequence within 
regulatory elements of NF-B target genes (5′ GGGPuNNPyPyCC-3′) is 
mediated by the amino-terminal part of RHD, while dimerization and 
interaction with IBs are underpinned by the carboxy-terminal part, as 
observed from crystal structures of p50 homo- and p50/p65 heterodimers 
attached to DNA (Ghosh et al., 1995). Several copies of an approximate 33 
amino acid sequence, known as ankyrin repeats, are present in every known 
IBs and are responsible for facilitating the interaction between IBs and NF-
B dimers. The nuclear translocation of NF-B is avoided through the 
interplay between the ankyrin repeats and a RHD region of NF-B proteins 
(Kawai and Akira, 2007, Müller et al., 1995). 
 
1.7.1.2 IB composition 
The inhibitor of NF-B (IB) was discovered in nine protein forms composed 
of IBα, IBβ, IBε, IBz, IBh, Bcl-3, IBNS in addition to the  homolog 
p100 and p105 proteins (Verma et al., 1995). Three of these polypeptides, 
IB, IBβ and IBε are associated with NF-B dimers and contain both 
RelA and c-Rel subunit or at least one of them with other subunit, this 
complex leads to the prevention translocation of NF-B to the nucleus (Anest 
et al., 2004).  
The three classic isoforms IB, IBβ and IBε, contain between 5-8 copies 
of an ankyrin repeat (Basith et al., 2013, Sachdev et al., 1998). It composed 
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of three main regions, the N-terminal region, where ubiquitination and 
inducible phosphorylation happens; the Ankyrin repeat domain (ARD) which   
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Figure 1.7 
Schematic illustrates domain of the mammalian NF-B family subunits. The five 
subunits are RelA (1-580bp), RelB (1-551bp), c-Rel (1-620bp), p100/p25 (1-415 bp) 
and p105/p50 (1-431bp). All subunits have the conserved Rel homology domain 
(RHD) consist of two folded domains referred to as the N-terminus domain (NTD, 
Red) and dimerization domain (DD, Green). A nuclear localization signal (NLS, light 
blue) lies at the extreme C-terminus of the RHD. A transcription activation domain 
(TAD, Orange) is located in the C-terminus. The p100 (p52) and p105 (p50) 
contains a glycine-rich region (GRR, Dark Blue) in addition to RHD. The C-terminus 
of p52 and p50 contain unique seven repeat sequences called Ankyrin repeat 
domain (ARD, Brown). 
 
 
responsible for NF-B binding, and an acid-based C-terminus sequence 
which is essential for basal degradation of unbound IB (Whiteside and 
Israël, 1997). IB in unstimulated cells freely shuttles between the 
cytoplasm and nucleus. However, the predominant migration in most cells is 
the nuclear export of IB, leading to its build up in the cytoplasm (Rao et al., 
2010). During stimulation by bacterial lipopolysaccharide, oxidants, phorbol 
esters, proinflammatory cytokines, UV light and viral infection, IBα is 
induced to be phosphorylated at the N-terminus of serine residues (S 32) 
and (S36) by IKKβ leading to IBα degradation which enables the free NF-
B dimer to translocate to the nucleus and activate B-dependent gene 
expression (Xu et al., 2011, Tsuchiya et al., 2010).  
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1.7.1.3 IKK Complex Structure 
1.7.1.3.1 IKK Kinases 
The NF-B cascade is centred on the IKK kinase complex, which consists of 
two IκB kinases, namely, IKKα and IKKβ, and a regulatory subunit, the NF-
B essential modulator NEMO (Mercurio et al., 1997, Yamaoka et al., 1998, 
Courtois et al., 2001). Activating signal and cell type determine two distinct 
NF-B pathways,  the canonical pathway, which is based on IKKβ and 
NEMO, and the non-canonical pathway, which is based predominantly on 
IKKα (Senftleben et al., 2001).   
The discovery of the kinases phosphorylating IB inhibitors was made when 
a cytoplasmic complex of high molecular weight that migrated around 700-
900 kDa and included two interconnected catalytic subunits (IKKα and IKKβ) 
was subjected to biochemical purification (Mercurio et al., 1997). These two 
subunits displayed a 52% sequence identity and were structurally similar, 
comprising a kinase domain (KD) at the N-terminus between residues 15 and 
301 which contains the catalytic function of protein kinases and leucine 
zipper (LZ) whose role is to allow homo- or heterodimerization of the 
kinases is present in residues 455-483 and 458-486 of IKKα and IKKβ 
respectively. They also share helix-loop-helix (HLH) domains that function in 
modulating IKK kinase activity and lie in residues 599-638 and 603-642 of 
IKKα and IKKβ respectively. Both IKKα and IKKβ contain a C-terminal NEMO 
binding domain (NBD) (DiDonato et al., 1997). IKKβ appears to have an 
additional ubiquitin-like domain (ULD) following the KD, this is implicated in 
proteasomal degradation and is not predicted in the corresponding region of 
IKKα (Kwak et al., 2000, May et al., 2004).  
A small peptide sequence at the carboxy terminus of both kinases has been 
established to be the interaction domain between NEMO and the kinase 
subunits. It is worth noting that the interaction between IKK and NEMO is 
suppressed by a deletion of an 11-amino-acid peptide (aa 735-745) at the 
carboxy terminus of IKKβ, thus serving as an efficient and specialised NF-B 
inhibitor (Figure 1.8) (May et al., 2000). 
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Figure 1.8 Domain organization schematic of the mammalian catalytic subunits of 
the IKK complex, IKKα (1-745bp) and IKKβ (1-756bp). Both subunits share four 
main domains, KD (Grey) refers to the kinase domain in N-terminus; LZ refers to 
leucine zipper (Green) which serves in dimerization; helix-loop-helix (HLH, Yellow) 
domain in C-terminal can regulate kinase activity of IKK. At the extreme C-terminus 
NEMO binding domains (NBD, Red) which are responsible for interaction with 
NEMO to form the IKK complex. IKKβ includes a unique motif required for 
ubiquitination called the ubiquitin-like domain (ULD, Light Blue) which sequenced 
between residues 311-388.  
 
 
1.7.1.3.2 NF-B essential modulator (NEMO, IKKγ) 
The NF-B pathway is regulated by the NF-B essential modulator NEMO, 
otherwise known as IKKγ, IKKAP1, and FIP3, since signalling as a reaction 
to extracellular stimuli is suppressed by genetic inactivation (Makris et al., 
2000). A 23 kb gene, NEMO contains ten exons and encoded a protein of 
419 amino acids with a molecular mass of 48 kDa. It represents the 
regulatory element of the IKK complex (Majumdar and Aggarwal, 2001). 
NEMO has a pivotal role in regulating the upstream receptor signalling 
complexes with the catalytic IKKs. The importance of NEMO was shown by 
Rudolph and colleagues when they generated NEMO-deficient mouse 
embryos. Mouse embryonic fibroblasts deficient in NEMO lacked NF-B 
activity and the knockout mice died due to high rates of hepatic apoptosis 
after stimulation with TNFα, IL-1, LPS, and the dsRNA mimic poly IC (Bonizzi 
and Karin, 2004, Rudolph et al., 2000).  
Structurally human NEMO protein is arranged in five domains; helix 1 (HLX1. 
αH1), coiled-coil 1 (CC1), helix 2 (HLX2, αH2) in N termin and a coiled-coil 2 
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(CC2), a leucine zipper (LZ) and a zinc finger (ZF) in its C terminal (Figure 
1.9) (May et al., 2002). 
NEMO is composed of two α helical regions, αH1 and αH2, positioned before 
and after CC1. The region of interaction with IKK lies between amino acids 
44-111 and is essential for IKK complex assembly, since mutations in this 
region of NEMO fail to form active IKK complexes (Ghosh and Karin, 2002, 
Marienfeld et al., 2006, Rushe et al., 2008, Cote et al., 2013).  
The C-terminus of NEMO comprises several domains critical for correct 
functioning of the IKK complex, including a second coiled coil domain (CC2 
residues 253–285), a leucine zipper (LZ 300–343), a Zinc Finger domain (ZF 
394–419), and a sequence called the NEMO Optineurin ABIN (NOA/UBAN) 
domain, found within residues 298–330 (Tegethoff et al., 2003, Huang et al., 
2002, Emmerich et al., 2013). This C-terminal region of NEMO is necessary 
for recognition of various types of ubiquitin molecules and essential for 
successful activation of the NF-B pathway in response to upstream 
signalling events. The UBAN domain and ZF have a high preference for 
binding to linear ubiquitin (M1-Ub) (Emmerich et al., 2013) and lysine-63 
(K63) linked ubiquitin chains (Rahighi et al., 2009, Hadian et al., 2011, 
Grubisha et al., 2010, Dynek et al., 2010, Kensche et al., 2012, Emmerich et 
al., 2013, Laplantine et al., 2009).  
Grubisha and colleagues observed that the UBAN domain displays more 
than 100 fold higher affinity for M1-Ub versus K63-Ub (Lo et al., 2009, 
Grubisha et al., 2010). The CC2-LZ region possesses ubiquitin-binding 
domain (UBD) that is believed to be the site of trimerisation or 
tetramerisation and responsible for interacting with ubiquitin sites (Grubisha 
et al., 2010).  
Several studies confirmed that the CC2-LZ domain of NEMO is responsible 
for oligomerisation and stabilization of NEMO. Mutant substitutions within this 
region obliterated NF-B activation due to disruption of CC2-LZ 
oligomerisation (Iwai and Tokunaga, 2009, Tokunaga et al., 2009, Cordier et 
al., 2008, Fusco et al., 2008). 
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Very recently, Vincendeau and colleagues identified that the NEMO-UBAN 
domain is critical for IKK activation in response to TNFα, but not IL-1β 
stimulation. They used chemical shift perturbations and Nuclear Magnetic 
Resonance (NMR) techniques to determine specific amino acids in the CC2-
LZ region required for NEMO to bind M1-Ub. Each of V300, A303, Q304, 
D311, E324 and E320 is required for the interaction with M1-Ub and 
mutation of these residues abolished NF-B signalling (Vincendeau et al., 
2016). 
The inclusion of the ubiquitin binding site of NEMO within the LZ region was 
indicated by the surface conservation pattern. The LZ region is identical with 
the UBAN domain possessed by NEMO, Optineurin (OPTN), and A20 
binding inhibitor of NF-B (ABIN) (Wagner et al., 2008). 
Table 1.2 Some proteins involved in NF-B pathway and their targets and     
                roles in the pathway. 
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Interestingly, all of these proteins function within the NF-B pathway, 
although their roles are likely to be antagonistic to inhibit the pathway. For 
example, NRP (NEMO related protein) or Optineurin is able to form a 
complex with the IKK-related kinase TBK1 and the ubiquitin ligase TRAF3. 
By this complex, Optineurin contests with NEMO in its interaction with RIP1 
and inhibits NF-B signalling responses to IFNβ stimulation (Mankouri et al., 
2010). Another way of blocking NF-B activation comes from interaction of 
ABIN1 with either NEMO or the deubiquitinating enzyme A20 to 
deubiquitinate NEMO and inhibit formation of the IKK complex (Mauro et al., 
2006). The loss of interaction between NEMO and A20 leads to prolonged 
accumulation of K63-ubiquitinated RIP within the TNFR1 signalling complex. 
Recruitment of A20 to the C-terminal domain of NEMO represents a 
mechanism that limits NF-B activation by NEMO, and its absence results in 
an autoinflammatory disease (Zilberman-Rudenko et al., 2016).  
It has very recently been shown that a group of males who develop 
autoinflammatory disease harbour mutations leading to truncation of the 
NEMO C-terminus which impaired its interaction with A20 (Zilberman-
Rudenko et al., 2016), This protein has been shown to inhibit NF-B 
activation as well as TNF-mediated apoptosis (Shembade et al., 2010).  
Notably, NF-B activation also disrupted by naturally occurring point 
mutations in the UBAN domain of NEMO, leading to various severe X-linked 
immunodeficiency diseases in humans including ectodermal dysplasia 
(Mancini et al., 2008). Human X-linked recessive anhidrotic ectodermal 
dysplasia with immunodeficiency (XR-EDA-ID) was determined to stem from 
a mutation in Aspartic acid residue (D311) of NEMO to Asparagine ( N ) or 
Glycine (G). The genetic disorder Incontinentia Pigmenti was discovered to 
develop when Glutaimc acid (E315) in NEMO was mutated to G315. 
Mutation occure in the ZF domain and adjacent proline-rich sequence of 
NEMO was associated with different inflammatory diseases like severe colitis 
and dermatitis (Zilberman-Rudenko et al., 2016). Hypomorphic mutations of 
NEMO also have been identified in up to one hundred male patients, while 
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αH1 αH2 CC1 CC2 NUB LZ ZF 
1 63 194   250   284   315   336   388   412 
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NF-B activation was found to be suppressed by around 43 distinct 
mutations (Chang et al., 2008, Filipe-Santos et al., 2006, Fusco et al., 2008).  
 
 
 
 
 
 
 
Figure 1.9 Schematic 
representation of different NEMO domain. At the N-
terminus,  there are the alpha helical region 1 (αH1, Gray) and coiled-coil 1 (CC1, 
Yellow). Part of these two domains contain the region for binding IKKα and β. 
Another alpha helical region (αH2, Gray) lies after CC1. The C-terminal another 
coiled coil called CC2 (Orange) is present and forms Ubiquitin binding in ABIN and 
NEMO region (UBAN) in cooperation with with the next two domains, NEMO 
ubiquitin binding (NUB, Purple) and Leucin Zipper (LZ, Light Blue). The UBAN 
domain is essential for ubiquitin linking. NEMO Optineurin ABIN (NOA) also 
identified within UBAN domain and in addition to its role as a binding domain for 
NEMO, OPTN and ABIN, it is important for binding linear ubiquitin chains (M1) and 
K63 polyubiquitination (Red circles). At the extreme C-terminus, there is a zinc 
finger (ZF, Blue) which may also help in binding with K63 ubiquitin chains. 
 
1.7.2 The Canonical NF-B Pathway 
NF-B affects most aspects of cellular physiology such as immunity, 
inflammation, apoptosis, cell survival, growth, and proliferation. Two 
signaling pathways known as the canonical (classical) and non-canonical 
(alternative) pathways are able to promote the activation of NF-B (Gilmore, 
2006, Scheidereit, 2006). This study concentrates on the role of MCPyV sT 
on the canonical pathway. The activity of NF-B is directly controlled by the 
IB protein in the cytoplasm of the cell through the formation of IB:NF-B 
complexes. A series of positive and negative regulatory elements are 
involved in regulation of the pathway starting from cell stimulation to 
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transcription of target genes (Whiteside and Isräel 1997). A wide array of 
stimuli including pro-inflammatory cytokines such as antigen receptors, IL-1, 
TNFα as well as pattern recognition receptors (PRRs), leads to the onset of 
signaling cascades that phosphorylate the IKK complex (Bonizzi and Karin, 
2004).  
 
The stimulation regulated by TNF receptor-associated factor 6 (TRAF6) is 
sufficient to activate the TRAF6-regulated IKK activator, TAK. A complex of 
TRAF6 and TAK protein kinase initiates phosphorylation of IKK and mediates 
proteasomal degradation of IB, enabling the active the NF-κB transcription 
factor subunits to translocate to the nucleus and induce target gene 
expression.  
As a result of IB phosphorylation by the IKK complex, IB is destroyed by 
activation of the E3 ubiquitin ligase of beta transducin repeat containing 
protein (SCFβTrCP), which mediates IB degradation by the proteasome. This 
allows the free NF-B to accumulate in the nucleus, where it binds to 
particular B DNA sequences. These sequences, which are located in 
promoter regions, are responsible for activating transcription of various 
genes implicated in cell adhesion, cell survival, growth regulation, and 
immune and inflammatory responses. It could also lead to the expression of 
the IBα genes, which function as a negative feedback loop to sequester NF-
B subunits and terminate signaling unless a persistent activation signal is 
present (Ohshima and Ichikawa, 2014, Hoffmann et al., 2006, Huang et al., 
2000). 
Zhang and colleagues demonstrated the importance of TAK in 
phosphorylation of S176 and S177 in IKKα and IKKβ respectively, which are 
also necessary for formation of M1 ubiquitin chains and mediate their 
interaction with NEMO (Zhang et al., 2014). 
Ubiquitin polypeptides are involved in a number of aspects of the NF-B 
pathway. Ubiquitin chain formation requires three enzymes, ubiquitin 
activating enzyme E1, an ubiquitin conjugating enzyme E2 and an ubiquitin 
ligase. The complex catalyses formation of single or poly ubiquitin chains 
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(Lewis et al., 2015). The most known ubiquitin chains that are involved in the 
NF-B pathway are M1-Ub which cause protein stability for NEMO and K63-
Ub are required for activation of a number of enzymes in the NF-B pathway 
and also prevent degradation by proteasomes and K48-linked ubiquitin 
chains (K48-Ub) which are responsible for mediating protein degradation by 
proteasomes (Figure 1.10) (Iwai et al., 2014, Nathan et al., 2013, Walczak et 
al., 2012). Another adapter protein involved in this pathway called receptor-
interacting protein 1 (RIP1), a kinase protein which has one site of 
ubiquitination at K377 and by this it bind K63-linked ubiquitination. By linked 
the polyubiquitination chain with NEMO, RIP1 induces activation of IKK 
(Yang et al., 2011). Ea and colleagues found that ubiquitinated RIP1 is 
associated with NEMO during TNF-α stimulation and mutation RIP1-K377R 
which prevent RIP1 polyubiquitination leads to abolish the interaction with 
NEMO and as a result impair IKK activation  (Ea et al., 2006).  
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Figure 1.10 NF-B pathway involves signalling by proinflammatory cytokines 
(Orange) or TLRs and LPS (Yellow). The pathway is activated when these 
stimulators associated with their cellular receptor on the cell membrane. This will 
activate TRAF are family proteins (Dark Blue) or RIPs (Pink) and this with allow the 
K63 ubiquitin link chain (circle Red) to NEMO (Purple) which also bind linear 
ubiquitin (M1, light Orange). TAB (Green) and TAK1 (Pink) phosphorylate IKK 
complex and mediate IκB (Black Red) phosphorylation which bind K48 ubiquitin 
chain (Circle Orange) and is subsequently degraded by 26S proteasome allow NF-
B (Blue) to be translocated to the nucleus, binding to κB DNA sites and activating 
gene transcription. 
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1.8 Role of Protein Phosphatases in cell signaling 
One major element of the intracellular signaling system is reversible protein 
serine/threonine phosphorylation. The findings of protein phosphatase 
studies have confirmed that cellular processes entailing protein 
phosphorylation depend as much on these enzymes for regulation as they do 
on kinases (Mumby and Walter, 1993). Protein kinases and phosphatases 
serve as essential checkpoint regulators and switches as they both 
contribute to the regulation of phosphorylation and de-phosphorylation of 
proteins in accordance with the physiological requirements of cells. The 
family of protein tyrosine phosphatases (PTP) encompasses over two thirds 
of the 150 members of the protein phosphatase superfamily and is 
responsible for the de-phosphorylation of phosphotyrosine and occasionally 
phosphoserine and phosphothreonine. Of the rest of the enzymes, most are 
associated exclusively with either phosphorylated serine or threonine 
residues, forming two distinct groups (Cohen, 2002, Moorhead et al., 2009), 
namely, phosphoprotein phosphatases (PPP) and protein phosphatases 
dependent on Mg2+ or Mn2+ (PPM). Protein phosphatase type 2C (PP2C) is 
the major representative of PPM, while PPP includes five subfamilies, among 
which are the PPP1 subfamily, comprising PP1, and the PP2/4/6 subfamily 
including PP2A, PP4 and PP6 (Cohen, 1997). 
 
1.8.1 Protein Phosphatase 2 
In their basic form, protein phosphatase 2 (PP2A) holoenzymes are mainly 
heterotrimers characterised by the correlation between a core dimer 
(PP2AD), consisting of a structural A subunit (PR65) and a catalytic C 
subunit (PP2AC), and a third variably regulatory B sub-unit (Kremmer et al., 
1997).  
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A number of different genes encode these sub-units and they are combined 
to form multiple heterotrimers (A-C-B) or heterodimers (A-C) present in 
various isoforms in cells (Mayer-Jaekel and Hemmings, 1994, Cohen, 1997). 
PP2AC is expressed in the majority of tissues, especially in the heart and the 
brain. To keep it constant, the level of PP2AC protein expression (37kDa) is 
subjected to translational regulation (Nishikawa et al., 1994). PP2C can 
occur in two isoforms, namely, Cα and Cβ, which have a sequence that is 
97% identical and are each made up of 309 amino acids. Furthermore, the 
plasma membrane is the main site of Cα expression, while the cytoplasm 
and nucleus are the locations of Cβ expression (Khew-Goodall and 
Hemmings, 1988). The PP2C amino acid sequence in humans and yeast is 
86% similar, and it is also 50% and 40% similar to the sequences in PP1 and 
PP2B, respectively (Evans et al., 1999). 
As in the case of PP2AC, two different genes, PPP2R1A and PPP2R1B, 
encode the PP2A scaffold sub-unit, giving rise to the isoforms Aα and Aβ 
which have broad expression, are identical in a proportion of 86%, and are 
fragmented within the cytoplasm (Price and Mumby, 2000, Hendrix et al., 
1993). However, of the two, PP2A Aα is the dominant sub-unit, representing 
around 90% of the PP2A and 0.1% of the overall cell protein.  
The rest of the 10% of PP2A is made up by Aβ, determining preferential 
interaction with catalytic subunit (C) and regulatory sub-units (B). The 
scaffold unit stands out from other sub-units in terms of structure. The 
Huntington/elongation/A sub-unit/TOR (HEAT) sequence consists of 15 
tandem repeats with 39 amino acids each making up the PP2A A (Zhou et 
al., 2003).  
Two α-helices are presented by every repeat, linked by inter- and intra-
repeat loops. The catalytic and regulatory sub-units respectively attach to 11-
15 and 1-10 repeats of the HEAT sequence. The catalytic subunit is 
associated with a scaffold unit that creates a base by folding and also display 
a structure in the shape of a horseshoe. The recruitment of the regulatory 
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sub-unit as well as other PP2A substrates is facilitated by such flexible 
folding (Cho and Xu, 2007). 
 
 
1.8.1.1 PP2A Function in Cellular Processes 
Although a considerable degree of ambiguity surrounds PP2A function and 
substrate, it has been confirmed to be involved in the regulation of different 
biological processes, including DNA replication, transcription and translation, 
signal transduction, cell proliferation, cytoskeleton dynamics, cell motility and 
apoptosis, as well as cell transformation and cancer (Sablina and Hahn, 
2007). In relation to this regulatory function, PP2A Aα contributes to the 
regulation of a number of pathways, including phosphatidylinositol 3-kinase 
(PI3K) and the AKT pathway (Sablina and Hahn, 2007). Studies have 
reported tumour suppressor p53 de-phosphorylation by PP2A Aα at Thr-55, 
as a result of which p53 and Cdk inhibitor p21 were activated while cell 
proliferation was suppressed (Li et al., 2007b). Additionally, PP2A Aα also 
dephosphorylates the c-Myc oncogene and CDC25c, inactivating c-Myc and 
hindering progression of the cell cycle, respectively (Arnold and Sears, 2006, 
Forester et al., 2007). What is more, PP2A Aα targets the M-type potassium 
channel and therefore contributes to the regulation of Glycogen synthase 
kinase-3β (Kapfhamer et al., 2010). Such research findings hint at the fact 
that PP2A links the PP2A AC core to the substrate proteins participating in 
cell development and proliferation, and it is from this that PP2A derives its 
tumour-inhibitory function. The observed displacement of the B sub-unit site 
of PP2A by certain viral oncoproteins validates this perspective. 
Furthermore, a number of cancers have been associated with PP2A 
mutations, such as lung carcinoma (E64D), breast carcinoma (E64G and 
Δ171–589), malignant melanoma (R418W), and ovarian carcinoma (R182W, 
R183W and R183G) (Ruediger et al., 2001, Ruediger et al., 2011). These 
mutations work together with LT, hTERT and H-RAS to transform healthy 
cells into transformed ones by inhibiting the expression of the PP2A B56γ 
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regulatory B sub-unit or partly exhausting the structural Aα sub-unit (Chen et 
al., 2004). 
RalA inactivation and suppression of its transforming function result from its 
de-phosphorylation at Ser183 and Ser194 undertaken by complexes that 
contain PP2A Aβ. Hence, through regulation of RalA function, PP2A Aβ 
converts immortalised human cells and therefore can be considered to be a 
gene that inhibits tumorigenesis. This is confirmed by the fact that cells 
where PP2A Aβ has been knocked down are not only cancerous in nature 
but also demonstrate activated RalA (Sablina and Hahn, 2007). Colon, neck 
and breast cancers are usually associated with Aβ inactivating mutations 
(Wang et al., 1998). Although various human cancers, including colon (8-
15%), lung (15%), breast (13%), and tumour cell lines (6%), manifest 
structural PP2A Aβ subunit mutations (e.g. point mutations, deletions, 
frameshifts, and splicing abnormalities) it is still unclear what functional 
implications these mutations have on cell transformation. Furthermore, 16 
out of 32 cancer cell lines extracted from human lung, colon, breast and 
cervical carcinomas also exhibited PP2A Aβ subunit expression, albeit 
decreased (Ruediger et al., 2001, Calin et al., 2000, Zhou et al., 2003). 
Research revealed that these mutations cannot bind to B and/or C subunits 
in vitro. Aside from mutations, the localisation of the PP2A Aβ at 11q23 is 
also worth noting, as human cancers usually exhibit deletion of this 
chromosomal region (Baysal et al., 2001).  
 
8.1.2 The Correlation between MCPyV sT and PP2A 
Cellular pathway deregulation via phosphatase targeting is the aim of many 
viruses and, to this end, they have devised complex strategies. For instance, 
PP2A is targeted by the Adenovirus and by the hepatitis C virus (HCV) to 
respectively trigger cell death and to deregulate the extracellular signal-
regulated kinase (ERK) pathway (Kleinberger and Shenk, 1993, 
Georgopoulou et al., 2006), while the human papillomavirus 16 (HPV 16) 
encoded E7 binds both catalytic and structural units of PP2A with the 
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purpose of preventing AKT from being dephosphorylated (Pim et al., 2005). 
Furthermore, research demonstrated that PP2A interacts with SV40 and that 
the virus gains control of different signalling pathways, such as PI3K-AKT-
mTOR, the MAPK pathway, and the stress-activated protein kinase (SAPK) 
pathway, through the mediation of SV40 sT (Buchkovich et al., 2008, Sontag 
et al., 1993). 
The discrepancies between the two A isoforms are detected by small DNA 
tumour viruses. Both PP2A Aα and Aβ are bound by MCPyV sT and murine 
Py sT, whereas PP2A Aα is bound by SV40 sT and monkey polyomavirus. In 
contrast, PP2A Aβ binds weakly with SV40 sT (Pallas et al., 1990, Hwang et 
al., 2013). The two isoforms of PP2A C subunit (Cα and Cβ) showed 
interaction with sT of both MCPyV and SV40 (Griffiths et al., 2013, Hwang et 
al., 2013, Kwun et al., 2015). Mutagenesis studies based on alanine 
substitution found three amino acids in MCPyV sT (R7, L142 and K134) are 
required for the interaction with PP2A Aα (Kwun et al., 2015). In contrast, the 
residues R7, R21 and P132 was shown to be required for SV40 to bind 
PP2A (Cho et al., 2007).  
The MCPyV sT mutants that stop binding to PP2A conserved their ability to 
hyperphosphorylate 4E-BP1 through their binding to Fbw7. This confirms 
that sT-mediated 4E-BP1 phosphorylation does not require PP2A 
recruitment. In addition, both SV40 and MCPyV sT block the assembly of 
B56α subunit to A sub-unit of PP2A (Kwun et al., 2015).  
Moreover, the interaction between MCPyV sT and PP2A Aα was not required 
to augment cell mobility and migration. Rather, an internal deletion mutant 
(∆95-111) which abrogates the interaction with PP2A Aβ and additional 
phosphatases like PP4C prevented the increased migration (Knight et al., 
2015). 
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1.8.2 Protein Phosphatase 4 
A widespread PP2A-related protein serine/threonine phosphatase belonging 
to the PPP family, protein phosphatase 4 (PPP4) or protein phosphatase X 
has roles in different cellular processes. PP4 is also a holoenzyme as PP2A 
and therefore is made up of structural (A), regulatory (B) and catalytic (C) 
sub-units (Kloeker and Wadzinski, 1999). Determined on the basis of 
multiple cDNAs, mammalian PP4C has an amino acid sequence that is 65% 
identical to that of PP2A Cα and PP2A Cβ isoforms. It was isolated from 
cytoplasmic and nucleus with molecular mass between 450-600 kDa. A 
number of regulatory subunits, including PP4R1, PP4R2, PP4R3α, PP4R3β, 
and PP4R4 were detected (Chowdhury et al., 2008, Gingras et al., 2005, 
Chen et al., 2008, Helps et al., 1998) 
PP4C works in association with these regulatory subunits to form a complex. 
PP4C-PP4R1 is present primarily in the cytoplasm while PP4C-PP4R2 can 
be found in the centrosome, possessing a molecular mass of 105 kDa and 
55 kDa, respectively. The regulatory sub-units possess a negative regulatory 
effect on PP4C. They prevent catalytic activity of PP4C or effect on substrate 
recognition (Chen et al., 2008). 
It is still not completely clear what the biological role of PP4 is, but there is 
some evidence that it is related to centrosome/spindle pole bodies and the 
processes of nucleation, development and/or stabilisation of microtubules 
which, through the formation of the mitotic spindle, are essential to all mitotic 
processes as well as to a range of subcellular activities (Helps et al., 1998, 
Kirschner and Mitchison, 1986). 
Different substrates were shown to have PP4C catalytic activity. In addition 
to initiating the de-phosphorylation of various proteins in a number of 
pathways, this catalytic activity also takes part in microtubule organisation of 
the cytoskeleton by dephosphorylating nuclear distribution element-like 1 
(NDEL1), which controls microtubule filament, and hence regulating cyclin-
dependent kinase 1 (Cdk1) in the interphase (Toyo-oka et al., 2008). 
Furthermore, it has been demonstrated that PP4C is involved in regulating 
57 
 
apoptosis, cell proliferation, and cell mutation rate. When PP4C was 
inhibited, apoptosis was impaired but cell proliferation was improved by 
dephosphorylating a number of important anti-apoptosis proteins, especially 
the astrocytic phosphoprotein (PEA-15) and Bcl-2-associated death promoter 
(Bad) (Mourtada-Maarabouni and Williams, 2008). Regarding T-cell 
signalling, the involvement of PP4C takes the form of control of 
haematopoietic progenitor kinase1 (HPK1) (Zhou et al., 2004). One study 
revealed that insulin signalling and TNF-α stimulated degradation IRS-4 were 
suppressed when PP4C negatively regulated at least one serine residue in 
the insulin receptor substrate (IRS). Moreover, transcriptional regulation and 
cell cycle progression were observed to be modified when PP4C was 
dephosphorylated in histone deacetylase 3 (HDAC3) (Zhang et al., 2005). 
The involvement of PP4C in a prolonged checkpoint arrest in human cells 
following damage to the DNA was confirmed by PP4C dephosphorylation of 
γH2AX (Nakada et al., 2008). 
The findings of recent studies indicate that PP4C may be actively involved in 
the progression of some cancers, such as breast and lung cancer, and 
pancreatic ductal adenocarcinoma, where it has shown elevated expression 
(Wang et al., 2008, Weng et al., 2012). PP4C overexpression causes 
deregulation of the PI3K/AKT-dependent signalling pathway, which has been 
shown to favour tumorigenesis and lung metastasis in vivo. Moreover, the 
correlation of PP4C with distant metastasis is suggested by its high 
expression in pancreatic ductal adenocarcinoma by contrast to non-
cancerous pancreatic tissue (Li et al., 2015b, Weng et al., 2012). Another 
study reported that PP4C was involved in metastasis as well, interacting and 
dephosphorylating the microtubule-associated protein (MAP) Stathmin during 
MCPyV sT expression. Stathmin and acetylated tubulin phosphorylation is 
augmented by the sT mutant which suppresses PP4C. This suggests that 
PP4C participates in microtubule destabilisation triggered by MCPyV sT and 
cell mobility (Knight et al., 2015). 
The importance of PP4C and its regulatory subunit PP4R1 in signalling 
pathway was explained by Tikhonova and Aifantis in T lymphocytes, they 
58 
 
demonstrated that NF-B is negatively regulated by PP4R1 which targets the 
phosphatase activity of PP4C to dephosphorylate and inactivate the IKK 
complex (Tikhonova and Aifantis, 2012). Primary human T lymphocyte 
activation and proliferation were observed to stimulate PP4R1 expression, 
whereas PP4R1 deficiency resulted in sustained and heightened IKK activity, 
T cell hyperactivation, and abnormal NF-B signalling in T cell lymphomas 
dependent on NF-B. As with PP4C, regulation of histone deacetylase 3 
activity and influence of centrosome microtubule development have also 
been attributed to PP4R1 (Tikhonova and Aifantis, 2012, Zhang et al., 2005). 
 
1.9 NF-B as a target for virus immune evasion 
Several viruses utilise their proteins to target the NF-kB pathway to facilitate 
their replication, host cell survival, and evasion of immune responses. A 
range of viruses have evolved mechanisms to activate the NF-kB pathway to 
enhance their replication by preventing apoptosis, whereas other viruses 
inhibit the pathway to trigger apoptosis as a mechanism of virus 
dissemination (Figure 1.11) (Ghosh et al., 1998). A good example of this can 
be seen in human immunodeficiency virus type 1 (HIV-1) that has two NF-B 
binding sites in its long terminal repeat (LTR) that bind to RHR sites in NF-B 
dimers, stimulating the NF-B pathway and as a result increase its 
replication activity. (Nourbakhsh et al., 2001). Furthermore, NF-B is 
augmented due to early-encoded HIV-1 TAT proteins interacting directly with 
IB and p65 and this can prevent apoptosis of the infected cell (Fiume et 
al., 2011).  
A further example is that of the human T-cell leukaemia virus type 1 (HTLV-
1) oncoprotein, TAX. This protein promotes viral replication and NF-B 
activation, enabling cells infected by HTLV-1 to endure, evolve, and multiply. 
TAX exerts its effect by binding to the regulatory NEMO sub-unit, which 
causes continual activation of IKK and IKKβ, the breakdown of IB and 
activation of NF-B pathway (Xiao and Sun, 2000). 
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The Epstein-Barr virus (EBV) is associated with several human cancers and 
is credited as being causal for lymphoproliferative disease. The EBV 
oncoprotein, LMP1 which stimulates the C–terminus activating region 1, 
interacts with signalling proteins, such as TRAFs, TRADD, or RIP. These in 
turn activate the IKK complex, and consequently IB is phosphorylated 
releasing NF-B (Edwards et al., 2015). 
Hepatitis B virus (HBV) interrupts the canonical NF-B pathways by 
encoding a protein polymerase (Pol), which retains NF-B sub-units in the 
cytosol through inhibition of the IKK assembly. This is achieved by 
preventing NEMO from combining with CDC37/Hsp90 which is an essential 
stage in IKK complex assembly (Liu et al., 2014). 
Other viruses succeed by preventing NF-B from leaving the cytosol and 
entering the nucleus. The viruses express proteins that interact with the IKK 
complex to inhibit IB destruction. Some viruses disrupt phosphorylation of 
the IKK complex catalytic sub-units. This method is used by EBNA1 protein 
of the Epstein-Barr virus to inhibit the classical NF-B pathway; it indirectly 
reduces the phosphorylation of IκB by stopping the IKK catalytic sub-units 
from being phosphorylated (Valentine et al., 2010) Hepatitis C virus (HCV) 
provides a further example of viral targeting of the IKK complex. To suppress 
NF-B, HCV core protein targets and prevents IKKβ kinase action (Rocak 
and Linder, 2004). Viruses, such as human cytomegalovirus (CMV) and 
Molluscum Contagiosum virus (MCV) take the approach of impeding NF-B 
activation by interacting with NEMO to interfere with the IKK complex and 
inhibit IB destruction. To inhibit the NF-B pathway, MCV proteins MC159 
and MC160 that bear two tandem death effector domains (DEDs) 
correspondingly interact with NEMO and IKK/β (Nichols and Shisler, 2006, 
Randall et al., 2012, Krause et al., 2014).  
Inhibition of apoptosis is another technique employed by viruses, as shown 
by research into KSHV. The virus can also prompt activation of the NF-B 
pathway by encoding a fragment of transactivator viral FLIP protein (vFLIP). 
The pathway is disrupted when the fragment binds to the CC region that 
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extends between residues 150 to 272, preventing NEMO regulation 
(Bagneris et al., 2008). 
By binding to PP2A, SV40 sT antigen disrupts the enzyme’s function and 
removing inhibitory regulation of the MAPK pathway and promoting cell 
growth (Sontag et al., 1993). The effect of PP2A inhibition is the activation of 
calcium-independent protein kinase Cζ isoform (PKCζ) and PI3K; in part due 
to NF-B activation, these kinases are critical for TNF-induced endothelial 
permeability (Leitges et al., 2001). PKCζ prompted by TNF results in the 
destruction of IκB and the activation of NF-B. Cells that have been 
transfected with SV40 sT have been shown to enhance the expression of 
NF-B-driven genes by 14 times compared to untransfected cells (Sontag et 
al., 1997). 
Further evidence to back the effect of MCPyV on NF-κB comes from the 
MCPyV-positive MCC cell line MKL-1 that exhibited 60% lower IB levels 
compared to MCPyV-negative MCC13 cells. In addition, MCC cells that were 
virus-positive displayed reduced expression of NF-B and related genes 
compared to virus-negative MCC. These studies deliver evidence that 
MCPyV has an unfavourable effect on the NF-B pathway. It also indicates 
that MCPyV sT promotes the survival of the virus by modifying immune 
responses. It is uncertain whether this quality is available to the sT of other 
HPyV; but it is noted that residues 95–111 are not conserved, yet these are 
critical to the interaction between MCPyV sT, NEMO, PP2A and PP4C 
(Griffith et al., 2013). 
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1.10 Aim of study. 
Whilst great strides have been made in our understanding of the oncogenic 
properties of MCPyV sT, we do not yet have a comprehensive knowledge of 
the molecular basis for its functions in cells. Moreover, we lack a detailed 
understanding of the host protein interaction partners required for sT 
mediated immune evasion. The ultimate aim of this PhD study was to 
characterise the molecular mechanisms by which MCPyV sT interacts with 
key components of the innate immune signalling pathway. We concentrated 
on the role of MCPyV sT in the NF-B pathway through its interaction with 
NEMO and phosphatase enzymes that may be involved in pathway 
regulation. For this purpose the specific objectives of this study were: 
 To investigate the molecular basis for the observed interaction with 
the NEMO adaptor protein 
 To define the contribution of host protein phosphatases to the 
observed inhibition of NF-B signalling 
 To investigate if these interactions are unique to MCPyV sT or can be 
found in other human polyomaviruses 
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Chapter 2 Material and Methods 
2.1 Competent Bacterial strain and storage 
Several Escherichia coli strains (New England BioLabs (NEB), USA) were 
used for cloning target genes (Tablet 2.1). Bacteria were cultured in Luria-
Bertani (LB medium, 3% w/v tryptone soya broth, 0.5 w/v yeast extract) and 
incubated for 24h at 37°C with shaking. For long term storage, 1ml of 24h 
bacterial culture was centrifuged 5 min at 3000 g. The supernatant was 
removed and the bacteria were re-suspended in equal volume of LB with 
antibiotic and 87 % glycerol. The bacteria were stored at -80°C until used. 
To use the storage bacteria again, some frozen bacteria was quickly 
scraped by sterile loop refreshed with 5 ml LB broth and incubated at 37ºC 
for 1h then streaked on LB agar plate with appropriate antibiotic. 
 
Table 2.1 Information about type of competent bacteria. 
E. coli strain The experiment Company 
DH5α General DNA manipulation Invitrogen 
BL21 (Rosetta) 
Expression of GST-sT in 
Bacteria 
New England Biolabs 
(NEB) 
NEB 5-alpha 
(C 2987) 
Q5 site directed mutagenesis 
New England Biolabs 
(NEB) 
XL1 Blue 
Internal deletion mutants 
transformation 
New England Biolabs 
(NEB) 
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2.2 Cloning Vectors. 
Circular DNA vectors were used to carry a target DNA fragment (Table 2.2). 
The double stranded DNA of the vector was cut by using compatible 
restriction endonucleases. 
Table 2.2 Information about cloning vectors. 
 
 
 
 
 
 
 
 
Vector Description Used for  
pEGFP-C1 
Eukaryotic expression vector 
for C-terminal Enhanced 
Green Fluorescent Protein 
(EGFP). 
To clone MCPyV sT and 
its truncations mutants, 
other polyomavirus sT.   
pEF4:HA 
Derivative of the pEF4 
eukaryotic expression vector 
with a 5’ single HA tag 
Encoding for HA-tagged 
human PP4R1, full-length 
protein (aa 1-950). 
pcDNA3.1+ 
Mammalian expression vector 
with the CMV promoter 
To clone FLAG-PP4C, 
IKKα, β, FLAG-NEMO. 
pGEX 
pGEX vectors, GST Gene 
Fusion System 
For producing bacterial sT 
protein and GST-NEMO 
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2.3 DNA manipulation and plasmid construction. 
2.3.1 Primers. 
Oligonucleotide primers were purchased in lyophilized form and dissolved in 
ddH2O to a final concentration of 100 pmol/µl and stored at -20ºC. 
Oligonucleotides used in this project are listed in (Table 2.3). 
 
Table 2.3 Primers and their sequences 
Primer DNA sequence (5’ to 3’) 
MCPyV sT full length Forward gcgcgaattctatggatttagtcctaaatagg 
MCPyV sT full length Reverse gcgggatccttagaaaaggtgcagatgc 
R7A MCPyV sT Forward gcgcgaattctatggatttagtcctaaatgcgaaagaaag
agag 
MCPyV-1-162 reverse gcgggatccttaagtaggaggaaatcc 
MCPyV-1-128 reverse gcgggatccttagcgagacaacttacagc 
MCPyV-1-95 reverse gcgggatccttacatataatcctttaaagttcc 
MCPyV-1-64 reverse gcgggatccttactggaatttgctccaaaggg 
MCPyV-1-32 reverse gcgggatccttaagctttcatcagaggg 
Δ95-111 MCPyV-sT Forward gcgcgaattcatgcttaagcaacttagagattct 
Δ95-111 MCPyV-sT Reverse gcgggatcccaaagtggatataat 
Δ111-128 MCPyV-sT forward gcgcgaattccttaagcaacttagagattctaagtgc 
Δ111-128 MCPyV-sT forward gcgggatccgctagattttgcagaggtcctggg 
A96-99 MCPyV-sT forward gcagctaatgctagattttgcagag 
A96-99 MCPyV-sT reverse agctgccatataatcctttaaagttccatattc 
 A100-103MCPyV-sT forward gcagcttgcagagtcctgggtgc 
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 A100-103 MCPyV-sT reverse agcagcatatccactttgcatataatcctttaaagttcc 
 A104-107 MCPyV-sT forward gctgctgggtgcatgcttaagcaac 
 A104-107 MCPyV-sT reverse tgcggcaaatctagcattatatccactttgc 
 A108-111 MCPyV-sT forward gcggctaagcaacttagagattctaag 
 A108-111 MCPyV-sT forward ggccgcaggacctctgcaaatctag 
N100A MCPyV-sT forward aagtggatatgctgctagattttgcagag 
N100A MCPyV-sT reverse tgcatataatcctttaaagttcc 
A101R MCPyV-sT forward tggatataatcgtagattttgcagaggtc 
A101R MCPyV-sT reverse ctttgcatataatcctttaaagttc 
R102A MCPyV-sT forward atataatgctgcattttgcagaggtc 
R102A MCPyV-sT reverse ccactttgcatataatcctttaaag 
F103A MCPyV-sT forward taatgctagagcttgcagaggtcc 
F103A MCPyV-sT reverse tatccactttgcatataatcc 
BKPyV sT forward  gcggaattctatggataaagttcttaacagg 
BKPyV sT reverse gcgggatccttaaagctttagatctctgaaggg 
SV40 sT forward  gcggaattctatggataaagttttaaacagagagg 
SV40 sT reverse gcgggatccttagagctttaaatctctgtaggtagt 
JCPyV MAD1 sT forward  gcggaattctatggacaaagtgctgaatagggagg 
JCPyV MAD1 sT reverse gcgggatccttaaagctttagatccctgtaggg 
 
 
 
67 
 
2.3.2 Polymerase Chain Reaction (PCR)  
Based on the method developed by Mullis and colleagues (Mullis et al., 
1992), PCR was performed for amplification of specific sequences. KOD 
DNA polymerase kit (Merck, UK) was used in a final volume of 50 µl 
containing template vector DNA (100-500 ng), 1 Unit of KOD DNA 
polymerase, 1 x KOD DNA polymerase buffer, 200 µM of deoxynucleotide 
triphosphates (dNTP), 2.5 nM MgCl2, with 10% v/v dimethyl sulphoxide 
(DMSO) and 0.5 µM of each forward and reverse primer (Table 2.3). The 
reaction was run in an MJ research PTC-200 Thermal Cycler (GMI). A 
typical program starts with a 20 sec denaturation at 95 °C in order to ensure 
that the majority of the DNA is denatured. Followed by denaturation (95°C, 
20 sec), primers annealing temperature by (50-68°C, 20 sec) or 5 degrees 
below the melting temperature of the primers and fragment extension 
(72°C, ~1 min/kb). This was repeated for 40 cycles and followed by a final 
extension (72°C, 1 min) before the end of the PCR. The time spent at the 
different steps was dictated by size of the template. 
 
 
2.3.3 Purification of PCR products  
Purification of PCR products was achieved using a QIAGEN Plasmid 
Purification Kit (Qiagen, Germany) according to the manufacturers’ 
instructions. Purification is based on providing a silica membrane for DNA 
binding in a high salt buffer. Impurities were removed by washing with an 
additional salt buffer and DNA was subsequently eluted by 50 µl of low-salt 
buffer or ddH2O. 
 
2.3.4 Colony PCR screening. 
Single colonies of bacteria were picked with a sterile tip from an LB plate 
and used to inoculate 200 μl of LB media and the residual bacteria on the 
tip was used as a template for a PCR reaction using Taq DNA polymerase 
and appropriate primer pairs. Positive PCR sequences were examined by 
agarose gel electrophoresis. 
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2.3.5 Internal deletion polymerase chain reaction. 
The QuikChange site directed mutagenesis kit (Stratagene) was used to 
generate internal deletion mutants, as described in the manufacturer’s 
instructions. Primers for the desired deletion mutation were designed using 
software for QuikChange site directed mutagenesis applications (Table 2.3). 
Amplification of mutation by PCR was performed using PfuTurbo® DNA 
polymerase. PCR products were treated with Dpn I endonuclease to digest 
the parental DNA template and to select for DNA containing the desired 
mutation. Mutants were transformed into XL1-Blue super competent cells 
and their sequences were confirmed by GATC-Biotech (Germany).  
 
2.3.6 Site directed mutagenesis  
Saturation alanine scanning mutagenesis was performed using the Q5 site 
directed mutagenesis kit (New England Biolabs) according to the 
manufacturer’s protocol.  Primer pairs were designed with 5’ends annealing 
back to back by using the online NEB primer design software 
(www.NEBaseChanger.neb.com).  The protocol is based on exponential 
PCR amplification using the Q5 hot start high fidelity DNA polymerase 
followed by treatment with a Kinase-Ligase-DpnI (KLD) enzyme mix to 
circularise the PCR products and remove the template DNA. The DNA was 
then transformed into NEB 5-alpha C 2987 competent cells. Bacteria were 
subsequently cultured in 950 µl of SOC media (2% (w/v) Tryptone; 0.5% 
(w/v) Yeast extract; 10 mM  NaCl; 2.5 sterilized at 121°C, and then sterile 10 
mM MgCl2 and 20 mM Glucose were added). 
 
  
2.4 DNA preparation  
2.4.1 Restriction enzyme digestion 
Amplified DNAs were cloned into a suitable vector (Table 2.2), both insert 
DNA and vector plasmid were digested using two high fidelity 
endonucleases (NEB, USA). For all mutagenesis, BamHI was used at the 5’ 
termini of the insert sequence and EcoRI at the 3’ termini. Reactions were 
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carried out in a total volume of 30 µl, 1µg of DNA was digested with 10 units 
of each endonuclease with 3 µl of NEB buffer 4 and the reaction volume 
was increased to 30 µl with ddH2O. Samples were incubated for 1 hour at 
37ºC. 
 
2.4.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed to confirm the presence of PCR 
and restriction digest products. DNA was separated on a 1.6% agarose gel 
which was prepared by dissolving 0.8 g of agarose in 50 ml of 1x TAE.  This 
was made molten by heating up in a microwave until boiling. Once cooled, 5 
µl of SYBR safe DNA gel stain (Invitrogen, USA) was added and the gel 
was poured in a 10 x 20 cm gel tank (mini-sub cell GT, BioRAD) and a 10-
well comb was inserted and the gel was left to cool down at room 
temperature (RT). DNA sample (10 µl) was mixed with 2 µl gel loading dye, 
the size of the DNA fragment was determined by comparison with a 
commercial size marker. SeeBlue prestained protein marker (Invitrogen, 
USA) or ColorPlus Prestained Protein Marker (NEB, USA) was performed. 
Electrophoresis was carried out in a horizontal tank containing 1×TAE buffer 
and run at 80 V for 40 min. The agarose gel was imaged using a Syngene 
InGenius gel documentation system (Synegene Bioimaging). 
 
2.4.3 DNA sequences 
Cloned DNAs were purified and their identity confirmed by DNA sequencing 
(GATC-Biotech Ltd (Germany)). Sequence analysis was performed using 
online tools (https://www.gatc-biotech.com/en/mygatc4/single-read-
sequencing/my-watchbox/my-singlerun.html#watchboxlist_watchbox_div), 
(http://blast.ncbi.nlm.nih.gov), 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html). 
 
2.4.4 Ligation of DNA fragments 
Ligation between restricted PCR products and digested vector was 
achieved using T4 DNA ligase (NEB). A typical reaction had a final volume 
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of 10 µl, and contained 400 units of T4 DNA ligase in 1× T4 DNA ligase 
buffer. The ligation reaction was performed in a ratio of 3:1 DNA to vector 
and incubated for 30 min at RT. Subsequently, the ligated products were 
transformed into competent cells. 
 
 
2.4.5 Transformation of competent bacteria  
DNA plasmids were transformed into appropriate competent bacteria (Table 
1) as described by Hanahan (Hanahan, 1983). Competent cells (50 μl), 
stored at -80ºC, were thawed on ice for 2 min and mixed gently with 2 μl of 
DNA. The suspension was incubated on ice before being exposed to heat 
shock at 42° C for 30 sec. Suspensions were incubated on ice for 2 min to 
allow the bacteria to recover from the heat shock. Subsequently, cells were 
grown by adding 200 μl LB medium with shaking at 180 rpm for 1h at 37°C. 
The suspension was then spread on to LB plates containing appropriate 
antibiotics and incubated at 37°C overnight to obtain individual colonies. 
 
2.5 Purification of DNA 
2.5.1 Small scale DNA purification (minipreps). 
Purification of plasmid DNA on a small scale was performed by using 
Sodium dodecyl sulphate (SDS)-alkaline denaturation method by the 
Wizard® Plus SV Minipreps DNA Purification System (Promega, UK) 
according to the manufacture’s protocol. Single colonies of bacteria were 
collected from LB-agar plates and cultured in 5 ml of LB medium with an 
appropriate antibiotic overnight at 37ºC. The bacterial suspension was spun 
down 5 min at 10,000 x g and the pellet resuspended with 250 µl of 
resuspension solution (50 mM Tris-HCl, (pH 7.5), 10 mM EDTA and 100 
µg/ml RNase). An Alkaline Lysis solution was used to release the small 
plasmid DNA from the bacteria, whilst retaining the larger genomic DNA. 
This was subsequently neutralised with an acidic solution. A high 
concentration of potassium acetate was added to precipitate the high 
molecular weight of cell debris and genomic DNA and the supernatant 
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containing plasmid DNA was decanted to a silica gel matrix to bind the 
DNA. The matrix was washed two times with high salt buffer to remove 
remaining genomic DNA and proteins, then the plasmid DNA eluted from 
the Wizard® SV Mini columns by 50 µl of low salt buffer or ddH2O. 
 
2.5.2 Large scale DNA purification (maxipreps) 
QIAGEN Plasmid Plus Kit (Qiagen, Germany) was performed according to 
the manufacture’s protocol to isolate highly concentrated plasmid DNA. 
Single bacterial colonies were picked from a petri dish and inoculated 5 ml 
and incubated at 37ºC for 2h to form starter culture. 200 ml LB 
medium/antibiotic were inoculated with starter culture and shaken over night 
at 37°C. The bacterial suspension was spun down 15 min at 10,000 x g and 
the pelleted resuspended by 15 ml of cell resuspension Solution (50 mM 
Tris-HCl, (pH 7.5), 10 mM EDTA and 100 µg/ml RNase). The protocol 
based on a modified alkaline lysis minipreps, the genomic DNA was 
removed by washing with low salt solution and bacterial debris were taken 
away by medium salt washing while plasmid DNA eluted in high salt 
solution. Subsequently the collected DNA was desalted by isopropanol 
precipitation. Determination of purified DNA concentration was obtained by 
using Nanodrop spectrophotometer (Thermo Fisher Scientific, USA). 
 
 
2.6 Mammalian Cell preparation. 
2.6.1 Cell culture. 
The study used MCC13 cell line which is a physiologically relevent cell to 
study MCPyV. It has been derived from a Merkel cell carcinoma from a 
metastasic cervical node of an 80 year old female patient (Leonard et al., 
1993). The cells were maintained in Roswell Park Memorial Institute 1640 
medium (RPMI 1640, Gibco/Sigma) supplemented with 10% foetal bovine 
serum (FBS, Biochrom/Gibco) and 50U/ml penicillin/streptomycin (GIBCO, 
UK). The optimal split ratio was 1:8 (seeding density 0.8 x104 cells/cm2). 
Cells were incubated at 37°C with a relative 5% CO2. Human Emberyo 
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Kidney 293 cells (HEK 293) was performed for studying gene silencing. All 
procedures were performed in a Class II cabinet. 
 
2.6.2 Thawing and preparing of cells 
A vial containing 1 ml (1x106 cells) of frozen cells was taken from liquid 
nitrogen and rapidly defrosted in a 37ºC water bath. Cells were washed once 
with 9 ml of media and centrifuged at 5000g for 5 min. Pelleted cells were 
resuspended in 9 ml of fresh media and plated in 75 cm3 flask. 
  
 
2.6.3 Counting cells and seeding out  
Determination of the cell density was determined by use of a Neubauer 
chamber slide. A metachromatic stain like methylene blue was used to 
measure the number of viable cells.  
 
 
2.6.4 Passage of cells: 
The cells were passaged when their monolayer density reached greater than 
80% conﬂuence. The cells were routinely passaged at a constant 1:3 ratio 
and required splitting every 5-6 days. Media was removed from the flask and 
the cells were washed with sterile phosphate buffer saline (PBS, Oxoid) 
before 4 ml of 1x Trypsin/EDTA (Tryp E, GIBCO) was added to the cells, and 
the flask incubated at 37°C for 5 min. Media (8 ml) was added to the flask to 
inactivate the TrypE, and a single cell suspension generated by pipetting the 
mixture gently.  Cells were subsequently added to the appropriate culture 
vessel at the required number. 
 
2.6.5 Transfection of cell lines 
Cells were plated in 6 or 12 wells at 2x105 or 1x105 cells/ml respectively. 
Cells were incubated 24h and transfected when at ~80% confluence. The 
culture medium was replaced with a serum free modification of Eagle's 
Minimum Essential Media (Opti-MEM®, Invitrogen, USA) 30 min before 
transfection after washing the cells once with PBS.  To prepare DNA for 
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transfection, polystyrene round-bottom test tube (BD Falcon) were prepared 
and 200 µl of Opti-MEM was mixed with 0.5-2.5 µg of each DNA plasmid 
depending upon the transfection efficiency and nature of the experiment. The 
mixture was incubated for 5 min at RT. Transfection reagent, a cationic 
liposome reagent Lipofectamine 2000 (Invitrogen, USA) or a cationic polymer 
transfection polyethylenimine (PEI; Polysciences Inc.) was added to the 
plasmids on a 3:1 ratio of transfection reagent (µg): total DNA (µg) and 
incubated 20 min at RT before added to each well. Transfected cells were 
incubated for 24-48h according to the experiment. 
For immunofluorescence assay, 1x105 cells were seeded on coverslip (No 
1.5; Appleton Woods, UK) into 12 well and incubated for 24h at 37ºC.  
 
2.6.6 Harvesting cells 
Media were aspirated from the well or plate and cells washed gently with ice-
cold PBS. Then 20 μl per 1x106 cells of ice-cold lysis buffer (10 mM Tris/HCl 
pH 7.5; 150 mM NaCl; 0.5 mM EDTA; 0.5% NP-40 and protease inhibitor 
cocktail (1:50; Roche) was added directly to the cells, which were then 
scraped into a labelled 1.5 ml Eppendorf tube. Lysed cells were incubated on 
ice for at least 20 min with extensive pipetting then centrifuged 10 min at 
17,000 × g in 4°C to pellet the insoluble cell debris. Supernatants containing 
soluble material were collected into fresh Eppendorf tubes. 
 
 
2.7 Protein preparation. 
2.7.1 Protein concentration estimation. 
 
The protein concentration of cell lysates was determined using the detergent-
compatible bicinchoninic acid (BCA) protein assay kit (Thermo Fisher 
Scientific, USA) according to the manufacturer’s protocol. Lysates were 
either used immediately or stored at -20ºC since freeze-thaw cycles can 
decrease protein stability, protein lysates were stored in single use aliquots 
which were not re-frozen. 
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2.7.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins were run in a mini gel system 
(BioRAD, USA). Two gels were prepared. The resolving gel was prepared 
by mixing 10%, 12% or 15%  v/v of Acrylamide with 375 mM Tris/Cl, pH 8.8 
and 0.1% SDS, 0.1% APS and 0.01% TEMED, and stacking gel made 
using 6% Acrylamide, 125 mM Tris/Cl, pH 6.8; 0.1% SDS, 0.1% APS, 
0.01% TEMED. The stacking gel was poured on top of the resolving gel 
after solidification and an appropriate comb was inserted in the stacking gel 
to create wells in which to load the samples. Samples were mixed 1:1 with 
2x SDS loading buffer (Invitrogen, USA) which contains 10% w/v SDS, 10 
mM 2-mercaptoethanol, 20% v/v Glycerol, 0.2 M Tris-HCl, pH 6.8 and 
0.05% w/v Bromophenol blue and protein were denatured by heating at 
80ºC for 10 min. SeeBlue prestained markers (Invitrogen, USA) or 
ColorPlus Prestained Marker (NEB, USA) (5 µl) were analysed in parallel to 
experimental samples and served as protein standards.  Electrophoresis 
was performed at 120-180 V in 1x SDS running buffer which contains 34.7 
mM SDS, 250 mM Tris Base and 1.92 M Glycine until the desired protein 
resolution was achieved. 
2.7.3 Western blotting 
Proteins analysed by SDS-PAGE were transferred using a Semi-Dry Cell 
(BioRAD) to HybondTM-C ester nitrocellulose membranes (Amersham 
Biosciences). A sandwich consisting of membrane stacked on the gel 
covered with sponges in both sides were soaked in 1x transfer buffer which 
contains 129 mM Glycine, 25 mM Tris Base and 20 % methanol before 
conducting the semidry transfer at 15 V for 60-90 min. Membranes were 
incubated in blocking solution, which contains 5% Marvel dried skimmed milk 
in TBS-T  (TBS: 25 mM Tris/Cl, pH 7.5; 138 Mm NaCl and 0.1% Tween-20) 
for 30 min at RT on a shaking platform. The membrane was then washed 
twice with TBS-T and incubated with diluted primary antibody (Table 2.4) for 
1h at RT with shaking or alternatively incubated overnight at 4˚C on a 
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shaking platform. Membranes were then washed 3 times for 10 min with 
TBS-T at shaking platform at RT and subsequently incubated 1-3h with 
diluted secondary antibody (Table 2.5), conjugated to horseradish 
peroxidase. Antibodies were diluted in blocking solution. The membranes 
were washed three times again, prior to development which used equal 
amounts of enhanced chemiluminescent solution (ECL1, 2.5 mM Luminol, 40 
nM pcoumaric acid, 100 mM Tris/Cl, pH 8.5 and ECL2 0.02% H2O, 100 mM 
Tris/Cl, pH 8.5) or SuperSignal West Femto Chemiluminescent Substrate 
(Thermo Fisher Scientific, USA), which was used only with faint protein 
bands. Membranes were then exposed to CL-Xposure film (Thermo Fisher 
Scientific, USA) or Amersham Hyperfilm ECL (GE Healthcare, UK) for an 
appropriate length of time (0.2-15 min). The film was automatically 
developed using a table-top processor (Konica SRX-101A).  
 
Table 2.4 Information of primary antibodies used in this study. 
antibody manufacturer description Immunogen 
size of 
target 
dilution 
WB 
α-GAPDH Abcam 
mouse 
monoclonal 
rabbit muscle 
glyceraldehyde-
3-phosphate 
dehydrogenase 
 
 
36 kDa 
 
1:20000 
α-GFP 
Santa Cruz 
Biotechtechnol
ogy 
mouse 
monoclonal 
 full length GFP 
of Aequorea 
victoria origin 
 
37 kDa 
 
1:1000 
α-GST 
obtained from 
Dr S. Griffin, 
University of 
Leeds 
sheep pure 
IgG 
GST His-p7 
 
26 kDa 
1:1000 
α-HA Sigma 
mouse 
monoclonal 
synthetic 
peptide 
corresponding 
to amino acid 
residues 98-106 
(YPYDVPDYA) 
of human 
Influenza virus 
32kDa 1:5000 
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antibody manufacturer description Immunogen 
size of 
target 
dilution 
WB 
hemagglutinin 
α- Myc 
Santa Cruz 
Biotechtechnol
ogy 
mouse 
monoclonal 
amino acids 
408-439 within 
the C-terminus 
of human c-Myc 
1.2kDa 1:1000 
 
α-FLAG 
Sigma 
Mouse 
monoclonal 
Synthetic 
peptide 
DYKDDDDK 
1.01 kDa 1:1000 
α-FLAG EnoGene 
Rabbit 
polyclonal 
Synthetic 
peptide 
DYKDDDDK 
1.01 kDa 1:1000 
 
α-transferrin 
receptor 
(TfR) 
 
Invitrogen 
mouse 
monoclonal 
Amino acids 3-
28 of human 
transferring 
receptor 
 
84 kDa 
 
1:1000 
α Glu-Glu Millipore 
Rabbit 
polyclonal 
Synthetic 
peptide          
Glu-Glu-
(EEEEYMPME) 
1.29 kDa 1:1000 
α -PP4R1 Abcam 
Rabbit, 
polyclonal 
PP4C 
Synthetic 
peptide: 
APQETRGIPSK
KPV 
107 kDa 1:1000 
 
α-PP4C 
 
Abcam 
Rabbit, 
polyclonal 
PP4R1 
Synthetic 
peptide: 
FVSQDEMLTPL
GRLD 
35kDa 1:1000 
α-NEMO Abcam 
Rabbit 
polyclonal 
Anti-full length 48kDa 1:1000 
α-IKKα Abcam 
 
 
Rabbit, 
polyclonal 
A synthetic 
peptide 
corresponding 
to residues in 
the N terminus 
of human IKK α. 
85kDa 1:5000 
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antibody manufacturer description Immunogen 
size of 
target 
dilution 
WB 
 
 
α-IKKβ 
Abcam 
 
 
Mouse,  IgG1 
This antibody 
was raised 
against the 
6xHis tag full-
length protein 
corresponding 
to human IKKβ. 
87kDa 1:5000 
α-Lamin B Abcam 
mouse 
monoclonal 
Synthetic 
peptide 
conjugated to 
KLH derived 
within residues 
550 to the C-
terminal of 
Human Lamin 
A. 
 
67 kDa 
 
1:1000 
 
 
Table 2.5 Information of secondary antibodies used in this study. 
Antibody Manufacturer Dilution WB 
α-mouse IgG (whole molecule) – peroxidase Sigma, USA 1:5000 
α-rabbit IgG (whole molecule) – peroxidase Sigma, USA 1:5000 
Alexa Fluor® 594 Goat Anti-Mouse IgG Invitrogen, USA 1:500 
 
 
2.7.4 Re-probing the membrane. 
Membrane was washed twice with TBST before being incubated with the 
Blot Restore Membrane Rejuvination kit (Millipore, UK). Initially membranes 
were incubated in Buffer A with gentle agitation for 15 min at RT to remove 
the secondary antibody, followed by incubation with Buffer B for 10 min to 
remove the primary antibody. Membranes were then incubated with blocking 
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buffer for 5 min to reduce the background and re-probed with an appropriate 
antibody.  
 
2.7.5 Densitometry analysis of Western blots 
To compare protein expression levels western blot films were digitalised by 
scanning on an Epson Perfection V600 Photo Scanner as a 24 bit image and 
a resolution of 600 dpi. Protein levels were quantified using ImageJ (National 
Institutes of Health, USA). Clear background blot images were chosen and 
inverted. Target protein bands were selected by lining the bands to compare 
their intensities which determined by the ‘measure’ function. Areas of the film 
with no protein bands were measured and deducted as background. The 
resulting data was entered into OriginPro8.6 (MicroCal Inc., USA) to perform 
a one-way analysis of variance (ANOVA). 
 
 
2.8 Protein interactions. 
2.8.1 Co-Immunoprecipitation (Co-IP) 
2.8.1.1 GFP Trap precipitation  
 
GFP fusion proteins were precipitated using GFP-Trap magnetic beads 
(ChromoTek) according to their manufacturer’s protocol. Cells expressing 
proteins of interest were lysed in GFP-Trap lysis buffer (10 mM Tris/Cl pH 
7.5; 150 mM NaCl; 0.5 mM EDTA; 0.5% NP-40 and 1x protease inhibitor 
cocktail) as described (2.2.6). A slurry of GFP-Trap magnetic beads was 
washed twice with ice-cold dilution buffer (10 mM Tris/Cl pH 7.5; 150 mM 
NaCl; 0.5 mM EDTA) before being incubated with the cell lysate for 2h at RT 
or 24h at 4ºC with shaking. GFP-TRAP beads were separated from the 
supernatant using a magnetic rack (Qiagen, Germany). The beads were then 
washed three times with dilution buffer before being resuspended in 50µl of 
2x SDS sample buffer with 0.1% (v/v) 2-mercaptoethanol.  
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2.8.1.2 FLAG Agarose precipitation 
 
Precipitation of proteins containing a FLAG epitope was performed using 
anti-FLAG M2 Agarose Affinity Gel (Sigma). Cells expressing proteins of 
interest were lysed in FLAG lysis buffer (50 mM Tris HCl, pH 7.4, with 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100 with 1x protease inhibitor cocktail) 
as described (2.2.6). FLAG agarose resin was washed with 0.5 ml ice-cold 
TBS and cleared by centrifuged at 2000 g for 30 seconds. The supernatant 
was removed from the resin before incubation with cell lysate for 1h at RT. 
The resin was then precipitated by centrifugation and washed five times (15 
min each) with TBS to decrease background. Proteins were eluted from the 
agarose resin with 50 µl of 2x SDS sample buffer without reducing factor to 
avoid contamination with heavy and light chains of the M2 antibody.  
 
2.8.2 Co-immunofluorescence (Co-IF) 
2.8.2.1 Cell fixation  
Cells were transfected as mentioned (2.6.5). Cells fixed using a 4% 
paraformaldehyde solution for 15 min at RT and permeabilised for 10 min 
with (1% Triton X-100) then blocked in PBS-1% bovine serum albumin 
(BSA) for 1 h before staining with appropriate antibodies. 
 
2.8.2.2 Staining cells with specific antibodies.  
Cells were washed three times with PBS and incubated with primary 
antibodies for 1h. Cells were washed three times again and incubated with 
the 594, Alexa Fluor-conjugated secondary antibody. Cells were washed 
again and coverslips mounted on glass slides with mounting medium 
containing the nuclear stain reagent 4', 6-diamidino-2-phenylindole) (DAPI, 
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UltraCruz™ Hard-set Mounting Medium, SantaCruz, UK). Coverslip edges 
were sealed with nail polish to prevent movement and drying out. 
 
2.8.2.3 Imaging and confocal microscopy. 
Cells were viewed on a Zeiss 700 Meta laser scanning confocal microscope 
under a 63 oil immersion objective lens. The LSM700 with 405 nm, 488 nm, 
555 nm and 639 nm laser which present four colour observations. 
Representative images were processed using the Zen 2012 software (Zeiss, 
Germany). 
 
 
2.9 Luciferase reporter assays. 
Duplicate wells of cells were transfected with the Concanavalin A NF-B 
reporter plasmid and an appropriate expression plasmid.  Co-expression with 
the promoter-Renilla luciferase thymidine kinase (pRLTK) plasmid was used 
for transfection normalization. Cells were transfected in serum free 
conditions to reduce background luciferase expression. Post transfection 
(24h), cells were stimulated by treating with 10 ng/ml TNF-α and incubated 
for a further 6-8h. Samples were lysed in passive lysis buffer (Promega,UK), 
according to the manufacturer’s instructions and 20 µl of the lysate was 
transferred to a 96 well luminometer plates and activity measured using a 
dual luciferase reporter assay (Promega,UK) in MicroLumat Plus LB 96V 
luminometer (Berthold Technologies). First, the luminescent signal was 
stabilized by injection of Luciferase Assay Reagent II (LARII), then Stop & 
Glo reagent was injected to stop measure the levels of Renilla luciferase. 
Finally, the luciferase activity of each lysate was measured in triplicate, the 
values were averaged, and standard deviations were calculated (Griffiths et 
al., 2013) 
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2.10 Subcellular fractionation 
2.10.1 Cytoplasm and nucleus isolation. 
Cells were grown in a 10 cm dish to approximate 80% confluence prior to 
transfection. Untransfected cells were used as a control (Mock). Cells were 
scraped and lysed with 200 µl cytoplasmic lysis buffer (20 mM Tris/Cl, pH 
7.4; 100 mM NaCl; 5mM MgCl2, 0.5% NP 40; 1x Protease inhibitor cocktail). 
The lysate were incubated in ice for 30min with extensive pipetting. Lysates 
were centrifuged at 9600g for 20 min at 4°C to separate the cytoplasmic 
fraction which remained in the supernatant from the pellet which contained 
cell nuclei. To collect the nuclear fraction, pellets were washed three times 
with cytoplasmic lysis buffer before re-suspending in 200 µl radio 
immunoprecipitation assay RIPA buffer (50mM Tris/Cl, pH7.5; 150 mM NaCl; 
1% NP 40; 0.5% w/v sodium deoxycholate; 0.1% SDS; 1 x Protease inhibitor 
cocktail). The suspensions were cleared by centrifugation at 96000 x g for 10 
min at 4°C. The supernatant accounted for the nuclear fraction. Both 
fractions were analysed by Western blot and immunoblotting with appropriate 
antibody. Anti Lamin B was used as a marker for nuclear fraction and 
GAPDH for the cytoplasmic (soluble) fraction, whereas Transferrin Receptor 
antibody (TfR) for membranous protein. 
 
2.10.2 Membrane fractionation. 
Cells were scraped into 1 ml of buffer M1 (10 mM PIPES, pH 7.4; 0.5 mM 
MgCl2; 1 x Protease Inhibitor Cocktail (Roche) and lysed by sonication on 
ice. A Sonics Vibracell VC750 sonicator (Newtown, CT) was used at 30% 
amplitude, using 4 cycles of 1 sec pulses for 1 min followed by a 30 sec 
pause. Salt concentrations were adjusted by adding 250 μl of buffer M2 (10 
mM PIPES, pH 7.4; 600 mM KCl; 150 mM NaCl; 22.5 mM MgCl2). Whole 
cytoplasmic fractions were separated by centrifugation at 3000 g for 10 min 
at 4°C and removed cell nuclei and unbroken cells. The supernatants were 
then subjected to ultracentrifugation in a Sorvall WX Ultra 100 ultracentrifuge 
(Thermo Fisher Scientific, Waltham, MA), using a TH-641 swinging bucket 
rotor at 100000 g for 10 min at 4°C to pellet the membranous fraction 
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(insoluble). The pellet was extensively washed with adjusted buffer M1 and 
resuspended in 2 x LDS sample buffer plus 0.1% 2-mercaptoethanol. The 
supernatant suspension which consisted of the soluble fraction was 
precipitated by four volumes of acetone at -20°C followed by spinning down 
for 30 min at 4000 g. After washing the pelleted soluble fraction once in 70% 
ethanol, the samples were resuspended in 2 x LDS sample buffer plus 0.1 % 
(v/v) of 2-mercaptoethanol as well. Both fractions were analysed on a 
Western blot. An antibody against GAPDH (1:20000; Abcam) identified the 
soluble fraction, while an antibody against human Transferrin Receptor 
(1:1000; Invitrogen,USA) served as marker for the membranous fraction. 
 
 
2.11 Protein expression in a cell free system. 
In vitro protein expression was conducted using the TNT® T7 Quick 
Coupled Transcription-Translation system (Promega, UK). The kit includes 
a mixture that contains both T7 polymerase for the production of mRNA 
from the DNA template and then translated to produce protein. T7 master 
mix (40 µl) was mixed in Eppendorf tube with 0.5 µg DNA template, the 
volume was adjust to 50 µl with ddH2O. After 90 min of incubation at 30˚C, 2 
µl of each proteins was detected by western blot (2.3.5) and the expressed 
proteins can store at -80ºC at this stage. 
 
2.11.1 Protein expression in bacterial cells 
Protein expression in E. coli was performed according to (Smith and 
Johnson, 1988). Recombinant GST-MCPyV sT was transformed in E.coli 
BL21 competent cell as mentioned (2.4.5). An overnight culture of 
transformed bacteria was grown in 100 ml LB broth with (100 μg/ml) 
ampicillin and incubated until the Optical Density (OD) reaches 0.6 at 600 
nm. Protein expression was induced by 1 mM isopropyl-1-thio-b-D-
galactosid (IPTG) per 50 ml culture and incubated again for further 2h at 
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37ºC. The cells were pellet and re-suspended with cold PBS containing 
0.1% protease cocktail inhibitor before harvest by sonication in ice using 3 
cycles of 10 sec pulses for followed by a 30 sec pause. Thus soluble GST-
MCPyV sT fusion proteins were released into the media and cleared by 
centrifugation of the suspension for 10 min at 10000 x g at 4°C. The GST-
tagged sT can keep at -80ºC in this stage. 
 
2.11.2 GST pulldown assays.  
Glutathione agarose gel (Thermo scientific pierce) was used to purify 
bacterial expressed GST fusion proteins. 40 µl of beads was washed twice 
with TBS and incubated with soluble GST fusion proteins for 2h at RT. 
Subsequently, the gel was collected by centrifugation at 2500 x g for 5 min 
and washed twice with PBS containing 1% TRITON X-100. The purified 
GST-sT in pierce glutathione agarose was incubated with TNT T7 products 
for 2h at RT. The agarose were washed three times with PBS to remove any 
non-specific interactions. 
 
2.12 Evaluation of siRNA-mediated gene silencing. 
Three oligos of each siPP4C and siPP4R1 (Table 2.6), that had been shown 
by the previous studies to be most potent in targeted gene silencing were 
used (Applied Biosystems) (Chowdhury et al., 2008, Brechmann et al., 
2012). Silencing of protein expression was performed in MCC13 cell line. 
Cells were prepared by seeding 2x10 5 cells in 6 well plate. Cells were 
transfected with 1, 1.5 or 2 µM of siRNA. Scrambled control siRNA were 
used in all experiments. Transfections were performed as described (2.6.5). 
Cells incubated for 48h to allow effective knockdown. Silencing of the 
targeted protein was assessed by SDS-PAGE and immunoblotting with 
appropriate antibodies. 
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Table 2.6  Sequences of siRNA of PP4C and PP4R1. 
siRNA 
Gene 
targeted 
Sequence (5’→3’) Company 
siPP4C #1 PPP4C UCAUCGAUGGCAAGAUCUUUU  
Applied 
Biosystems 
siPP4C #2 PPP4C UCGACCGAAAGCAAGAGGUUU 
siPP4C #3 PPP4C GGCCAGAGAGAUCUUGGUAUU 
siPP4R1#1 PPP4R1 GCCCGGAGUUUGCUCGAUA 
siPP4R1#2 PPP4R1 UGUGAGAUGUGCUGCGAUU 
siPP4R1#3 PPP4R1 GGAUAGGUGUUCUUAAACATT 
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Chapter 3. MCPyV sT inhibits the NF-B pathway by 
targeting NEMO. 
 
3.1 Introduction 
The possible contribution of the MCPyV virus to human cancer aetiology was 
first hinted at by the discovery made by Feng and colleagues (2008) that 
around 80% of MCC contained MCPyV DNA. Further research validated that 
MCPyV LT and sT proteins did indeed possess oncogenic potential. For 
instance, sT involvement in tumour development is suggested by high sT 
expression in MCC cells.  
Furthermore, sT also participates in cellular modifications such as increasing 
DNA damage and delaying DNA repair in sT-expressing cells. In addition, 
MCPyV-positive MCC cells stop growing when sT is knocked down. 
Identification and analysis of related cellular proteins have enhanced 
understanding of sT function (Shuda et al., 2011). 
Evidence from a number of laboratories, including our own, suggests that sT 
has a cytoplasmic localisation (Shuda et al., 2011; Griffith et al., 2013). 
Bioinformatic analysis predicts that the C-terminus of MCPyV sT is not 
conserved amongst the Polyomaviridae, and this may account for some of 
the unique features of this virus.  
Most viruses that cause chronic disease disrupt the host innate immune 
response, the first line of immune defence, to establish infection. NF-B has 
been investigated as a potential target for several viruses as it is implicated 
in the regulation of more than 100 target genes, most of them participate in 
the host immune response (Ghosh et al., 1998).  
Given the chronic nature of MCPyV infection it is highly likely that it encodes 
one or more immune antagonists. To address a potential role for MCPyV sT 
as an immune antagonist, a gene array screen was performed.  
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Of note, genes containing NF-B consensus binding sequences in their 
promoters showed a substantial reduction in expression in cells containing 
FLAG-sT compared to control cells (Griffiths et al., 2013). These data 
suggested that sT might target the NF-B pathway. 
This chapter focuses on our initial analysis of the basic biology of MCPyV sT, 
including an analysis of its subcellular localisation. It also documents 
attempts to understand the molecular basis for inhibition of the NF-B 
pathway. In particular, studies in our laboratory identified an interaction with 
the NEMO adaptor protein (Griffiths et al., 2013). NEMO is an essential 
element of the IKK complex, which functions to link upstream stimuli to 
activation of hetero-dimeric NF-B transcription factors.  
NEMO lacks catalytic activity and instead interacts with polyubiquitin chains, 
either in isolation or conjugated to upstream signalling proteins (Walczak et 
al., 2012, Clark et al., 2013, Vincendeau et al., 2016), to spatially organise 
the IKK complex in order to activate NF-B signalling. The importance of the 
IKK complex in anti-viral immunity resulted in the evolution of a number of 
evasion strategies evolving in viruses. Some of these viruses such as 
Hepatitis B virus inhibits activation of NF-B by targeting both IKKβ and IKKα 
(Liu et al., 2014). Whilst Herpes simplex viruse uses ICP27 protein to inhibit 
IKKα (Hargett et al., 2006).  
It has also been shown that M protein of SARS coronavirus targets IKKβ to 
suppress NF-B activity (Fang et al., 2007). Other viruses, like human 
cytomegalovirus (CMV) and Molluscum Contagiosum virus (MCV) prevent 
NF-B activation by targeting NEMO to disrupt the IKK complex and prevent 
IB degradation (Randall et al., 2012, Krause et al., 2014).  
This chapter describes the thorough mapping strategy employed to 
understand the molecular basis for the interaction between MCPyV sT and 
NEMO. 
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3.2 Results 
3.2.1 Subcellular fractionation of sT in MCC13. 
In order to investigate the distribution and localization of MCPyV sT within 
cells, subcellular fractionation of sT was performed in MCC13 cells. Two 
complementary experiments were performed, a biochemical analysis to 
determine whether sT could associate with cellular membranes, and 
immunofluorescence to visualize sT localisation in the cytoplasm. 
 
3.2.1.1 MCPyV sT is a soluble protein localised in the cytoplasm.  
Biochemical extraction of sT was based on differential centrifugation in 
density gradient buffers. At the time of performing these experiments there 
was no access to a specific sT antibody. Accordingly, we expressed sT fused 
to a FLAG epitope for immune detection. The FLAG epitope is 8 amino acids 
with a molecular weight of 1.01 kDa, which is small and unlikely to interfere 
with the function of sT. MCC13 cells were transfected with a plasmid 
encoding FLAG-sT and then incubated for 24h before lysis. The crude cells 
were fractionated into nuclear and cytoplasmic fractions using a cytoplasmic 
lysis buffer. Cell nuclei were separated from the cytoplasm by centrifugation 
at 9600xg for 20 min at 4°C. The supernatant containing the cytoplasmic 
fraction was resolved by SDS PAGE and probed with a monoclonal antibody 
against the FLAG epitope. The Western blot result showed that the majority 
of sT was localized within the cytoplasm, with a minor fraction of the protein 
detectable in the nucleus (Figure 3.1A). The integrity of the fractionation was 
confirmed using Western blot against host proteins associated with either the 
cytoplasmic or nuclear fractions.  In this case Lamin B was used as a marker 
for the nucleus and GAPDH for the cytoplasm. The cytoplasmic fraction was 
further fractionated into soluble cytosol and membrane bound (2.10.1). 
FLAG-sT was only detected in the soluble (cytosolic) fraction (Figure 3.1B). 
In these assays GAPDH served as a marker of the soluble fraction, whereas 
Transferrin receptor was used to identify the membranous fraction. 
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3.2.1.2 Localization of MCPyV sT in the cytoplasm of MCC13. 
Biochemical fractionation studies demonstrated that a FLAG-sT fusion 
associates predominantly in the soluble fraction of the cytoplasm. To 
investigate this further co-immunofluorescence was used to visualise sT in 
whole cells.  MCC13 cells were transfected with plasmids encoding pEGFP 
or a pEGFP-sT fusion and after incubation for 24h, cells were fixed and then 
analysed using a confocal microscope. The pEGFP and pEGFP-tagged sT 
were visualised by their green fluorescent emission. The assay showed that 
EGFP-sT localized in the cytoplasm with no specific spatial localization, 
whereas the cells transfected with pEGFP alone established diffuse 
expression in both nucleus and cytoplasm (Figure 3.2).  
 
3.2.2 MCPyV sT blocks NF-B signalling pathway.  
Preliminary data from our laboratories indicated that in the presence of an 
inducible FLAG-sT, levels of NF-B-dependent gene expression were lower 
than in control cells (Griffiths et al., 2013).  These data suggested that sT 
might be able to antagonise this critical pathway.  
To determine whether sT could regulate NF-B activity, a luciferase reporter 
assay was performed in which luciferase expression was driven from NF-B 
sequences from the concanavalin A promoter. MCC13 cells expressing 
EGFP or EGFP-sT were treated with TNFα, to activate the NF-B pathway. 
After an 8 hour incubation, cells were lysed and levels of luciferase detected 
using a Dual-luciferase reporter system. Results from triplicate experiments 
showed that levels of luciferase were reduced approximately five fold in cells 
expressing EGFP-sT compared to EGFP (Figure 3.3A). Expression levels of 
each protein were confirmed by Western blot and GAPDH used as a loading 
control (Figure 3.3B). 
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Figure 3.1: Transfected MCPyV sT enriched in the soluble fraction in a subcellular 
fractionation assay. MCC13 cells (A, B) were lysed by sonication and the 
membranous proteins separated from soluble protein by ultra-centrifugation. A. 
FLAG-sT was overexpressed in MCC13 cells and underwent subcellular 
fractionation 24h post transfection to isolate cytoplasmic fraction from nucleus. 
Untransfected cells (Mock) were used as a control. B. Cytoplasmic fraction of 
transfected MCC13 with FLAG-sT was fractionated into soluble and membranous 
fractions. Proteins of both fractions were separated by SDS-PAGE and the 
Western blot probed for FLAG-sT and a marker for nuclear protein (Lamin B) and 
Cytoplasmic and soluble protein (GAPDH) and for membranous protein (TfR). 
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Figure 3.2 Determination of the cellular localisation of GFP-sT. MCC13 cells 
were transfected with GFP alone or GFP-sT. The expression of proteins was 
examined 24 post transfection by GFP fluorescence emission (green) and cell 
nuclei were labelled with DAPI (blue). Images were acquired with Zeiss 
LSM700 confocal microscope Representative images are shown. Scale bars = 
20µm. 
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Figure 3.3: MCPyV sT mediated downregulation of NF-B. A. Luciferase reporter 
assay was performed by expressing pEGFP or EGFP-sT in MCC13 cells with 
reporter plasmid and firefly luciferase under the control of the NF-B elements from 
the concanavalin A promoter. posttransfection 24 h, cells were treated with 10 ng/ml 
TNF-α for 8 h. Cells were transfected with GFP and leave without stimulated as a 
control. Samples were then subjected for luciferase activity. To normalize 
transfection efficiency, 10 ng pRLTK Renilla luciferase reporter plasmid was used, 
and values were normalized relative to the expression levels of the EGFP and 
EGFP sT vector signals. *, P <0.05 versus GFP plus TNF-α (t test). B. Cell lysate 
was subjected to Western blot to detect proteins expression and GAPDH used for 
equal loading.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
kDa 
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3.2.3 Screening for potential host binding proteins of MCPyV sT 
involved in NF-B activation. 
A range of viruses have evolved mechanisms to inhibit the NF-B pathway 
that result in antagonism of the innate immune response ( Ghosh et al., 
1998, Valentine et al., 2010, Fiume et al., 2011). To reveal the molecular 
mechanism by which MCPyV sT was able to prevent NF-B-mediated 
transcription, co-immunoprecipitation assays were performed to screen for 
proteins implicated in NF-B signalling that might be targeted by MCPyV sT. 
Given the cytosolic nature of MCPyV sT, we focussed on constituents of the 
multi-protein complexes associated with NF-B activation rather than known 
interacting partners of nuclear NF-B. Preliminary pulldown experiments 
using GST fusions of host proteins and FLAG-sT identified a putative 
interaction with a constituent of the IKK complex (data obtained by Dr David 
Griffiths, University of Leeds) (Griffiths et al., 2013). 
  
3.2.3.1 MCPyV sT interacts with the NEMO. 
The trimolecular IKK complex, containing IKKα, IKKβ and NEMO plays a 
central role in the canonical NF-B signalling pathway (Solt et al., 2009). 
Preliminary GST pulldowns indicated that MCPyV sT might target this 
complex by binding to the NEMO adaptor protein. To explore this possible 
interaction further a GFP-TRAP co-immunoprecipitation approach was 
adopted.  For all co-immunoprecipitations data are shown from a minimum of 
three independent experiments. Expression of all over-expressed proteins 
was confirmed by Western blot. 
To investigate the possible interaction between NEMO and MCPyV sT, 
MCC13 cells were transfected with plasmids encoding EGFP-sT and a Myc 
epitope NEMO fusion.  Cell lysates were incubated with GFP-TRAP 
magnetic beads or protein G-agarose beads as a control and immune 
complexes were resolved by SDS PAGE and precipitates analysed by 
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Western blot with appropriate antibodies. Western blot of the lysates 
confirmed expression of all of the exogenous proteins. As shown in Figure 
3.4A, immunoprecipitation with protein G-agarose beads showed no protein 
reactivity with either the NEMO or the GFP antibody (Figure 3.4A), 
suggesting that neither protein interacts non-specifically with the bead matrix. 
A band was observed in the EGFP-sT precipitates, corresponding to Myc-
NEMO (Figure 3.4B), which was absent in the EGFP precipitate.  
To exclude the possible impact of overexpression artefacts, co-
immunoprecipitations of MCPyV sT with endogenous NEMO were performed 
in MCC13 cells. Untransfected cells (Mock) or cells transfected with pEGFP 
or pEGFP-sT were coimmunoprecipitated with endogenous NEMO. The 
pEGFP and pEGFP-sT were precipitated with the GFP-TRAP beads and 
NEMO was detected using a rabbit polyclonal antibody to NEMO. A band 
corresponding to NEMO was detected in the precipitates from cells 
expressing EGFP-sT but not EGFP (Figure 3.4C). Together, these data 
demonstrate that MCPyV sT can interact with NEMO in cells (Griffiths et al., 
2013).   
 
3.2.3.2 Colocalization of MCPyV sT with endogenous NEMO in MCC13  
The co-immunoprecipitation results indicated that MCPyV sT was able to 
interact with endogenous NEMO in a cell lysate. Whilst these data are 
encouraging, they do not confirm that sT is able to interact with NEMO in an 
intact cell. To further validate the interaction, the localisation of both proteins 
was assessed in cells. MCC13 cells were transfected with plasmids 
expressing EGFP or EGFP-sT and incubated for 24 hours prior to fixation 
and analysis. Endogenous NEMO was detected with a NEMO specific 
primary antibody and an Alex fluor 594 conjugated secondary. EGFP 
containing cells showed a diffuse green staining, whilst cells expressing 
EGFP-sT showed cytoplasmic green staining. NEMO was restricted to the 
cytoplasm, and co-localisation was suggested by significant yellow staining 
in the cytoplasm (Figure 3.5). In conjunction with the co-immunoprecipitation 
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Figure 3.4: Co-immunoprecipitations confirming the interaction of MCPyV sT with 
NEMO. MCC13 cells were cotransfected with either pEGFP or pEGFP sT and 
Myc-NEMO. Expression of proteins were confirmed by the input lysates. Co-
immunoprecipitations were performed by incubation cellular lysate either with 
protein A-Sepharose beads (A) for the negative control or GFP-Trap magnetic 
beads (B) to precipitate pEGFP sT. expressed proteins were resolved by SDS 
PAGE and probed by GFP or Myc antibodies. (C) Co-immunoprecipitation of 
endogenous NEMO with pEGFP-sT. Cells were transfected with pEGFP-sT and 
precipitated by GFP-TRAP beads with NEMO antibody. Untransfected cells (Mock) 
was used as a control. GAPDH was used as a loading control. Marker in kDa, IP = 
immunoprecipitation, IB = Immunoblotting 
results, these data suggest that MCPyV sT and NEMO are able to associate 
in intact cells. 
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Figure 3.5: Co-immunofluorescence investigating putatiive colocalization of sT 
with NEMO in the cytoplasm of MCC13. Cells were transfected with pEGFP or 
pEGFP-sT. Post transfection (24h.) cells were fixed and permeabilized. The 
pEGFP and pEGFP-sT were detected by their green fluorescence emission and 
NEMO was indicated by anti NEMO (primary) and Alexa fluor 594 red fluorescent 
antibody (secondary). Colocalization was shown by (Yellow) puncta. Cells were 
stained with 4, 6-diamidino-2-phenylindole (DAPI) to stain the nuclei (blue). 
Images were acquired with a Zeiss LSM700 confocal microscope. Representative 
images were shown. Scale bars = 20µm. 
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3.2.4 Generating mutations in MCPyV sT to map the interaction with 
NEMO. 
A mutagenesis strategy was employed to broadly define the residues within 
MCPyV sT required for the interaction with NEMO. A series of carboxyl-
terminal truncation mutants were generated terminating at the highlighted 
residues (1-162, 1-128, 1-95, 1-63, 1-32) as represented in the schematic 
(Figure 3.6A). In addition, a point mutation was engineered into full-length sT 
to abolish the interaction with PP2A Aα (R7A) based on a previous 
publication (Shuda et al., 2012). All truncations were generated by PCR and 
analysed by agarose gel electrophoresis (Fig. 3.6B). Truncation and point 
mutant PCR products were sequenced (GATC) and cloned into the 
mammalian expression plasmid pEGFP-C1. Prior to co-immunoprecipitation 
studies, the expression levels of each mutant were confirmed in MCC13 
cells, by Western blotting. As can be seen, each mutant expressed to similar 
levels and migrated at the expected molecular weight. Equal total protein 
loading was confirmed using GAPDH expression (Figure 3.6C). 
 
3.2.4.1 Residues 95-128 within MCPyV sT are required for the interaction 
with NEMO. 
Co-immunoprecipitation assays were performed from MCC13 cell lysates 
expressing Myc-NEMO and the panel of MCPyV sT truncations. Over-
expressed proteins were precipitated using GFP-TRAP beads and 
precipitates probed by Western blot with antibodies against GFP and the 
Myc epitope, respectively. Co-immunoprecipitation confirmed the interaction 
between the wild-type sT, and NEMO (Figure 3.7).  Binding was also 
observed for the R7A point mutant as well as truncation mutants 1-162 and 
1-128. Mutants that removed amino acids beyond 95 (1-95, 1-63 and 1-32) 
failed to precipitate NEMO, despite expressing to similar levels as the wild-
type. Thus, residues between 95-128 are likely required to bind to NEMO in 
cells.  
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Figure 3.6: Generation of sT truncation mutants attached a C-terminal pEGFP. 
(A) Schematic representation of the sT truncation mutants. Truncation mutants 
named consist either of one letter changed (R7A) or a number of amino acid 1 to 
the number of the final amino acid before truncation. The truncation were 
designed in pEGFP-C1 between BamHI (forward) and EcoRI (reverse) restriction 
sites. (B) Truncation mutants were amplified by PCR and detected by gel 
electrophoresis which they showed right sizes compare with full length sT (Wt 
sT). Markers in (base pair). (C) Wild type GFP-sT and truncation mutants as well 
as R7A were expressed in MCC13 cells. Cells were lysed and proteins were 
isolated by SDS-PAGE and immunoblotting with GFP antibody. pEGFP alone 
was expressed for control and GAPDH was used as a loading control. Marker in 
kDa. 
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Figure 3.7: Mapping of pEGFP-sT binding site to Myc-NEMO. (A) Schematic 
representation of sT truncation mutant as pEGFP fusion proteins. The name of 
truncations were listed at the left and the star symbol refers to R7A mutant site, (+) 
mutation bound to NEMO and (-) mutation non-bound to NEMO (B) Co-
immunoprecipitation of pEGFP-sT truncation mutants with Myc-NEMO. The pEGFP 
alone (control), pEGFP-sT and sT truncations were co-expressed alongside with 
Myc-NEMO in MCC13 cells. The Co-immunoprecipitations were performed with 
equal amounts of total protein using GFP-TRAP magnetic beads and probed with 
GFP and Myc antibodies. Representative blot is shown. Marker in kDa. 
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3.2.4.2 NEMO binds to amino acids within 95-111 of sT. 
Two internal deletion mutants were generated to characterise the residues 
necessary for the MCPyV sT-NEMO interaction in cells. In this case a 
strategy was employed to generate internal deletion mutants that each 
removed half of the 32 amino acids shown to be important using the carboxy-
terminal truncation studies. MCPyV sT∆95-111 and MCPyV sT∆111-128 
were created by site directed mutagenesis. MCC13 cells were co-transfected 
either with wild type sT or with the deletion mutants in addition to Myc-
NEMO. The cell lysates were coimmunoprecipitated using GFP-TRAP beads 
and any interaction assessed by Western blotting. Results of the co-
immunoprecipitation indicated that the ∆95-111 mutant was not able to bind 
NEMO, whereas ∆111-128 retained the interaction (Figure 3.8). 
 
3.2.4.3 MCPyV sT residues 101-103 are required for the interaction with 
NEMO. 
Alanine scanning mutagenesis was next performed to probe the region of 
MCPyV sT between amino acids 95 and 111. Four sT mutants were 
generated, each containing four amino acids converted to alanine (A96-99, 
A100-103, A104-107 and A108-111). All mutants expressed to similar levels 
and were precipitated from MCC13 cell lysates using GFP-TRAP beads and 
interactions with co-expressed Myc-NEMO determined by Western blot. 
MCPyV sT A100-103 failed to interact with Myc-NEMO, whereas the other 
mutants retained their binding ability. This finding indicates that residues 
100-103 are essential for this interaction (Figure 3.9).  
Truncations and internal deletion mutants are critical for identifying regions of 
interaction between proteins. However, there are caveats to their use, 
including unexpected global changes to protein structure. Therefore, the 
ideal scenario would be to identify point mutations within a protein that 
abrogate the interaction with a binding partner under study. To determine 
whether such a mutant could be generated in sT to prevent the interaction 
100 
 
with NEMO, single amino acid mutations were introduced at residues 100-
103 (N100A, A101R, R102A, and F103A) using the Q5 site directed 
mutagenesis kit. Mutants were sequenced and cloned into pEGFP. Co-
immunoprecipitations were performed between each mutant and Myc-
NEMO. The pEGFP alone and the wild type sT were used as a negative and 
positive controls, respectively. Western analysis revealed that N100A 
retained the ability to bind NEMO, whereas A101R, R102A, and F103A all 
lost their interaction properties (Figure 3.10), implying that the three amino 
acids A101, R102 and F103 are required for interaction with NEMO.  
 
3.2.5 Impact of point mutations on the ability of MCPyV sT to inhibit the 
NF-B pathway. 
Luciferase assays were employed to demonstrate whether recruitment of 
MCPyV sT to NEMO and the IKK complex was necessary for the inhibition of 
NF-B signalling observed (Griffiths et al., 2013). Cells were transfected with 
the ConA luciferase reporter plasmid and the sT point mutants used to 
determine the binding requirements to NEMO. Transfected cells were 
subsequently treated with TNFα for 8 hours to activate NF-B signalling. 
Cells were lysed in Passive Lysis Buffer (PLB) and assayed using a Dual 
Luciferase reporter system (Promega). The results demonstrated that N100A 
and A101R inhibited NF-B-driven luciferase to similar levels as the wild-type 
sT (Figure 3.11A). The R102A and F103A mutants, which no longer interact 
with NEMO, were still able to inhibit NF-B activity, although to less of an 
extent than the wild-type sT. Equal expression of each protein was 
demonstrated by Western blot (Figure 3.11B).  
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Figure 3.8: MCPyV sT required residues 95-111 to interact NEMO. (A) 
Schematic representation of sT internal deletions between residues 95-128 
(dash lines), (the symbols ∆ refers to the area of deletion, (+) mutation bound to 
NEMO and (-) mutation non-bound to NEMO). (B) Co-immunoprecipitations of 
pEGFP alone (control), pEGFP-sT and two deletion mutants ∆95-111 and ∆111-
128 with Myc-NEMO. Proteins were expressed in MCC13 cells and precipitated 
by GFP-TRAP magnetic beads. GFP and Myc antibodies were used to probe 
GFP tagged proteins and NEMO respectively. GAPDH used for loading control. 
Representative blot is shown. Marker in kDa. 
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Figure 3.9: MCPyV sT required residues 100-103 to interact NEMO. (A) 
Schematic representation of sT alanine mutants within 95-111, (the letters 
AAAA refers to the amino acid replaced to alanine), (+) mutation bound to 
NEMO) and (-) mutation non-bound to NEMO). (B) Co-immunoprecipitations of 
pEGFP alone (control), pEGFP-sT and four mutants with Myc-NEMO. Proteins 
were expressed in MCC13 cells and precipitated by GFP-TRAP magnetic 
beads. GFP and Myc antibodies were used to probe GFP tagged proteins and 
NEMO respectively. GAPDH used for loading control. Representative blot is 
shown. Marker in kDa. 
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Figure 3.10: MCPyV sT required residues 101,102 and 103 to interact NEMO. (A) 
Schematic representation of sT point mutants within 100-103, (the letters A or R 
refers to the amino acid replaced). The symbol (+) refers to the mutation bound to 
NEMO and (-) for mutation non-bound to NEMO. (B) Co-immunoprecipitations of 
pEGFP alone (control), pEGFP-sT and the four point mutants with Myc-NEMO. 
Proteins were expressed in MCC13 cells and precipitated by GFP-TRAP magnetic 
beads. GFP and Myc antibodies were used to probe pEGFP tagged proteins and 
NEMO respectively. GAPDH used for loading control. Representative blot is 
shown. Marker in kDa. 
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Figure 3.11: Two amino acids in MCPyV sT mediate NF-B inhibition. A. 
Luciferase reporter assay was performed by expressing pEGFP, EGFP-sT or one 
of the point mutants in HEK 293 T cells with reporter plasmid and firefly luciferase 
under the control of the NF-B elements from the concanavalin A promoter. Post 
transfection 24 h, cells were treated with 10 ng/ml TNF-α for 6-8 h. Unstimulated 
GFP was used as a control. Samples were then subjected for luciferase activity. To 
normalize transfection efficiency, 10 ng pRLTK Renilla luciferase reporter plasmid 
was used, and values were normalized relative to the densitometry expression 
levels of the EGFP and EGFP-ST vector signals. *, P<0.05 versus GFP plus TNFα 
(t test) 
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3.2.6 Identifying the regions within NEMO necessary for the interaction 
with MCPyV sT. 
NEMO has no catalytic activity but it is required for IKK activity by mediating 
kinase oligomerization and interactions with upstream signalling components 
(Chiaravalli et al., 2011). In the absence of NEMO, the IKK complex cannot 
be activated and the canonical NF-B signalling pathway is blocked due to 
the essential role of NEMO in IKK activity (Rudolph et al., 2000, Yang et al., 
2011). Our studies demonstrated an interaction between MCPyV sT and 
endogenous NEMO (Figure 3.4). To characterise the regions in NEMO 
necessary for the interaction with sT a series of NEMO truncations was 
employed.  
 
3.2.6.1 Generation and analysis of NEMO truncation mutants. 
In order to broadly define the residues within NEMO required for interaction 
with MCPyV sT, a series of carboxy-terminal truncation mutants were 
generated terminating at the highlighted residues (1-246, 1-110, 30-246, 
246-419, 246-337) as represented in the schematic (Figure 3.12A). The 
truncations were cloned into the mammalian expression plasmid pcDNA3.1 
with an in-frame amino terminal FLAG epitope. Three of these truncations in 
the N terminus of NEMO (1-246, 1-110, 30-246), necessary for binding to the 
IKK catalytic subunits as reported by (Cote et al., 2013), and two in the C 
terminus (246-419, 246-337), necessary for oligomerization and 
ubiquitination (Emmerich et al., 2013). Co-immunoprecipitation experiments 
with the FLAG-NEMO truncations and GFP-sT was performed from MCC13 
lysates and the protein complexes precipitated by GFP-TRAP beads. The 
co-immunoprecipitation illustrated that the area of interaction lies between 
residues 246 to 337 (Figure 3.12). This area contains the second coiled coil 
domain (CC2) and leucine zipper (LZ) domains that are thought to mediate 
NEMO oligomerization and ubiquitin binding (Grubisha et al., 2010).  
  
106 
 
Figure 3.12: Mapping the domains within NEMO which are required for the 
interaction with MCPyV-sT. (A) Schematic representation of the full length NEMO 
(1-419) and five truncations were listed at the left side. The symbol (+) refers to 
the NEMO mutants bound to sT and (-) for mutation non-bound to sT. (B) Co-
immunoprecipitations of full length NEMO and NEMO truncations each with GFP 
sT, GFP alone transfect with full length FLAG-NEMO (as a control). Cells were 
lyses and proteins were incubated with GFP-TRAP beads to precipitate GFP-sT. 
Immune complexes resolved by SDS-PAGE and immunoblotted with FLAG 
antibody for FLAG-NEMO and GFP antibody for GFP sT. The GAPDH performed 
to confirm equal loaded of lyses proteins input. Representative blot is shown. 
Marker in kDa. 
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3.2.6.2 MCPyV-sT interacts with the NEMO ubiquitin-binding domain. 
The CC2 and LZ domains of NEMO have been shown to be essential for 
both the ubiquitin-binding and oligomerisation properties of NEMO, and 
mutations of these domains impact NF-B activation (Agou et al., 2004). To 
reveal a minimal domain required for the interaction with sT, two internal 
deletion mutants of NEMO FLAG-∆246-302 and FLAG-∆302-365 were used 
in coimmunoprecipitation assays with GFP-sT. The results showed that the 
∆246-302 mutant retained its ability to interact with sT, whereas loss of 
amino acids ∆302-365 abolished the interaction with sT (Figure 3.13). Thus, 
residues 302-365 are essential for the interaction with MCPyV sT. 
 
3.2.6.3 Disease associated mutations within the ubiquitin-binding domain 
of NEMO prevent the interaction with MCPyV sT. 
The essential nature of the Ubiquitin-binding domain of NEMO is known from 
the presence of disease-associated mutations in NEMO that prevent NF-B 
activation. Several of the identified mutations in this domain abrogate the 
interaction with ubiquitin molecules, and likely prevent the recruitment of the 
IKK complex to the correct spatial localisation to interact with the TAK1 
complex. To further assign a role for this domain in the interaction with sT in 
cells, a small number of published mutations were engineered into NEMO. 
These mutants were cloned into the pEBG6P plasmid to express amino-
terminal GST fusion proteins in mammalian cells. The mutants were co-
transfected into MCC13 cells with GFP-sT and precipitated using GFP-TRAP 
beads. Precipitates were detected using antibodies against GFP and GST. 
Wild-type NEMO, the A288R and A317Q mutants retained an ability to 
interact with sT. In contrast the D311N mutation abrogated the interaction 
with sT and C417R significantly reduced binding (Figure 3.14).  
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Figure 3.13: The residues 302-365 of NEMO required for the interaction with 
MCPyV-sT. (A) Schematic representation of the full length NEMO (1- 419) and 
two internal deletion truncations were listed at the left side. The symbol (+) refers 
to the NEMO mutants bound to sT and (-) for mutation non-bound to sT). (B) Co-
immunoprecipitations of full length NEMO and ∆246-302 and ∆302-365each with 
GFP sT, GFP alone transfect with full length FLAG-NEMO (as a control). Cells 
were lyses and protein were incubated with GFP-TRAP beads to precipitate GFP-
sT. Protein complex was resolved by SDS-PAGE and immunoblotted with FLAG 
antibody for FLAG-NEMO and GFP antibody for GFP sT. The GAPDH performed 
to confirm equal loaded of lyses proteins input. Representative blot is shown. 
Marker in kDa. 
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Figure 3.14: NEMO required Aspartate (D311) for interaction with MCPyV-sT. (A) 
Sequence alignment of the UBAN domain of NEMO. Full length (1- 419) and four 
point mutants were listed at the left side. The Red stars refers for mutant sites, 
symbol (+) refers to the NEMO mutants bound to sT and (-) for mutation non-bound 
to sT). (B) Co-immunoprecipitations of full length NEMO and point mutants each 
with GFP sT, GFP alone transfect with full length FLAG-NEMO (as a control). Cells 
were lyses and protein were incubated with GFP-TRAP beads to precipitate GFP-
sT. Immune complexes resolved by SDS-PAGE and immunoblotted with FLAG 
antibody for FLAG-NEMO and GFP antibody for GFP sT. The GAPDH performed 
to confirm equal loaded of lyses proteins input. Representative blot is shown. 
Marker in kDa.
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3.3 Discussion: 
3.3.1 MCPyV sT is a soluble, cytoplasmic protein in MCC13 cells. 
This study established that MCPyV sT localises in the cytosol of MCC13 
cells. Further, co-immunofluorescence experiments demonstrated that sT 
showed a diffuse distribution throughout the cell and more concentrated in 
cytosol. These results are in agreement with other work showing an 
interaction between sT and the cytoplasmic actin regulatory protein Stathmin 
(Knight et al., 2015) and other localisation studies in the liver hepatoma cell 
line Huh7 (Griffiths et al., 2013). In contrast the MCPyV LT localises mainly 
in the nucleus, with a small percentage of the protein also found in the 
cytoplasm (Liu et al., 2011, Nakamura et al., 2010). Interestingly, the 
localisation of MCPyV sT differs from that of other Polyomaviridae. For 
example, SV40 sT localises within the nucleus, while LT can be found both in 
the cytoplasm and nucleus (Montano and Lane., 1984, Deppert, 2000). 
These data might allow speculation of MCPyV specific functions for the sT. A 
time course of detection of sT within the cell may be required to determine 
whether the sT can change its localisation or if it is localised mainly in the 
cytoplasm over the time course. 
 
3.3.2 MCPyV sT inhibits NF-B activation.  
Using a transcriptomics approach, our laboratory previously demonstrated 
that sT expression correlated with a down-regulation of NF-B driven gene 
expression (Griffiths et al., 2013). To confirm these data, luciferase reporter 
assay was performed in MCC13 using a well-characterised NF-B driven 
reporter (Mankouri et al., 2010). This assay showed an sT-dependent 
decrease in NF-B mediated luciferase expression. Instead of studying the 
role of sT in the pathway in MCPyV negative MCC cell line, it may be better 
to detect the action of sT in a MCPyV positive MCC cell line like MKL1 or 
MKL2, however these cell lines did not grow well. Griffith and colleagues 
were shown an inhibition of CCL20, IL-6 and IL-8 at the transcript and protein 
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level in MCC13 and MKL1 (David Griffiths and Andrew Macdonald; Griffiths 
et al., 2013). Among the polyomaviruses, only BKPyV and MCPyV have 
been shown to down-regulate NF-B activation. A couple of mechanisms 
have been postulated; firstly direct targeting of the NF-B pathway by 
MCPyV sT (Griffiths et al., 2013) and alternatively down-regulation of Toll-
like receptor-9 (TLR9) gene expression, which would impact on NF-B 
activation in response to the presence of viral nucleic acids (Shahzad et al., 
2013). MCPyV uses both LT and sT to inhibit TLR9 expression, whereas 
BKPyV utilizes its LT to interact with the CCAAT/enhancer-binding protein 
beta (C/EBPβ) to prevent expression of the TLR9 gene (Shahzad et al., 
2013). In addition to the Polyomaviridae, a number of viruses target the NF-
B pathway to evade modify the innate immune system. Epstein-Barr virus 
(EBV) expresses latent membrane 1 (LMP1), which leads to the activation of 
NF-B, whereas human papillomavirus 16 (HPV16) and Hepatitis B virus 
(HBV) manipulate NF-B pathway through inhibiting of TLR9 which induce 
the pathway (Fathallah, et al., 2010, Martin et al., 2007, Vincent et al., 2011, 
Hasan, et al., 2014, Edwards et al., 2015). HPV E7 has also been shown to 
prevent NF-B activation by reducing acetylation of the p65 protein (Richards 
et al., 2015).  
 
3.3.3 Interaction of MCPyV sT with NEMO.  
Pulldown experiments indicated that MCPyV sT was likely to interact with a 
protein in the NF-B signalling pathway. Data presented in this chapter 
shows that one candidate for this protein is the adaptor NEMO. This 
interaction was shown using co-immunoprecipitation assays with over-
expressed NEMO and confirmed with endogenous NEMO both by co-
immunoprecipitation and co-immunofluorescence experiments. Moreover, 
NEMO could be found in discrete puncta that co-stained with sT in Huh7 
(Griffiths et al., 2013)    and in the more physiologically relevant MCC13 cells 
(Figure 3.5).                               NEMO is absolutely required for the 
canonical NF-B activation pathway. The amino-terminal part of NEMO is 
responsible for interaction with the IKK catalytic subunits (May et al. 2000, 
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Rushe et al. 2008, Vincendeau et al., 2016). Structurally, NEMO lacks 
catalytic properties but its regulatory role is essential for activation NF-B 
and mouse embryonic fibroblasts cells that lack NEMO could not activate 
NF-B signalling (Bonizzi and Karin, 2004). This may illustrate that MCPyV 
sT targets NEMO to manipulate the NF-B pathway. It is intriguing that 
NEMO was not identified in the initial SILAC-based proteomic screen of 
MCPyV sT binding proteins (Griffiths et al., 2013). This may indicate a 
transient interaction between the proteins or that this is a low affinity 
interaction, destabilised during the lysis and precipitation protocols. 
Alternatively, peptides derived from NEMO may not have contained the 
appropriate properties for detection during the mass spectrometry analysis. 
When these studies were initiated MCPyV was the only polyomavirus known 
to target NEMO. Despite this, a number of viruses have been shown to 
manipulate immune signalling by targeting NEMO. Human T-lymphotrophic 
virus types 1 and 2 (HTLV 1, HTLV2) encode TAX1 and TAX2, which both 
contain NEMO binding domains. TAX1 protein is ubiquitinated by lysine-63 
polyubiquitin (K63-Ub) and subsequently interact with NEMO to activate the 
IKK complex and NF-B pathway (Higuchi & Fujii, 2009,), whilst TAX2 
mediates NF-B activation independent to the link with K36-Ub (Lavorgna 
and Harhaj, 2013 Journo et al., 2013). In addition, the viral FLICE inhibitory 
protein (vFLIP, K13) protein encoded by Kaposi's sarcoma-associated 
herpesvirus (KSHV) targets NEMO to activate the NF-B pathway and 
prevent infected cells from undergoing apoptosis (Tolani et al., 2014, 
Bagneris et al., 2008). The interaction between murine cytomegalovirus 
(MCMV) protein (MC45) and NEMO has been demonstrated to inhibit TNF-
induced apoptosis and suppresses the NF-B pathway (Randall et al., 2012). 
Similarly, an HBV-encoded polymerase (pol), interacts with NEMO and 
isolates it from IKK kinases to disrupt the IKK complex formation (Liu et al., 
2014). 
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3.3.4 Residues 101-103 in MCPyV sT are required for targeting NEMO. 
A mutagenesis strategy was employed to broadly define the residues within 
sT required for the interaction with NEMO. Full length MCPyV sT was 
truncated into five truncations, three in the N-terminus 1-95, 1-63 and 1-32 
and two were in the C-terminal 1-162, and 1-128 (Figure 3.6A), in addition to 
one point mutant R7A which has previously been reported to prevent binding 
to PP2A Aα  (Shuda et al., 2011). The expression abilities of these mutations 
was confirmed by MCPyV sT early promoter activity and the results showed 
they do not have a protein-folding problem (Griffith et al., 2013). The co-
immunoprecipitation undertaken in this study firmly identified the region 95-
128 of MCPyV sT as necessary for the interaction with NEMO. The 
truncation lies in the C terminal of sT, the N-terminal truncations failed to 
bind NEMO. In addition, the mutant R7A interacted with NEMO as well as 
the wild type protein. It is therefore likely that the binding area is within 
residues 95-128 (Figure 3.7 B). To refine the region necessary for binding to 
NEMO, internal deletions were employed (∆95-111 and ∆111-128). These 
precipitations confirmed that residues 95-111 are needed to bind to NEMO in 
cells. This area is not conserved with LT, 57KT and ALTO, which are all 
expressed in the early region. This may suggest that neither LT nor 57KT are 
able to bind NEMO, however, this needs to be experimentally investigated.   
Despite the promoter reporter studies, which indicated that our truncation 
analysis had not impacted on the global structure and function of sT (Griffiths 
et al., 2013), it was necessary to refine our understanding of the interaction 
between sT and NEMO to a minimal region. This was achieved, firstly 
through alanine scanning of discrete clusters of residues within the region 
between 95-111, and finally by use of single point mutants. These studies 
demonstrated that the mutants A101R, R102A and F103A abolished the 
interaction with NEMO in cells. 
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3.3.5 The role of the point mutants of sT in NF-B pathway. 
Whilst the mapping exercise identified residues in sT necessary for the 
interaction with NEMO in cells, it was imperative to show that preventing the 
interaction had an impact on the ability of sT to impair NF-B signalling. Use 
of luciferase reporter assays provided some data potentially supporting the 
importance of the sT interaction with NEMO. Whilst the wild type, N100A and 
A101R mutants all inhibited NF-B activation, the R102A and F103A mutants 
failed to achieve this to the same level. Firstly, none of the point mutants was 
able to completely prevent inhibition of NF-B using the artificial promoter 
plasmid. Similar observations were recorded for inhibition of NF-B by the E7 
oncoprotein (Richards et al., 2015). In this study, mutants in the E7 protein 
reduced the ability of E7 to inhibit the same reporter plasmid but did not 
return levels of luciferase to control level. However, the same mutants were 
incapable of inhibiting endogenous NF-B driven gene expression as shown 
by qRT-PCR or ELISA for the protein (Richards et al., 2015). It is possible 
that analysing endogenous gene expression rather than using the reporter 
construct would find similar results. It is also possible that another protein 
rather than NEMO is also required for the inhibition of NF-B signalling. This 
might explain why the A101R mutant could still block NF-B but did not bind 
to NEMO in co-immunoprecipitation studies. Other proteins like IKKα, IKKβ, 
TANK and RIP which form complexes with NEMO may act as a scaffold 
between sT and NEMO. Each of these possibilities needs to be studied in 
detail. 
 
3.3.6 The NEMO ubiquitin-binding domain is needed for the interaction 
with sT in cells. 
NEMO is a multi-domain adaptor protein and both the protein-protein 
interaction partners and the purpose of specific domains has well been 
characterised (Kensche et al., 2012, Emmerich et al., 2013, Vincendeau et 
al., 2016). We used a truncation approach to establish the region(s) of 
NEMO necessary for the interaction with sT in cells. This strategy identified a 
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stretch of residues in NEMO consisting of the so called ubiquitin binding 
domain (UBD), which encompasses the second coiled-coil and leucine 
zipper domains, as essential for the interaction with sT. Located in the C-
terminal region of NEMO, this region is important both for oligomerisation 
and for binding to various forms of ubiquitin (Grubisha et al., 2010; Emmerich 
et al., 2013; Yoshikawa, et al., 2009). To back up the truncation data, we 
generated a small number of clinical mutants of NEMO associated with 
immunodeficiency disorders.  Importantly, most of these mutations can be 
found within the UBD (containing the CC2-LZ region). One of the more 
successful finding was observed by interacting sT with all previous mutants 
except the mutant D311N (Figure 3.13). This suggests that the residue D311 
in NEMO is necessary for the interaction with sT in cells. This mutant has 
been reported to prevent the interaction with ubiquitin chains (Rahighi et al., 
2009, Hadian et al., 2011). D311 is located in NEMO-NOA domain and 
showed to be required for interacting the residues H68 and L8 of ubiquitin 
chains which are necessary for NEMO ubiquitination (Lo et al., 2009). Any 
mutation in this residues as well as A288 and A317 showed to completely 
abrogate the interaction to K63-Ub. They also been isolated from people who 
have sever (EDA-ID) as a result of NF-B inhibition and the patient suffering 
with skin inflammation (Courtois and Gilmore, 2006, Sebban-Benin et al., 
2007, Chiaravalli et al., 2011). Herein, we found that the mutant D311N 
alone can abolish the interaction with sT whilst the other A288R, A317Q and 
C417R retain binding to sT. It is likely that any mutant in D311 loss the ability 
to bind K63-linked di-Ub, whilst the A288G, A317 and C417R have not been 
shown to effect the interact with K63-linked di-Ub (Vinolo et al., 2006). Thus 
it was likely the residues D311 is necessary to sT to disrupt K63 di-Ub 
ubiquitin chain.     
Substitution mutations in D311 also detected in cDNA from EBV-B cells and 
SV40-transformed fibroblasts from the patient (Hubeau et al. 2011). 
Recently, Vincendeau and colleague studied different point mutants within 
the region NOA including D311R and they identified that this mutant can 
prevent ubiquitination of NEMO and disrupt NF-B activation (Vincendeau et 
al., 2016).  
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Data in this chapter indicate that two amino acids 102 and 103 in MCPyV sT 
required to mediate NF-B inhibition and this is highly likely through 
recruitment of NEMO. The amino acid D311 in NEMO was observed to be 
necessary for this effect. 
 
 
 
Chapter 4. MCPyV sT interacts with a number of                 
Protein phosphatase subunits in cells  
  
4.1 Introduction 
Protein phosphatases work in contrast to kinases in cells. They hydrolyse 
phosphate groups from proteins that have been phosphorylated by kinases 
and this process is called ‘dephosphorylation’. Most phosphatases hydrolyse 
phospho-serine (which account for 86.4%) and the others hydrolyse 
phospho-threonine (11.8%) as their substrate. A minority target phospho-
tyrosine (1.8%) residues. It is thought that about 30 serine/threonine 
phosphatases can regulate thousands of dephosphorylation events in all 
living cells (Olsen et al., 2006). The pivotal role played by these 
phosphatases makes them an attractive target for viruses to develop 
strategies to manipulate a myriad of cellular pathways. For example, HCV 
utilizes its non-structural proteins (NS3/4A and NS5A) to recruit PP2A to 
manipulate the MAPK-ERK pathway (Duong et al., 2004). Whilst Adenovirus 
E4orf4 and HIV-1 Vpr proteins bind phosphatases to regulate apoptosis (Mui 
et al, 2015, Janoo et al., 2005) .HPV-E7 recruits PP2A to inhibit the AKT 
pathway (Pim et al., 2005). Polyomaviruses have also been shown to target 
phosphatases. For example, SV40, BKPyV and JCPyV utilize their sT 
proteins to manipulate different pathways by targeting PP2A (Duong et al., 
2005, Shtrichman et al., 1999, Guergnon et al., 2011, Griffith, et al., 2013, 
Kwun et al., 2015). A limited number of polyomaviruses are also able to 
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target other phosphatases including PP4C (Griffith, et al., 2013, Kwun et al., 
2015). Two structural A subunits of the major protein phosphatase, PP2A, 
were identified, Aα and Aβ. Each of these isoforms is involved in different 
pathways (Jin et al., 2003, Calin et al., 2000). Accordingly, viruses display 
selectivity of binding between these isoforms according to their pathogenic 
mechanism. For instance, Murine polyomavirus sT interacts with PP2A Aβ to 
negatively regulate the AKT-mTOR pathway. Whereas SV40 is unable to 
bind PP2A Aβ (Andrabi et al., 2011, Kwun et al., 2015). On the other hand, 
MCPyV sT disrupts the NF-B pathway via recruitment of either PP4C or/and 
PP2A Aβ (Griffith et al., 2013).  
In normal cells, NF-B transcriptional activity is reduced when no longer 
required in part through the dephosphorylation activity of PP2A and PP4C 
(Brechmann et al., 2012, Zhang et al., 2014). This observation serves to 
reinforce the key function of phosphatases associated with NF-B whilst also 
possibly elucidating why they are targeted not only by MCPyV but also by 
other viruses (e.g. SV40 and HCV) through the sT and NS5A proteins 
respectively (Sontag et al., 1997, Jiang et al., 2011). 
Several point mutants were mapped in MCPyV sT observed to be required 
for interaction with phosphatase subunits. The first of these domains to be 
identified was R7 and L142 which they observed as essential for sT to 
interact with PP2A Aα (Shuda et al., 2011). Whilst other amino acids K118 
and K134 were also shown to be important for the interaction with PP2A Aα 
(Kwun et al., 2015). 
This chapter aims to increase our understanding of the molecular 
requirements for the interactions between MCPyV sT and PP4C and PP2A 
subunits. It identifies residues in MCPyV sT necessary for the interaction with 
these phosphatases. Mutant sT proteins, based on these studies, have been 
used to explore the functional roles of sT in MCPyV pathogenesis and 
immune evasion (Griffith, et al 2013, Knight et al., 2015). 
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4.2 Results 
4.2.1 MCPyV sT targets the protein phosphatase 4 C subunit. 
Screening for proteins involved in the NF-B pathway has previously 
identified PP4C as a novel interaction partner for MCPyV sT (Griffith et al, 
2013). PP4C is a serine - threonine phosphatase and plays a number of key 
roles in host cell physiology. A critical role for PP4C in the control of NF-B 
activation was recently reported (Tikhonova and Aifantis, 2012; Griffith et al, 
2013) through targeting the IKK complex. 
To confirm a putative interaction between PP4C and MCPyV sT, MCC13 
cells were transfected with pEGFP-sT and PP4C containing an in-frame 
amino terminal FLAG epitope fusion (FLAG-PP4C). Cell lysates were 
incubated with GFP-TRAP magnetic beads or control protein G-agarose 
beads. Protein complexes were resolved by SDS PAGE and the precipitates 
analysed by Western blot with antibody of GFP or FLAG. Western blotting of 
proteins input confirmed the expression of all of the exogenous proteins. The 
precipitation with protein G-agarose beads showed no protein reactivity with 
either the FLAG or the GFP antibody (Figure 4.1A). A clear interaction was 
observed between GFP-sT and FLAG-PP4C (Figure 4.1B), in contrast with 
GFP alone which showed no interaction.  
Co-immunoprecipitations were also performed between GFP-sT and 
endogenous PP4C. MCC13 cells were transfected with pEGFP or pEGFP-sT 
and coimmunoprecipitated with endogenous PP4C using GFP-TRAP beads. 
PP4C was detected using a rabbit polyclonal antibody to PP4C. A band 
corresponding to PP4C was detected in the precipitates from cells 
expressing pEGFP-sT but not pEGFP (Figure 4.1C) Untransfected cells were 
used as a negative control (Mock). Together, these data demonstrate that 
MCPyV sT can interact with PP4C in MCC13 cells (Griffiths et al., 2013). 
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4.2.2 Colocalization of MCPyV sT with endogenous PP4C in MCC13 
cells. 
Colocalization of MCPyV sT and endogenous PP4C was visualized in 
MCC13 by confocal microscop. Cells were transfected with pEGFP or 
pEGFP-sT and incubated for 24 hours before fixation. Endogenous PP4C 
was detected by PP4C antibody and probed by an Alex fluor 594 conjugated 
secondary antibody, whilst GFP-sT was visualized by its Green fluorescece. 
EGFP-sT and PP4C showed putitive colocalized in the cytoplasm (Figure 
4.2). This result would be consistent with an interaction of sT and PP4C 
which was also observed by co-immunoprecipitation. 
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Figure 4.1: Co-immunoprecipitations confirming the interaction of MCPyV sT with 
the catalytic subunit of protein phosphatase 4 (PP4C). (A, B) MCC13 cells were 
cotransfected with either pEGFP or pEGFP sT and FLAG-PP4C. Post transfection 
24h expression of proteins were confirmed by input the lysates. Co-
immunoprecipitation were performed by incubate cellular lysate either with protein 
A-Sepharose beads (A) for the negative control or GFP-Trap magnetic beads (B) to 
precipitate pEGFP sT. expressed proteins were resolved by SDS PAGE and probed 
by GFP or FLAG antibodies. (C) Co-immunoprecipitation of endogenous PP4C with 
pEGFP-sT confirmed the interaction between them. Cells were transfected with 
pEGFP-sT and coimmunoprecipitated by GFP-TRAP beads with PP4C antibody. 
Untreated cells (Mock) was used as a control. GAPDH was used as a loading 
control. Marker in kDa. 
 
 
 
 
 
 
Figure 4.2: Co-immunofluorescence investigating putative colocalization of sT with 
PP4C in the cytoplasm of MCC13. Cells were transfected with pEGFP or pEGFP-
sT. 24 h post transfection cells were fixed and permeabilized. PEGFP, pEGFP-sT 
was detected by their green fluorescence emission and PP4C was indicated by anti 
PP4C (primary) and Alexa fluor 594 red fluorescent antibody (secondary). 
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Colocalization was shown (Yellow) puncta. Cells were stained with 4´, 6-diamidino-
2-phenylindole (DAPI) to stain the nuclei (Blue). Images were acquired with Zeiss 
LSM700 confocal microscope. Representative images are shown. Scale bars = 
20µm. 
 
 
 
 
 
 
4.2.3 Residues 95-128 within MCPyV sT are required for the interaction 
with PP4C. 
Mapping experiments were performed by co-immunoprecipitation assay to 
delineate the regions of sT required for binding to PP4C. MCC13 were 
transfected with FLAG-PP4C and the panel of sT truncations (Figure 3.6). 
Cells were cotransfected for 24h and then harvested. Cell lysates were 
precipitated using GFP-TRAP beads and protein complexes were probed by 
Western blot with antibodies against GFP and the FLAG epitope, 
respectively. The results confirmed the interaction between full length sT and 
PP4C (Figure 4.3). Surprisingly, co-immunoprecipitation results 
demonstrated that the same region that is essential for interacting with 
NEMO is also required for binding PP4C. The R7A point mutant as well as 
truncation mutants 1-162 and 1-128 were showed to interact with PP4C 
comparing with the mutants that removed amino acids beyond 95 (1-95, 1-63 
and 1-32) which failed to precipitate PP4C. Thus, residues 95-128 are likely 
to be necessary for binding PP4C (Figure 4.3). Together, these data suggest 
that residues 95-128 are required for the interaction with both NEMO and 
PP4C (Griffith and et al, 2013). 
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4.2.4 PP4C binds to residues 95-111 within sT. 
Further mutagenesis studies were performed to identify a short stretch of 
MCPyV sT necessary for binding PP4C. The mutant sT∆95-111 or MCPyV 
sT∆111-128 were co-transfected with FLAG PP4C in MCC13 cells. GFP and 
GFP-sT were used as a negative and positive control. Cell lysates were co-
immunoprecipitated using FLAG- agarose affinity beads and any interaction 
assessed by Western blotting. Interestingly, co-immunoprecipitation results 
indicated that the mutant ∆95-111 stopped binding PP4C, whereas ∆111-128 
retained the interaction (Figure 4.4). Thus, residues the residues 95-111 are 
likely to be required to bind to PP4C in cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Mapping of GFP-sT binding site to FLAG-PP4C. (A) Schematic 
representation of sT truncation mutant as pEGFP fusion proteins. The name of 
truncations were listed at the left. The star refers to R7A mutant, (+) mutation bound 
to PP4C and (-) mutation non-bound to PP4C (B) Co-immunoprecipitation of 
pEGFP-sT truncation mutants with FLAF-PP4C. PEGFP alone (control), pEGFP-sT 
and sT truncations were co-expressed alongside with FLAF-PP4C in MCC13 cells. 
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Figure 4.4: MCPyV sT required residues 95-111 to interact PP4C. (A) Schematic 
representation of sT internal deletions between residues 95-128 (dash lines), (the 
symbols ∆ refers to the area of deletion, (+) refers to the mutations bound to PP4C 
and (-) to mutation non-bound to PP4C. (B) Co-immunoprecipitations of pEGFP 
alone (control), pEGFP-sT, ∆95-111 and ∆111-128 with PP4C. Proteins were co-
expressed in MCC13 cells and precipitated by PP4C agarose affinity beads. GFP 
and FLAG antibodies were used to probe pEGFP tagged proteins and PP4C 
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respectively. GAPDH used for loading control. Representative blot is shown. Marker 
in kDa. 
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4.2.5 MCPyV sT residues 100-103 are required for the interaction with  
PP4C.  
The four sT alanine mutants (A96-99, A100-103, A104-107 and A108-111) 
were used to map the interaction site between MCPyV sT and NEMO. Co-
immunoprecipitation between these mutants and FLAG-PP4C were 
performed from MCC13. Cell lysates were incubated with GFP-TRAP beads 
and interactions with co-expressed FLAG-PP4C determined by Western blot. 
The results showed that only the stretch A100-103 failed to interact with 
FLAG-PP4C, whereas the other mutants conserved their ability to bind 
PP4C. Thus, these results indicate that the residues 100-103 are essential 
for interaction with PP4C (Figure 4.5).  
 
4.2.6 Two amino acids (102-103) in MCPyV sT are required for the 
interaction with PP4C. 
To analyse the individual contribution of each residue between 100-103 to 
the MCPyV sT interaction with PP4C, the sT point mutant panel (N100A, 
A101R, R102A, and F103A) were co-immunoprecipitated with FLAG-PP4C. 
The pEGFP alone and the wild type sT were used as a negative and positive 
controls, respectively. Western analysis revealed that N100A and A101R 
retained the ability to bind PP4C, whereas, R102A and F103A lost their 
interaction properties (Figure 4.6), implying that amino acids R102 and F103 
are required for the interaction with PP4C. These residues in addition to 
residue 101 appeared also necessary for the interaction with NEMO as 
previously shown (Figure 3.10).  
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Figure 4.5: MCPyV sT required residues 100-103 to interact PP4C. (A) Schematic 
representation of sT alanine mutants within 95-111, the letters AAAA refers to the 
amino acid replaced to alanine, (+) refers to mutations bound to PP4C and (-) refers 
to mutation non-bound to PP4C. (B) Co-immunoprecipitations of pEGFP alone 
(control), pEGFP-sT and four mutants with FLAG-PP4C. Proteins were expressed in 
MCC13 cells and precipitated by GFP-TRAP magnetic beads. GFP and FLAG 
antibodies were used to probe GFP tagged proteins and PP4C respectively. 
GAPDH used for loading control. Representative blot is shown. Marker in kDa. 
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Figure 4.6: MCPyV sT required residues 102 and 103 to interact PP4C. (A) 
Schematic representation of sT point mutants within 100-103, (the letters A or R 
refers to the amino acid replaced). The symbol (+) refers to the mutation bound to 
PP4C and (-) for mutation non-bound to PP4C. (B) Co-immunoprecipitations of 
pEGFP alone (control), pEGFP-sT and the four point mutants with FLAG-PP4C. 
Proteins were co-expressed in MCC13 cells and precipitated by GFP-TRAP 
magnetic beads. GFP and FLAG antibodies were used to probe pEGFP tagged 
proteins and PP4C respectively. GAPDH used for loading control. Representative 
blot is shown. Marker in kDa. 
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4.2.7 MCPyV sT targets other protein phosphatases in cells. 
Besides the interaction with PP4C, other phosphatases were also detected in 
the proteomic screen with MCPyV sT. The SILAC screen identified a 
potential interaction with the major Serine/threonine-protein phosphatase 2A 
A subunit of PP2A Aβ (Griffiths et al., 2013). These data also confirm 
previous observations of an interaction with PP2A A 
 
4.2.8 Co-immunoprecipitation of sT with the Aα, Aβ and catalytic (C) 
sub-units of PP2A. 
To investigate the possible interaction between PP2A subunits and MCPyV 
sT, MCC13 cells were cotransfected with pEGFP-sT and EE epitope fusions 
of PP2A Aα, PP2A Aβ or a FLAG epitope fusion of PP2A C. Prior to co-
immunoprecipitation studies, the expression levels of each protein were 
confirmed in MCC13 cells, by Western blotting. For co-immunoprecipitations, 
cell lysates were incubated with GFP-TRAP magnetic beads and immune 
complexes were resolved by SDS PAGE and the precipitates were analysed 
by Western blot with appropriate antibodies. As shown in Figure 4.7A, a 
band was observed in the pEGFP-sT precipitates, corresponding to EE-
PP2A Aα (Figure 4.7A). Similarly, results of the co-immunoprecipitation 
indicated that MCPyV sT is able to bind both PP2A Aβ and PP2A C 
respectively (Figure 4.7B, C). 
 
3.2.9 Mapping the regions of sT necessary for interacting with PP2A Aα 
and PP2A Aβ. 
In order to verify MCPyV sT domains necessary for interaction MCPyV sT 
with PP2A Aα and PP2A Aβ, the internal deletion mutants MCPyV sT∆95-
111 or MCPyV sT∆111-128 were expressed with PP2A Aα or PP2A Aβ.  
MCC13 cells were co-transfected either with wild type sT or with the deletion 
mutants in addition to PP2A Aα or PP2A Aβ.  
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The cellular lysates were coimmunoprecipitated using GFP-TRAP beads and 
any interaction assessed by Western blotting. Results of the co-
immunoprecipitation indicated that the wild type sT and ∆111-128 bind to 
PP2A Aα. In addition, the point mutant R7A abolished the interaction with 
PP2A Aα, and this finding is consistent with (Shuda et al., 2011). On the 
contrary, ∆95-111 showed only a weak interaction (Figure 4.8A). 
Intriguingly, co-immunoprecipitation assays of sT with PP2A Aβ showed 
similar results, the full length interacts with PP2A Aβ, whereas the R7A and 
∆111-128 retained their interaction ability. In addition, ∆95-111 lost its 
interaction property (Figure 4.8B).  
 
3.2.9.1 Mutation of amino acid 103 in MCPyV sT decreases the interaction 
with PP2A Aβ.  
To distinguish which sT residues between100-103 are required for the 
interaction with PP2A Aβ, co-immunoprecipitations were performed between 
each sT point mutant (N100A, A101R, R102A or F103A) and EE-PP2A Aβ. 
The pEGFP alone and the wild type sT were used as a negative and positive 
controls, respectively. All mutants expressed to similar levels and were 
precipitated from MCC13 cell lysates using GFP-TRAP beads and 
interactions with co-expressed EE-PP2A Aβ determined by Western blot. 
The full length and all sT mutants, except F103A, retained their binding 
ability with PP2A Aβ. F103A significantly decreased the interaction with 
PP2A Aβ (Figure 4.9).  
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Figure 4.7: Co-immunoprecipitations confirming the interaction of MCPyV sT with 
PP2A A α, PP2A A β and PP2A C (A, B, C) MCC13 cells were cotransfected with 
either pEGFP or pEGFP sT and either EE-PP2A A α, EE-PP2A A β and FLAG-
PP2A C. 24 post transfection expression of proteins were confirmed by input the 
lysates. Co-immunoprecipitation was performed by incubate cellular lysate with 
GFP-Trap magnetic beads to precipitate pEGFP sT. Precipitates were resolved by 
SDS PAGE and probed by GFP or EE antibody for PP2A A α and PP2A A β or 
FLAG for PP2A C (A) Co-immunoprecipitation of pEGFP-sT with PP2A Aα (B) Co-
immunoprecipitation with PP2A Aβ (C) Co-immunoprecipitation with PP2A C. Cells 
transfected with GFP were used as a control. GAPDH was used as a loading 
control. Marker in kDa. 
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Figure 4.8: Mapping of pEGFP-sT binding site to (A) PP2A Aα and (B) PP2A Aβ. 
Co-immunoprecipitation of pEGFP alone (control), pEGFP-sT and sT mutants R7A, 
∆95-111 and ∆111-128 with each PP2A Aα and PP2A Aβ. Proteins were expressed 
in MCC13 cells and precipitated by GFP-Trap magnetic beads. GFP and Glu-Glu 
(EE) antibodies were used to probe pEGFP, pEGFP-sT and PP2A Aα or PP2A Aβ 
respectively. GAPDH was used for loading control. Representative blot is shown. 
Marker in kDa. 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: MCPyV sT required residue 103 to interact PP2A Aβ. (A) Schematic 
representation of sT point mutants within 100-103, (the letters A or R refers to the 
amino acid replaced). The symbol (+) refers to the mutation bound to PP2A Aβ and 
(+/-) for mutation has weak interaction. (B) Co-immunoprecipitation of pEGFP alone 
(control) or pEGFP-sT and the four point mutants with EE- PP2A Aβ. Proteins were 
co-expressed in MCC13 cells and precipitated by GFP-TRAP beads. GFP and EE 
antibodies were used to probe pEGFP-sT and EE-PP2A Aβ respectively. GAPDH 
used for loading control. Representative blot is shown. Marker in kDa. 
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4.3 Discussion 
4.3.1 MCPyV sT targets PP4C 
In this study, co-immunoprecipitations confirmed the interaction of MCPyV sT 
with PP4C (Figure 4.1). Similar results have recently been published by the 
Chang-Moore laboratory (Kwun et al., 2015). Herein the mutagenesis results 
showed that the same amino acid residues in sT (R102 and F103) that are 
needed to bind NEMO, are required to interact with PP4C. These amino 
acids are not conserved in LT and other MCPyV proteins as well as the other 
polyomavirus sT proteins. Moreover, these residues have been shown to be  
required for inhibiting the NF-B pathway (Figure 3.11). This may suggest 
that MCPyV sT recruits PP4C to deregulate NF-B either alone or in a 
complex with NEMO.  
Targeting of viruses to PP4C is not well studied compared to the well-studied 
PP2A. The first investigation demonstrating targeting of PP4C by a virus was 
reported by our group in Leeds University based on co-immunoprecipitation 
and SILAC-based immunoprecipitation strategy (Griffith et al., 2013). Since 
then our group has extended these findings to demonstrate a role for PP4C 
in the deregulation of the microtubule-associated protein (Stathmin) in 
MCPyV sT-expressing cells. Subversion of Stathmin results in microtubule 
destabilization and cell motility. These findings suggest a possible molecular 
mechanism for the highly metastatic phenotype associated with MCC with 
the action of PP4C (Knight et al., 2015).  
The results from co-immunofluorescence assay confirmed the localization 
between MCPyV sT and PP4C in the cytoplasm of MCC13 cells (Figure 4.2). 
One study highlighted shuttling of PP4C to the nucleus, where it co-localised 
with nuclear nuclear distribution element-like 1 (NDEL1) during microtubule 
regulation (Toyo-oka et al 2008). Our studies did not indicate a nuclear 
localisation, however, it is plausible that this shift in localisation can only be 
seen upon during specific stages of the cell cycle.  
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4.3.2 MCPyV sT interacts with the two isoforms of PP2A. 
The co-immunoprecipitations results confirm the SILAC data showing an 
interaction with the structural subunit A for both PP2A isoform α and β (PP2A 
Aα and PP2A Aβ).  Moreover, a weak interaction with the catalytic C subunit 
of PP2A (PP2A C) was also observed (Figure 4.7 A, B, C). Presumably the 
interaction with PP2A C was mediated through interactions with the A sub-
unit. The interaction of MCPyV sT with PP2A Aα is well-defined. Despite this, 
studies have failed to demonstrate a role for the MCPyV sT-PP2A Aα 
interaction in MCPyV pathogenesis. On the contrary, SV40 tumorigenic 
activity is strictly dependent on the interaction with PP2A, since mutant 
versions within residues 97-103 of SV40 sT that are unable to bind PP2A 
failed to induce tumorigenic activity (Mateer, et al., 1998, Hahn et al., 2002).  
PP2A regulates multiple signalling pathways, for example it contributes to the 
NF-B pathway by targeting RelA (Yang, J. et al, 2001). The ability to bind 
PP2A is a conserved function of polyomavirus sT proteins and this 
association has been shown to play an important role in virus-induced 
cellular transformation by other polyomaviruses (Pallas et al., 1990). 
Evidence reported by Shuda and colleagues provided a physical interaction 
between MCPyV sT and PP2A Aα subunit and showed it has no effect on the 
phosphorylation of 4E-BP1 (Shuda et al., 2011). So far, the MCPyV sT 
protein has been implicated in the process of viral DNA replication (Feng et 
al., 2011, Kwun et al., 2009) and cellular transformation (Shuda et al., 2011). 
Mutational analysis of sT indicates that association with PP2A is required for 
its ability to enhance LT's viral DNA replication function. The most recent 
studies were done on PP2A Aα. The interaction between PP2A Aβ and 
MCPyV sT was first identified using co-immunoprecipitation and SILAC 
immunopre-cipitations (Griffith et al., 2013). Herein the results showed that 
MCPyV sT interacts with both PP2A Aα and Aβ. 
Mutagenesis of MCPyV sT found that residues between 95-111 are required 
for the interaction with both PP2A isoforms (Figure 4.8). Further mutations 
were generated in an attempt to create a single point mutation unable to bind 
to PP2A Aβ, in an effort to recapitulate the usefulness of the R7A mutant in 
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delineating the role of the PP2A Aα interaction in MCPyV pathogenesis. The 
extensive mutagenesis performed in this chapter identified that the F103A 
mutant significantly reduces binding to PP2A Aβ. Importantly, the R102A 
mutant retains an interaction with PP2A Aβ whilst losing binding to both 
PP4C and NEMO, allowing for discrimination of the roles of cellular binding 
partners. 
The results in this chapter showed that sT interacts with PP4C and both 
structural subunits of PP2A as well as the PP2A C subunit. The thorough 
mapping strategy identified that the residues essential for binding NEMO are 
also required for recruiting protein phosphatases. This may illustrate that sT 
targets both NEMO and the phosphatases in a complex to inhibit the NF-B 
pathway (Griffith et al., 2013). 
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Chapter 5. Characterisation of the protein complexes 
associated with MCPyV sT  
5.1 Introduction  
We have shown that an interaction between MCPyV sT and NEMO is 
necessary for the negative regulation of NF-B, helping MCPyV to evade the 
host antiviral response (Griffith et al., 2013). Evidence for the inhibition of 
NF-B originated from the observation that levels of phosphorylated IκBα 
were reduced in cells inducibly expressing sT, and this correlated with a 
reduction in the nuclear translocation of p50 and p65 NF-B proteins (Griffith 
et al., 2013). Co-immunoprecipitation assays were used to determine 
potential host targets for sT that may mediate the observed effects. These 
revealed interactions in cells with NEMO, and a number of phosphatase sub-
units (Chapters 3 and 4) (Griffith et al., 2013). Further mutagenesis studies 
revealed that a short stretch of amino acids (residues 101-103) in MCPyV sT 
was necessary for these interactions. These observations are perplexing, 
given the potential for steric hindrance between putative binding partners for 
binding to such a short region of the protein. Moreover, NEMO was not 
identified in the initial SILAC proteomic screen (unlike all of the phosphatase 
sub-units), suggesting either a transient low-affinity interaction, an 
incompatibility of NEMO peptides for mass spectrometry or the possibility 
that NEMO associates with sT as part of a larger protein complex, potentially 
consisting of one or more phosphatase sub-units.  
The aim of this chapter was to determine whether the interactions of MCPyV 
sT with the panel of identified host-binding partners occurs in a direct manner 
in vitro to begin to understand the nature of these interactions.  
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5.2 Result 
5.2.1 Identification of protein-protein interactions in vitro. 
To elucidate the nature of the interaction between MCPyV sT and the 
proteins identified in Chapters 3 and 4, we applied an in vitro protein-protein 
interaction assay. Cell proteins were translated in a cell-free system using 
the TNT in vitro translation/transcription system (IVT) (Figure 5.1A) and 
MCPyV sT was expressed in bacteria as a GST fusion protein (Figure 5.1B). 
Direct binding assays were then performed with purified recombinant GST-
sT and the IVT host protein, either alone or in combinations.  
 
5.2.2 Validating the expression of bacterial GST-sT. 
To validate the production of GST-sT from bacteria, soluble lysates were 
incubated with glutathione-agarose affinity matrix beads for 2h and the 
precipitates analysed by Western blotting with an anti-GST antibody (Figure 
5.2A). Western blotting confirmed the presence of GST and GST-sT at the 
appropriate molecular weight, indicating that sT is expressed as a soluble 
protein in bacteria. 
 
5.2.3 IVT production of sT binding partners.  
Synthesis of cell proteins in free cell system was performed using IVT. A 
panel of host proteins (FLAG-NEMO, FLAG-PP4C, HA-PP4R1, EE-PP2A Aα 
and EE-PP2A Aβ) were expressed by IVT and their expression confirmed by 
Western blotting using appropriate antibodies. A control reaction containing 
no added DNA was used to allow measurement of any background 
incorporation of any protein in IVT. The results revealed that each protein 
expressed at its expected molecular weight, and at easily detectable levels 
(Figure 5.2B). Together, these data indicate that the appropriate reagents 
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can be produced in order to study interactions with sT and its binding 
partners in vitro.    
 
 
 
  
A 
B 
Figure 5.1: Protocols for synthesis proteins for direct binding assay. (A) Bacterial 
expression of GST and GST-sT. The plasmids were transformed in BL21 E. coli 
competent cells. GST and GST-sT proteins were extracted from bacteria by 
sonication and centrifugation. Protein purification was performed by Glutathione 
agarose beads and resolved by Western blotting. (B) Cell proteins were 
synthesized using IVT. Cellular plasmids cloned in vectors containing T7 
promoter and incubated 2h with TNT master kit to produce cellular proteins which 
then  resolved by Western blotting.  
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Figure 5.2 Expression of GST-sT and host proteins. (A) GST and GST-sT were 
cloned in BL21 and grown for 24h. Cells were harvested by centrifugation and 
sonicated to release the proteins from bacteria which were then purified by 
Glutathione agarose beads. (B) Host cell protein were produced by IVT system, 
names of proteins listed on the top side. The triangle symbols refer to the target 
proteins. Proteins were analysed by Western blotting. Representative blots are 
shown. Marker in kDa. 
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5.2.4 MCPyV-sT does not bind NEMO directly.  
By co-immunoprecipitations, MCPyV sT was shown to interact with NEMO in 
MCC13 cells (Figure 3.4). In order to verify whether sT interacts with NEMO 
directly or through a complex, in vitro protein binding assays were performed 
using bacterial expressed recombinant GST-sT and IVT produced FLAG-
NEMO. First, bacterial expressed GST or GST-sT was incubated with 
glutathione-sepharose beads for 2h at room temperature to bind the fusion 
proteins to the bead matrix (Frangioni and Neel, 1993), then this was used to 
precipitate IVT FLAG-NEMO for a further 2h. The protein complexes were 
resolved by SDS-PAGE and analysed by Western blot. The anti-GST 
Western blots confirmed equal expression of the GST fusion proteins, 
however, the anti-FLAG blot failed to identify a specific band relating to 
FLAG-NEMO. Absence of this band indicated that IVT produced NEMO is 
unable to interact directly with GST-sT (Figure 5.3). 
 
5.2.5 MCPyV-sT binds to PP4C directly.  
The results from the direct protein-protein interaction assay revealed that 
MCPyV sT did not bind NEMO directly. Thus it was likely that sT may interact 
with NEMO through another partner within a protein complex. One possible 
candidate is PP4C, which has previously been shown to be recruited to the 
IKK complex (Tikhonova, and Aifantis, 2012). Direct binding assays were 
subsequently performed using GST-sT and FLAG-PP4C. This assay showed 
a clear band associated with PP4C in the GST-sT sample, suggesting a 
direct interaction between sT and PP4C (Figure 5.4). It was possible that 
PP4C could act as a bridge between sT and NEMO, given that all three 
proteins co-localise in cells (Griffith et al., 2013). To determine if this was the 
case, GST-sT was mixed with a combination of IVT produced NEMO and 
PP4C.  The results of this assay once again confirmed our previous data, 
that NEMO does not interact directly with sT. They also showed that the 
presence of PP4C was not sufficient to incur an interaction between NEMO 
and sT (Figure 5.4). 
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Figure 5.3: No direct interaction between MCPyV-sT and NEMO. (A) Schematic 
representation of GST-tagged sT and FLAG-NEMO. (B) Co-immunoprecipitation of 
GST (control) or GST-sT with FLAG-NEMO by using Glutathione agarose beads to 
precipitate GST. Input of FLAG NEMO also load to show its expression. Antibodies 
against GST and FLAG were used to probe GST, GST-sT and FLAG NEMO 
respectively. Representative blot is shown. Marker in kDa.  
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Figure 5.4: MCPyV-sT interacts directly with PP4C independent of NEMO. (A) 
Schematic representation of GST-tagged sT, FLAG-NEMO and FLAG-PP4C. (B) 
Co-immunoprecipitation of GST (control) or GST-sT with FLAG-PP4C alone, FLAG-
NEMO alone or both combined. Co-immunoprecipitation was performed by using 
Glutathione agarose beads to precipitate GST or GST-sT. In vitro FLAG-PP4C or 
FLAG-NEMO or equal combination of them were incubated with GST or GST-sT in 
Glutathione agarose beads. Antibodies against GST and FLAG were used to probe 
GST, GST-sT, FLAG-PP4C and FLAG-NEMO respectively. Representative blot is 
shown. Marker in kDa.  
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5.2.6 PP4R1 is a PP4C binding protein and novel target of MCPyV sT.  
The dephosphorylation activity of PP4C is regulated through a range of sub-
units to modulate its substrate specificity. One such PP4C binding protein, 
PP4R1, was recently shown to be necessary to link PP4C to the IKK 
complex to regulate NF-B activity (Brechmann et al., 2012). Given that 
PP4C was not sufficient to bridge sT to NEMO, attention was directed to 
identifying whether PP4R1 was required for this function. 
 
5.2.6.1 PP4R1 interacts with NEMO in cells. 
Whilst PP4R1 has been shown to interact with the IKK complex in 
lymphocytes, we wished to establish whether such a complex could form in 
MCC13 cells. Co-immunoprecipitations were performed between 
endogenous PP4R1 and FLAG-NEMO using anti-FLAG M2 affinity gel. As 
depicted (Figure 5.5), PP4R1 was successfully precipitated by FLAG-NEMO 
but not with beads alone, demonstrating an interaction between PP4R1-
NEMO in Merkel cells.  
 
5.2.6.2 Co-immunoprecipitation assay confirmed the interaction of 
PP4R1 with PP4C. 
PP4R1 works together with PP4C as a central negative regulator of NF-B 
activity (Tikhonova and Aifantis, 2012, Brechmann et al., 2012). Next, the 
association between PP4C and PP4R1 was confirmed by co-
immunoprecipitation. MCC13 cells were transfected with FLAG-PP4C and 
the lysates precipitated with FLAG affinity resin. As expected, endogenous 
PP4R1 was precipitated by FLAG-PP4C (Figure 5.6). Together, these 
experiments indicate that PP4R1 is able to interact with both PP4C and 
NEMO in MCC13 cells. 
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Figure 5.5: Co-immunoprecipitation confirming the interaction between FLAG-
NEMO and PP4R1 in MCC13. (A) Schematic representation of co-
immunoprecipitation of NEMO and PP4R1 by FLAG agarose beads. (B) Co-
immunoprecipitation of FLAG-NEMO with endogenous PP4R1. Cells untransfected 
(Mock) or transfected with FLAG-NEMO were lysed and incubated with FLAG 
agarose beads to precipitate FLAG-NEMO. Protein complex resolved by SDS-
PAGE and probed with FLAG or PP4R1 antibody respectively. GAPDH was used 
as a loading control. Representative blot is shown. Marker in kDa.  
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Figure 5.6 Co-immunoprecipitation confirming the interaction between FLAG-PP4C 
and PP4R1 in MCC13. (A) Schematic representation of co-immunoprecipitation of 
PP4C and PP4R1 by FLAG agarose beads. (B) Co-immunoprecipitation of FLAG-
PP4C with endogenous PP4R1. Cells untransfected (Mock) or transfected with 
FLAG-PP4C were lysed and incubated with FLAG agarose beads to precipitate 
FLAG-PP4C. Immune complex resolved by SDS-PAGE and probed with FLAG or 
PP4R1 antibody respectively. GAPDH was used as a loading control. 
Representative blot is shown. Marker in kDa.  
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5.2.6.3 MCPyV-sT targets PP4R1. 
To test whether PP4R1 was a novel sT binding protein, co-
immunoprecipitations were performed with EGFP-sT and endogenous 
PP4R1 in MCC13 cells. Western blot analysis of the GFP-TRAP 
precipitations clearly showed a band corresponding to PP4R1 in the EGFP-
sT sample but not in the EGFP alone sample (Figure 5.7). These data 
indicate that PP4R1 is a novel MCPyV sT binding protein.  
 
5.2.6.4 Mapping the region in sT required for the interaction with PP4R1 
Mapping experiments were performed to delineate the regions of sT 
necessary for binding to PP4R1 in cells. Given that to date all identified 
binding partners of sT interacted with a short sequence of amino acids, we 
initially utilised the internal deletion mutant ∆95-111 and ∆111-128 and an 
overexpressed HA-epitope fused PP4R1 in MCC13 cells. As detected by 
SDS-PAGE and immunoblotting, wild type sT and ∆111-128 retained their 
ability to target PP4R1, whereas ∆95-111 abolished this interaction (Figure 
5.8). Thus, PP4R1 also interacted with residues between 95-111. 
5.2.6.5 Amino acids 101-103 in sT are required for the interaction with 
PP4R1 
Given the results of the co-immunoprecipitations using the internal deletion 
mutants of sT it is possible that the same amino acid residues in sT required 
for the interactions with NEMO and PP4C are also required for association 
with PP4R1. To answer this question, the panel of sT point mutants were 
used in co-immunoprecipitations with HA-PP4R1. Cell lysates were 
incubated with GFP-TRAP affinity beads to precipitate the GFP-sT mutants. 
Protein complexes were resolved by SDS-PAGE then immunoblotted with 
GFP and HA antibodies. The results showed that wild type and N100A 
retained their ability to bind to PP4R1, whereas A101R, R102A and F103A 
abolished this interaction (Figure 5.9). Thus, residues 101,102 and 103, 
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which we observed were essential for binding to NEMO are also important 
for PP4R1 interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Co-immunoprecipitation confirming the interaction of MCPyV-sT with the 
endogenous PP4R1 in MCC13 cells. (A) Schematic representation of co-
immunoprecipitation between GFP-sT with endogenous PP4R1 by GFP-TRAP 
beads. (B) Untransfected cells or transfected with either pEGFP or pEGFP sT. Post 
transfection 24h, cells were harvested and co-immunoprecipitation were performed 
by incubating the cellular lysates with GFP-TRAP beads. GFP antibody was used to 
detect GFP and GFP-sT proteins, anti PP4R1 antibody was used to probe PP4R1. 
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GAPDH was used as a loading control. Representative blot is shown. Marker in 
kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: MCPyV-sT required residues 95-111 to interact PP4R1. (A) Co-
immunoprecipitations of GFP alone (control), wild type GFP-sT and two deletion 
mutants ∆95-111 and ∆111-128 with HA-PP4R1. Proteins were expressed in 
MCC13 cells and precipitated by GFP-TRAP magnetic beads. GFP and HA 
antibodies were used to probe GFP-sT and HA-PP4R1 respectively. GAPDH used 
for loading control. Representative blot is shown. Marker in kDa. 
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Figure 5.9: MCPyV-sT required residues 101,102 and 103 to interact PP4R1. (A) 
Schematic representation of sT point mutants within 100-103, (the letters A or R 
refers to the amino acid replaced). The symbol (+) refers to the mutation bound to 
PP4R1 and (-) for mutation non-bound to PP4R1). (B) Co-immunoprecipitations of 
pEGFP alone (control), pEGFP-sT and the four point mutants with HA-PP4R1. 
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Proteins were expressed in MCC13 cells and precipitated by GFP-TRAP magnetic 
beads. GFP and HA antibodies were used to probe GFP-sT and PP4R1 
respectively. GAPDH used for loading control. Representative blot is shown. Marker 
in kDa. 
 
5.2.7. MCPyV-sT recruits PP4R1 to interact with NEMO. 
To evaluate a potential role for PP4R1 in the NEMO-PP4C-sT complex, 
direct binding assays were once again performed. MCPyV sT binding 
proteins were generated by IVT and incubated with recombinant GST or 
GST-sT, as described. Western blot showed that all proteins were generated 
successfully.  Binding assays showed that PP4R1 was able to interact 
directly with GST-sT but not GST alone. Interestingly, whilst NEMO could not 
be precipitated by GST-sT when incubated alone or in combination with 
either PP4C or PP4R1, a band corresponding to FLAG-NEMO was clearly 
observed in samples where it was co-incubated with both PP4R1 and PP4C 
(Figure 5.10). These data indicate that the presence of a PP4R1-PP4C 
complex may be required to mediate the interaction between NEMO and sT 
in vitro.  
 
5.2.8 Direct interaction of PP2A Aα or PP2A Aβ with MCPyV sT. 
Whilst a number of studies have shown essential roles for PP4C in MCPyV 
sT mediated immune evasion (Griffiths et al., 2013) and metastasis (Knight 
et al., 2015), the work shown in this thesis also identifies an interaction with 
PP2A phosphatases (Chapter 4). We sought a better understanding of these 
interactions and so performed direct binding reactions with EE-PP2A Aα or 
EE-PP2A Aβ to ascertain whether they are able to interact directly with sT or 
like NEMO may constitute part of a sT binding complex. The assay clearly 
showed a direct interaction between GST-sT and PP2A Aβ, with a weaker 
interaction observed for PP2A Aα (Figure 5.11). These data mirror the SILAC 
proteomic results (Griffiths et al., 2013).  
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Figure 5.10: MCPyV-sT interacts NEMO through its interaction with PP4C-PP4R1 
complex. (A) Schematic representation of GST-tagged sT, NEMO, PP4C and 
PP4R1. (B) Co- immunoprecipitations of GST (control) or GST-sT with FLAG-
PP4R1 alone or with equal combinations named in the top side. Co-
immunoprecipitations were performed by using Glutathione agarose beads to 
precipitate GST or GST-sT. Antibodies against GST, FLAG and HA were used to 
probe the proteins. R1 refers to PP4R1. Representative blot is shown. Marker in 
kDa.  
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5.2.9 MCPyV sT residues 102 and 103 necessary for the direct 
interaction with host proteins. 
Co-immunoprecipitation assays in cells confirmed the importance of residues 
101-103 in sT for the observed interactions with a number of host proteins 
(Chapters 3 and 4). The interactions between sT and NEMO/PP4R1 requires 
three residues (amino acids 101,102 and 103), the interaction with PP4C 
requires amino acids 102 and 103, whereas amino acid 103 is essential for 
binding to PP2A Aβ. To further understand the binding requirements for each 
protein, direct binding assays were performed with two point mutants of sT 
(R102A and F103A) and the panel of cellular proteins. 
First, the two mutants were cloned into pGEX-6P1 to generate GST fusion 
proteins. GST-R102A and GST-F103A were expressed in BL21 E. coli strain 
and isolated as described (2.11.2). Direct binding assays were then 
performed with IVT produced NEMO, PP4C, PP2A Aβ, and PP4R1. Input 
proteins were used as loading control and GST alone as a negative 
interaction control (Figure 5.12). Binding assays confirmed that wild type sT 
did not bind NEMO directly, as well as either of the two mutants (Figure 
5.12). This confirmed the previous results that showed no interaction 
between sT and NEMO. In contrast, wild type sT exhibited a strong direct 
interaction with PP4C, PP4R1 and PP2A Aβ. Both mutants completely 
abolished the interaction with PP4C, whereas PP4R1 showed a very low 
level interaction with R102A. Furthermore, PP2A Aβ retained its ability to 
bind both R102A and F103A, although at a reduced level (Figure 5.12). 
Thus, these results indicate that we have successfully generated sT mutants 
capable of discriminating between host binding partners both in cells and in a 
direct binding assay.  
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Figure 5.11: MCPyV-sT targets PP2A Aβ directly. (A) Schematic representation of 
GST-tagged sT, PP2A Aα and PP2A Aβ. (B) Co-immunoprecipitations of GST 
(control) or GST-sT with EE-PP2A Aα or EE-PP2A Aβ. Input of in vitro PP2A 
proteins were loaded to confirm their expressions. Co-immunoprecipitations were 
performed by using Glutathione agarose beads to precipitate GST or GST-sT. 
Antibodies against GST and EE were used to probe the proteins. Representative 
blot is shown. Marker in kDa.  
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Figure 5.12: Mapping of direct interaction site of sT to the cellular protein in vitro. (A) 
Schematic representation of possible interaction between GST-sT, mutants R102A 
and F103A with NEMO, PP4C and PP4R1.(B) Co-immunoprecipitations of GST 
(control), GST-sT, R102A or F103A with in vitro cellular protein were performed by 
incubate the proteins with Glutathione agarose beads to precipitate GST-sT. Input in 
vitro cellular proteins detected their expression. Antibodies against GST, FLAG, EE 
and HA were used to probe the proteins. Representative blot is shown.  
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5.3 Discussion 
5.3.1 MCPyV sT does not interact with NEMO directly. 
Co-immunoprecipitation assays illustrated that MCPyV sT binds a number of 
proteins including NEMO, PP4C and PP2A. A number of avenues indicate 
that these interactions could lead to the disruption of NF-B signalling 
(Griffiths et al., 2013). Co-immunoprecipitation results demonstrated an 
interaction between MCPyV sT and NEMO. To better understand this 
interaction, a direct binding assay was performed between bacterial GST-sT 
and in vitro produced binding partners. Both GST-sT and the cellular proteins 
were produced and detected by Western blot and appeared in their 
approximate sizes. The direct binding assay provided the intriguing 
observation that MCPyV sT does not bind NEMO directly (Figure 5.3). This 
result is compatible with the SILAC proteomic screen performed at Leeds, 
which did not detect NEMO as a sT binding protein (Griffith et al., 2013). The 
lack of a direct interaction between sT and NEMO opens up the question 
about which other host cell proteins involved in NF-B signalling might 
mediate binding with NEMO. Previous studies have shown that PP4C and 
PP4R1 work as partner proteins to NEMO and we showed that they are 
capable of interacting with MCPyV sT. Initially, the obvious candidate for 
acting as a bridge between NEMO and sT was PP4C, and indeed direct 
binding assays demonstrated a direct interaction between PP4C and sT. 
However, co-incubation with GST-sT and IVT produced NEMO and PP4C 
still failed to recapitulate the interaction with NEMO and sT. Together, these 
data show that whilst PP4C is a direct binding partner of sT, alone it is not 
enough to mediate the interaction with NEMO, indicating that either binding 
with NEMO is not required or another sT-binding protein is necessary for this 
function. However, the IVT was observed to have minimal background of 
different proteins which may interfere with MCPyV sT. To avoid potential 
interference, purification of all required proteins in bacteria may provide a 
better understanding of the specificity of protein-protein interaction. 
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5.3.2 A novel interaction between MCPyV sT and PP4R1.  
The literature demonstrates that one of the PP4C regulatory subunits, 
PP4R1, is necessary for PP4C-mediated IKK dephosphorylation in T cells 
(Tikhonova and Aifantis 2012, Brechmann et al., 2012). It was possible that 
in Merkel cells sT subverts PP4R1 function to target PP4C to NEMO. Our 
precipitation studies confirmed interactions between PP4R1 with PP4C and 
NEMO. They also provided the first demonstration of an interaction between 
PP4R1 and sT in cells. PP4R1 was first identified associated with PP4C in a 
105 kDa complex by co-immunoprecipitation, microcystin-Sepharose and 
Mass spectrometry analysis, (Kloeker and Wadzinski, 1999). The PP4R1 N-
terminus contains two heat repeats which have been observed to be required 
for protein- protein interaction and contains a binding domain for 
PP4C.(Kloeker and Wadzinski, 1999). Depletion of PP4R1 from T cells by 
siRNA resulted in increased secretion of NF-B-dependent cytokines 
including IFN-γ, IL-2 and TNF-α. In addition, luciferase reporter assays 
showed an increase in NF-B-dependent transcription after PP4R1 silencing 
(Brechmann et al., 2012). In this study, the phenotype was explained as a 
defect in the dephosphorylation of the IKK complex, resulting in constitutive 
IKK activation and enhanced NF-B signalling (Brechmann et al., 2012). 
However, PP4R1 has also been shown to interact with the ubiquitin ligases 
TRAF2 and TRAF6 to negative regulate the NF-B pathway (Hadweh et al., 
2014). These findings imply that PP4R1 might regulate NF-B activity by a 
number of mechanisms. 
 
5.3.3 MCPyV sT forms a complex consisting of PP4R1-PP4C-NEMO. 
Mutagenesis studies also revealed that the same residues in sT (residues 
101, 102 and 103) necessary for interacting with NEMO are needed to bind 
to PP4R1 in cells. This could be interpreted that sT interacts with these 
proteins in a complex. To determine whether PP4R1 functions as a scaffold 
in the sT-NEMO complex, direct binding assays were performed with all 
three host proteins and GST-sT. Similar to PP4C, PP4R1 was shown to 
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directly bind to recombinant sT in vitro. Interestingly, as with PP4C, the 
presence of PP4R1 alone was not sufficient to bridge sT to NEMO, however, 
when PP4R1 and PP4C were combined in the reaction, sT was able to 
interact with NEMO, as evidenced by the appearance of a protein band of 
the correct molecular mass in the anti-FLAG Western blot. These data 
highlight that a trimeric protein complex consisting of PP4R1-PP4C-NEMO is 
necessary and sufficient to mediate the sT-NEMO interaction in vitro. Why 
both PP4C and PP4R1 are required to bridge NEMO to sT is currently 
unclear. It is conceivable that the presence of PP4C-PP4R1 results in a 
conformational change in either protein allowing the formation of the protein 
complex. Alternatively, we have not yet explored the binding requirements of 
NEMO using a similar direct binding assay. It is possible that only together 
do PP4C-PP4R1 interact directly with NEMO. Such experiments should be 
performed in the future to generate a clearer understanding of this protein 
complex.  
 
5.3.4 Direct interaction between MCPyV sT and PP2A isoforms. 
Interactions with the PP2A family of phosphatases are the hallmark of 
Polyomaviridae sT protein (Khalili et al., 2008, Cheng et al., 2009, Shuda et 
al., 2011, Griffith et al., 2013, Kwun et al., 2015) .The SILAC screen showed 
a potential interaction with both PP2A Aα and PP2A Aβ, and these 
interactions were confirmed by co-immunoprecipitations (Chapter 4 and 
Griffiths et al., 2013). Whilst the interaction with PP2A Aα was discounted as 
necessary for NF-B disruption due to the lack of phenotype observed with 
the R7A mutant (Griffiths et al., 2013), the broad scale truncation mutants 
used during this study were unable to distinguish between a role for PP4C 
and PP2A Aβ in cells. However, use of dominant negative versions of PP4C 
gave a clear steer that this phosphatase was predominantly necessary for 
perturbation of NF-B in our studies (Griffiths et al., 2013). Despite this, it 
was necessary to further understand the binding requirements for both 
isoforms of PP2A with sT in vitro.  Both isoforms were able to interact directly 
with recombinant sT, although PP2A Aβ interacted to a greater extent than 
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PP2A Aα. These data mirror the SILAC proteomic results, which showed that 
PP2A Aβ was a major binding partner of sT in cells. They also implicate 
PP2A Aβ as a potential mediator of sT complex formation, given the in vitro 
binding. 
 
5.3.6 Amino acids R102 and F103 in sT mediate the direct interactions 
with phosphatase sub-units in vitro.  
Our thorough mutagenesis approach identified residues in sT essential for 
interacting with a range of host binding partners including NEMO and the 
phosphatase sub-units in cells (Chapters 3 and 4). To further validate these 
results, we engineered two key mutants to allow recombinant expression in 
bacteria as GST fusions and compared their interactions with the panel of 
host proteins to wild type GST-sT. No GST-sT protein could interact with 
NEMO directly. Despite this, the mutants retained similar binding properties 
to those identified in cells and loss of R102 and F103 abrogated binding to 
PP4C and significantly reduced the interaction with PP4R1. Interestingly, 
both of these mutants retained a level of interaction with PP2A Aβ that was 
greater than with either PP4C or PP4R1, mirroring data generated in cells. 
These in vitro data thus confirm our data generated from the cell-based co-
immunoprecipitations in showing that we have generated a panel of mutants 
capable of discriminating between phosphatase binding partners. These 
mutants will be essential to allow a detailed study of which host partners are 
necessary for modulating cellular processes including modulation of NF-B. 
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Chapter 6. Contribution of PP4C-PP4R1 to the inhibition 
of NF-B activation in MCPyV sT expressing cells 
  
6.1 Introduction 
Since signal transduction from activated receptors to NF-B largely relies on 
phosphorylation events, phosphatases are expected to play a major role in 
the modulation and termination of NF-B activity. Dephosphorylation of NF-
B can be accomplished by PP4C and PP4R1 in lymphocytes. These 
phosphatases have been shown to interact with NEMO and as a result 
dephosphorylate the IKK complex (Brechmann et al., 2012). Previous results 
demonstrated a direct interaction between MCPyV sT and PP4C-PP4R1, 
through which a complex is formed between sT and NEMO in vitro.  
Studies described in this thesis have mapped the regions of each host 
binding partner with sT and have shown the importance of PP4C-PP4R1 for 
recruiting sT to NEMO in vitro (Chapter 5). In conjunction with the use of 
dominant negative forms of PP4C, we highlight the importance of PP4C for 
NF-B signalling in sT expressing cells (Griffiths et al., 2013). Given the 
possible off-target impacts of dominant negative proteins, we now wished to 
confirm these results and also demonstrate the importance of PP4R1 for NF-
B regulation by depleting cells of both proteins using siRNA.   
Given our observations of novel sT binding partners, we wished to extend 
our studies to determine whether interactions with these host proteins were 
unique to MCPyV or conserved amongst other human polyomavirus (e.g. 
BKPyV and JCPyV) and the paradigm PyV, SV40. Understanding the 
conservation of these interactions might give insight into conserved 
pathological processes.  
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6.2 Results 
6.2.1 Validation of the efficiency of siRNA targeting PP4C. 
Gene silencing of PP4C was performed using a series of previously validated 
oligonucleotide sequences targeting PP4C (Brechmann et al, 2012). The 
level of knockdown of endogenous PP4C in MCC13 cells transfected with 2 
µM of the siRNA-PP4C (#1, #2 or #3) was assessed by Western blot. 
Scrambled siRNA (siCtrl) was used as a negative control. Cells were 
harvested 48h post-transfection and the expression level of endogenous 
PP4C was assessed by Western blotting and densitometry. The results 
indicated a detectable reduction in the level of endogenous PP4C with each 
siPP4C compared with siCtrl. The most potent was siPP4C #3 
(GGCCAGAGAGAUCUUGGUAUU), which showed a approximate 5 fold 
reduction in PP4C expression (Figure 6.1). GAPDH was used for protein 
loading control and was unaffected by the presence of the siRNA.  
 
6.2.2 Validation of siRNA PP4R1 efficacy 
In addition to PP4C, we also wished to understand the contribution of PP4R1 
to the NF-B inhibition. Accordingly, PP4R1silencing experiments were 
performed in parallel using three oligo sequences of siRNA-PP4R1 (#1, #2 
and #3). MCC13 were transfected with 2 µM of the siPP4R1 for 48h to knock 
down the PP4R1 expression in the cells. SiCtrl was used as a negative 
control. Validation of the expression level of PP4R1 was detected by SDS-
PAGE and Western blot of endogenous protein using a PP4R1 antibody. The 
result showed a reduction in PP4R1 expression level with each siPP4R1 in 
comparison with the negative control. PP4R1 #3 
(GGAUAGGUGUUCUUAAACATT) yielded the best knock down efficacy of 
approximately 2.5 fold (Figure 6.2). Protein loading was controlled by the 
detection of GAPDH.  
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Figure 6.1: Alteration of cellular protein expression by using siRNA of PP4C (A) 
Western blot of cellular protein expression in MCC13. Cells were transfected with 
control siRNA or three different siPP4C #1, #2 or #3. After 48 h, the cellular lysates 
were analysed by immunoblotting using appropriate antibodies for endogenous 
PP4C. Marker in kDa. (B) Densitometry quantification of the Western blots was 
carried out using Image J software and is shown as a percentage of relative 
densitometry normalized to the loading control GAPDH (n = 3). 
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Figure 6.2: Alteration of cellular protein expression by using siRNA of PP4R1. (A) 
Western blot of cellular protein expression in MCC13. Cells were transfected with 
control siRNA or three different siPP4R1 (#1, #2 or #3). After 48 h, the cellular 
lysates were analysed by immunoblotting using endogenous PP4C antibody. 
Marker in kDa. (B) Densitometry quantification of the western blots was carried out 
using Image J software and is shown as a percentage of relative densitometry 
normalized to the loading control GAPDH (n = 3). 
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6.2.3 Co-immunoprecipitation of MCPyV sT with cellular proteins during 
PP4C silencing. 
In order to understand the role of the PP4C-PP4R1 complex in MCPyV sT 
targeting of the NF-B complex, co-immunoprecipitation of MCPyV sT with 
NEMO was performed during knock down of PP4C. MCC13 cells were 
cotransfected with sT and 2 µM of siPP4C #3, which was shown to be the 
most effective siRNA. Cells were lysed 48 h after transfection. The 
expression of PP4C and other target proteins were validated by Western blot 
prior to co-immunoprecipitation. A reduction in PP4C expression was 
observed (Figure 6.3A). Co-immunoprecipitations of pEGFP-sT with 
endogenous PP4C, PP4R1, NEMO and exogenous EE-PP2A Aβ were 
performed using GFP-TRAP beads. Protein complexes were assessed by 
SDS-PAGE and Western blotting with appropriate antibodies. The assay 
showed that sT retained a low level interaction with PP4C during the knock 
down (Figure 6.3C). This is likely mediated by the residual PP4C present. 
PP4R1, NEMO and PP2A Aβ retained their interaction with sT.  
 
6.2.4 Co-immunoprecipitation of MCPyV sT with cellular proteins during  
silencing of PP4 R1. 
Previous co-immunoprecipitations of PP4R1-NEMO (Figure 5.5) and PP4R1-
PP4C (Figure 5.6) demonstrated possible association in protein complexes. 
To understand the necessity for PP4R1 in this complex formation with sT, 
co-immunoprecipitations of sT with the target cellular proteins were 
performed after silencing of PP4R1. MCC13 cells were cotransfected with 
pEGFP-sT and 2 µM of siPP4R1 #3 and cells were lysed 48h after 
transfection. The expression of PP4R1 and other target proteins was 
confirmed prior to co-immunoprecipitation. A reduction in PP4R1 expression 
was demonstrated (Figure 6.4A). Co-immunoprecipitation of pEGFP-sT with 
endogenous PP4R1, PP4C, NEMO and exogenous EE-PP2A Aβ was 
performed by GFP-TRAP beads. Protein complex was assessed by SDS-
PAGE and  Western blotting with appropriate antibodies. The blots showed 
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that the interaction was lost between PP4R1 and sT in depleted cells. 
Interestingly, both protein phosphatases PP4C and PP2A Aβ retained an 
interaction with sT in PP4R1 depleted cells. In contrast NEMO failed to be 
precipitated by EGFP-sT in PP4R1 depleted cells, suggesting that PP4R1 is 
essential for the sT-NEMO interaction in cells (Figure 6.4).  
 
6.2.5 Specificity of host binding partners amongst PyV sT proteins.   
Studies reported in this thesis and in publications from our group (Griffiths et 
al., 2013; Knight et al., 2015) demonstrate the importance of interactions with 
NEMO and a number of host phosphatases for MCPyV pathogenesis. To 
address whether these interactions are unique to MCPyV or conserved 
amongst the Polyomaviridae, sT sequences were amplified from a limited 
number of PyV and cloned into pEGFP-C1 for expression in mammalian 
cells.  Sequences were amplified from the two major human PyV, BKPyV 
and JCPyV and the paradigm PyV, SV40. Cloned sequences were verified 
and plasmids were co-transfected into HEK293 cells in combination with 
FLAG-PP4C, HA-PP4R1, EE-PP2A Aα and EE-PP2A Aβ. Prior to co-
immunoprecipitation studies, the expression levels of each exogenous 
protein were verified by Western blotting (Figure 6.5A). Co-
immunoprecipitations were performed using GFP-Trap beads and 
precipitates analysed by Western blotting with appropriate antibodies. The 
results demonstrate that MCPyV sT was able to interact with the panel of 
identified proteins, as previously described.  Consistent with the published 
literature, all PyV sT bound PP2A Aα, whereas only MCPyV sT could interact 
with PP2A Aβ, PP4R1 and NEMO (Figure 6.5B). Surprisingly, SV40 sT was 
also able to interact with PP4C, although BKPyV and JCPyV could not. At 
the time this was the first observed interaction between SV40 sT and PP4C, 
although others have now confirmed this (Kwun et al., 2015). Despite the 
interaction with PP4C, SV40 sT was not able to interact with NEMO or 
PP4R1 (Figure 6.5B). In conclusion, whilst SV40 sT could also interact with 
PP4C, interactions with PP4R1 and NEMO are not conserved amongst the 
human PyV sT tested.  
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Figure 6.3 Co-immunoprecipitation of sT with 
target cellular proteins during PP4C silencing. Cells were cotransfected with siPP4C 
and pEGFP-sT then lysed after 48h. Co-immunoprecipitation was performed 
between sT and the endogenous proteins listed in right side. GFP-TRAP beads was 
used to precipitate pEGFP-sT and the immune complex was resolved by SDS-
PAGE and probed with appropriate antibodies. (A) Alteration of cellular protein 
expression in knock down of PP4C. (B) Schematic representation of sT and PP4R1, 
NEMO and PP2A Aβ. Knock down of PP4C. (C) Co-immunoprecipitation of sT with 
endogenous target cellular proteins. GFP was used as acontrol and GAPDH for 
protein loading control. Representative blot are shown. Marker in kDa.  
A 
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Co-immunoprecipitation of sT with target cellular proteins during knock 
down of PP4R1. Cells were cotransfected with siPP4C and pEGFP-sT then lysed 
after 48h incubation. Co-immunoprecipitation was performed between sT and the 
endogenous proteins that listed in right side. GFP-TRAP beads was used to 
precipitate pEGFP-sT. The immune complex was resolved by SDS-PAGE and 
probed with appropriate antibodies (A) Alteration of cellular protein expression in 
knock down of PP4R1. (B) Schematic representation of sT and PP4C, NEMO and 
PP2A Aβ. Knock down of PP4R1. (C) Co-immunoprecipitation of sT with 
A 
B C 
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endogenous target cellular proteins. GFP was used as a control and GAPDH for 
protein loading control. Representative blot are shown. Marker in kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 6.5 Interaction of MCPyV sT and other polyomavirus sT with target 
proteins. (A) Expression of GFP tagged MCPyV sT, SV40 sT, BKV sT and JCV 
sT. HEK 293 cells were co-transfected with one of polyomaviruses sT and one of 
cellular protein (listed in right side). Cells were harvested 24h post transfection 
and expressions were detected by SDS PAGE and probed by appropriate 
antibody. (B) Co-immunoprecipitation of sTs with cellular proteins. Cellular lysate 
was incubated 2h with GFP-Trap beads to precipitate GFP-sT. Binding proteins 
were detected by probing with appropriate antibodies. GFP was used as a 
control and GAPDH for protein loading control. Representative blot are shown. 
Marker in kDa. 
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6.3. Discussion 
 
6.3.1 PP4R1 is essential for the interaction with NEMO in cells.  
Previous studies to test the importance of protein phosphatases in 
modulation of NF-B and Merkel cell migration had relied on the over-
expression of dominant active and negative forms of each enzyme (Griffiths 
et al., 2013; Knight et al., 2015). Whilst this approach provides useful 
information, there are possible off-target effects. It was necessary to deplete 
cells of PP4C and PP4R1 in order to understand their contribution to the sT-
NEMO complex formed in cells. A number of oligonucleotides were 
generated from the literature and tested for their abilities to knock-down 
target protein expression (Chowdhury et al., 2008, Brechmann et al, 2012). 
In both cases, the siRNA with the optimal level of knock-down was taken for 
further analysis. Co-immunoprecipitation of pEGFP-sT with endogenous host 
targets was performed in cells depleted of either PP4C or PP4R1. 
Interestingly, knockdown of PP4C did not prevent the interaction between sT 
and NEMO, or the interaction with PP2A Aβ. This either means that in cells 
PP4C is not essential for the observed interaction with NEMO or that despite 
a significant reduction in PP4C levels, there was still sufficient protein 
present to function as a molecular bridge. A greater range of knock-down 
conditions will need to be tested to ascertain which of these is correct. In 
contrast, depletion of PP4R1 prevented the interaction with NEMO in cells 
whilst maintaining the interactions with PP4C and PP2A Aβ. These results 
indicate that PP4R1 is critical for the interaction with NEMO in cells but is not 
needed for sT binding to either PP4C or PP2A Aβ. However the presence of 
PP4R1 alone is not enough to link MCPyV sT with NEMO as shown in the 
direct interaction result (Figure 5.10). It also raises a question of whether 
another protein complex plays a role in this interaction, like IKK catalytic 
subunits, especially since PP4R1 serves as a scaffold between NEMO and 
PP4C and links the complex with  IKKβ (Brechmann et al, 2012). Significant 
additional experiments would require an analysis of NF-B-driven gene 
expression in cells transfected with sT that have been depleted of either 
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PP4C, PP4R1 or both, to determine whether loss of either protein impairs the 
inhibitory abilities of sT.  
 
6.3.2 MCPyV sT binds to a unique range of host proteins associated 
with immune evasion.   
Virus pathogenesis can, in part, be traced to the its interactome with host 
proteins and the range of cellular processes that these interactions modulate. 
It was of great interest to determine whether the interactions observed for 
MCPyV sT with NEMO and the panel of phosphatase subunits was 
conserved amongst other human PyV, which have also been shown to be 
significant pathogens. Cloning issues limited this analysis to three other PyV 
sT. Efforts focussed on BKPyV and JCPyV as they are the best understood 
human PyV. We also studied SV40 since this virus is a paradigm for sT 
function. Our studies confirmed the promiscuous interactions between sT 
from all PyV studied and PP2A Aα. In contrast PP2A Aβ was only bound by 
MCPyV sT. Our finding fits with previous studies, which have shown that 
SV40 does not interact with this isoform of PP2A, whereas murine PyV sT 
can interact with PP2A Aβ and use this interaction to deregulate the AKT 
pathway (Hwang et al., 2013). In addition, only MCPyV and SV40 sT were 
found to bind to PP4C. This finding was recently confirmed by Kwun and 
colleagues (2015). Despite being able to interact with PP4C, SV40 sT did not 
bind to either PP4R1 or NEMO in cells. Indeed, these two proteins only 
interacted with MCPyV sT. This observation provides further evidence that 
the interaction with PP4R1 is more important for bridging sT to NEMO given 
that SV40 sT binds to PP4C but does not interact with NEMO. These data 
would suggest that MCPyV might be unique in its ability to inhibit the IKK 
complex, since phosphorylation activity of IKKα and IKKβ was decreased 
during sT expression and this will induce IB phosphorylation leading to a 
block in translocation of NF-B into the nucleus (Griffith et al., 2013). A 
similar mechanism has been detected in other viruses like CMV and MCV 
through targething NEMO to disrupt IKK activation. The interaction of SV40 
with PP4C also raises the question of the role of PP4C in the SV40 life cycle. 
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Unlike MCPyV, there is a robust life cycle model for SV40 and an exciting 
project might entail an analysis of the effect of depleting PP4C from cells or 
expressing a dominant active mutant of the enzyme. Finally, here we just 
studied the interaction of sT of some other polyomavirses with targeted 
proteins and we think its worth to study the contribution of other 
polyomaviruses with NF-B in detailes which has not been previously 
addressed. 
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Chapter 7. Summary and conclusion 
 
The work described in this thesis contributed to a multi-group research 
programme aimed at increasing our understanding of the role of the small 
tumour (sT) antigen in MCPyV pathogenesis. It focussed on uncovering the 
molecular mechanisms by which sT inhibited NF-κB mediated signal 
transduction. This study showed that specific amino acids in MCPyV sT are 
required for interaction with NEMO and mediated NF-B inhibition. This 
inhibition effect was shown to be controlled by targeting of sT to phosphatase 
enzymes like PP4C, PP2A A and PP4R1.  
Modulation of NF-B signalling was initially identified using a transcriptomic 
array protocol that measured levels of gene expression in an inducible 
FLAG-sT cell line.  In cells inducibly expressing FLAG-sT, a significant 
reduction in NF-B-driven gene expression was observed (Griffiths et al., 
2013). These results were subsequently confirmed using a luciferase 
reporter assay system with GFP-sT (Chapter 3). A proteomic approach was 
adopted to identify possible host candidate binding partners that might be 
necessary for mediating the inhibition of NF-B. Whilst this approach 
identified a number of host partners, the results were inconclusive in that 
they did not identify proteins within the NF-B pathway. An alternative 
screening approach was adopted, based on over-expression of GST-fusions 
of proteins from the canonical NF-B pathway. This method tentatively 
revealed an interaction with the NEMO adaptor component of the central IKK 
complex, which is essential for NF-B activation in response to a number of 
stimuli, including virus infection. The goal of the work in this thesis was to 
understand the contribution of the interaction with NEMO for inhibition of NF-
B. Binding of MCPyV sT to NEMO was confirmed by co-
immunoprecipitation in MCC13 cells. MCC13 cells are a MCPyV negative 
MCC cell line and as such are a physiologically relevant cell line of choice. 
This is particularly important given that primary Merkel cells are extremely 
difficult to source and appropriate life cycle models for the study of MCPyV 
are not yet available. However, during preparation of the final version of  this 
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thesis, a human dermal fibroblast cell line that support the cultivation of 
MCPyV was described (Liu et al., 2016). This should develop our 
understanding of virus interference with the NF-B pathway and confirme 
whether interaction of MCPyV sT with NEMO is required for NF-B inhibition. 
After the co-immunoprecipitation was confirmed the interaction between 
MCPyV sT and NEMO, a substantial mapping exercise was performed, using 
a large number of truncation and point mutants of both proteins. In particular 
it was necessary to identify point mutations in sT that would ablate the 
binding to NEMO. Such point mutants have previously been developed to 
prevent interaction with other cellular partners of sT (Shuda et al., 2011). 
These have proven effective at understanding the contribution of specific 
host proteins to known sT functions. My mutagenesis studies revealed that 
three point mutants within sT ablate (A101, R102 and F103) were necessary 
for the interaction with NEMO.  
Reciprocal experiments were performed to identify the domains of NEMO 
that are necessary for the interaction with sT. NEMO contains a number of 
well-studied domains, each responsible for interacting with host binding 
partners necessary for mediating the activation, and regulation, of NF-B 
signalling (Rushe et al., 2008, Cordier et al., 2008, Fusco et al., 2008, 
Grubisha et al., 2010, Emmerich et al., 2013, Zilberman-Rudenko et al., 
2016). Truncations were designed to specifically target these key domains 
within NEMO. Interestingly, truncations studied showed that the UBAN 
domain was necessary and sufficient for mediating the interaction with sT in 
cells.  Recently, this domain has been shown to be essential for interacting 
with ubiquitin moieties, allowing the recruitment of the IKK complex to 
upstream kinase complexes. The essential nature of the UBAN domain was 
recognised when specific mutations in this region were linked to a number of 
immunodeficiency disorders (Vinolo et al. 2006, Hubeau et al., 2011, 
Zilberman-Rudenko et al., 2016). To address whether the ubiquitin binding 
properties of UBAN might be necessary for the sT-NEMO interaction, a 
number of disease-associated point mutants were engineered into NEMO. 
Abrogation of ubiquitin binding resulted in a loss of sT binding in cells.  
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Whether this is suggestive of sT interacting with ubiquitin, or ubiquitinated 
proteins is not currently clear.  It is possible that loss of ubiquitin binding 
alters the sub-cellular localisation of NEMO and prevents sT binding. To 
address this, future studies would need to address whether sT (or sT-
associated proteins) can interact with the forms of ubiquitin bound by the 
UBAN (linear and K-63 linked). We found that the MCPyV sT abrogated its 
interaction with the mutant D311N of NEMO. This mutation has been 
detected in people who have severe EDA-ID as a result of NF-B inhibition. 
Future studies will be required to determine the specificity of the amino acid 
D311 in its interaction with sT, along with more analysis of the NEMO 
domain which is involved in interation of NEMO with sT. 
Interaction studies with recombinant GST-sT and IVT produced host partners 
revealed the surprising observation that NEMO does not interact directly with 
sT, and that the interactions observed by co-immunoprecipitation assays 
must be as a result of a larger protein complex (Chapter 5). In spite of the 
fact that sT failed to bind NEMO in IVT and the SILAC assay also confirmed 
this result, we highly recommend the isolation of both NEMO and MCPyV sT 
in bacteria to exclude the interference of proteins that are present in the IVT 
system. 
To address wether sT required other proteins for interaction with NEMO, we 
focussed attention on other proteins identified from our proteomic screen.  In 
keeping with other PyV sT, we identified a number of potential host 
phosphatases as putative binding partners. One of these, PP2A A, had 
previously been shown to interact with sT (Shuda et al., 2011), whilst the 
others were novel (PP2A A and PP4C). Given the importance of 
phosphatases for sT function in other PyV, we set out to characterise the 
requirements for their interaction with sT. A single point mutant (R7A) had 
previously been shown to abrogate the interaction between sT and PP2A A 
(Shuda et al., 2011). This mutant thus became a control in our assays. 
Importantly, introduction of this amino acid change did not prevent sT binding 
to the other phosphatases tested.  Rather, we once again demonstrated the 
importance of residues 102-103 for mediating binding to PP4C. These 
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studies allowed the development of point mutants that discriminated between 
the different phosphatase binding partners. This is an important 
development, given that previous studies from our group (Griffiths et al., 
2013; Knight et al., 2015) had shown that these enzymes are important for 
sT function but had not been able to provide the identity of the specific host 
binding partners. Instead, our studies had resorted to the use of dominant 
active/negative forms of each phosphatase, which could potentially have off 
target effects. The development of these mutants will now allow an 
interrogation of the specific requirements of each phosphatase in sT function. 
Future studies could examine the interaction of sT with cellular proteins in 
human dermal fibroblasts using both MCPyV pseudovirus carrying a GFP 
reporter and MCPyV virions produced through cotransfection of sT 
expression plasmids (Liu et al., 2016). Then we can use 
coimmunoprecipitation assays to probe for sT with a mouse monoclonal 
antibody that is specific for MCPyV sT (CM5E1 isotype), and detect any 
proteins partners using specific antibodies. 
Given that PP4C has been functionally linked to the NF-B pathway 
(Tikhonova and Aifantis 2012, Brechmann et al, 2012) in its ability to 
dephosphorylate IKK complex and as a result stop IB phosphorylation and 
turn off the pathway. We hypothesised that PP4C may bridge sT with NEMO. 
In contrast, despite demonstrating that PP4C is a direct binding partner of sT 
in vitro, in our hands the presence of PP4C was not enough to rescue the 
interaction between sT and NEMO. These data were highly suggestive of the 
need for an additional binding partner in this protein complex that would link 
sT with NEMO. Here we suggest confirming this result by using protein-
protein interaction techniques  other than IVT, like the yeast two hybrid 
screening (Y2H) or visualizing the MCPyV sT structure at the atomic level by 
X-ray crystallography which we think is essential for and will enhance our 
understanding of how sT interacts with cellular proteins. 
An obvious target was the PP4 subunit, PP4R1, which had previously been 
shown to be required for negative regulation of NF-B activation in T cells, 
through an interaction with the IKK complex. This study provided the first 
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evidence for PP4R1 as a novel sT binding partner (Chapter 5), and 
confirmed that in MCC13 cells PP4R1 was able to bind to both NEMO and 
PP4C. Moreover, mutagenesis mapping showed that the interaction was 
dependent on residues 102-103 in sT, which are the same as those needed 
to bind to NEMO. However, despite being a direct binding of sT, PP4R1 
alone was not enough to rescue the interaction with NEMO in vitro. Instead, 
a trimeric complex is necessary, consisting of PP4C, PP4R1 and sT, to 
bridge sT to NEMO. The stoichiometry of this interaction is not clear, nor is 
the mechanism by which all proteins interact with such a small region of sT. 
It is plausible that there are distinct populations of sT, each binding either 
PP4C or PP4R1, and that a multi-protein complex forms to link with NEMO. 
Certainly, high molecular weight complexes consisting of multimers of the 
same proteins are common in inflammatory signalling pathways, and NF-B 
activation. The nature of this complex also would need to be studied further. 
In the shorter term, a crucial experiment that would reinforce the importance 
of PP4C/PP4R1 in bridging NEMO to sT would involve performing co-
immunoprecipitations with the NEMO mutations that abrogate sT binding 
with PP4C and PP4R1 to test if these prevent their recruitment. In the 
studies presented we did not test whether PP2A A was necessary for 
mediating the interaction with NEMO, despite also identifying it as a direct 
binding partner of sT. This was a conscious decision based on the results of 
the direct binding assay with sT point mutants. In these assays, mutants that 
abrogate binding to NEMO in cells retained binding to PP2A A, albeit at 
reduced levels, in vitro. Given that a role for PP2A A in MCPyV 
pathogenesis is not clear, future studies will need to focus on the contribution 
this phosphatase plays to the virus. This is particularly important given the 
link between this phosphatase and cancer.  
Much of this thesis involved the characterisation of proteins interactions in 
cells or in vitro. Whilst this is informative, it is critical that it is linked with a 
functional analysis of these interactions. Towards this end, the final chapter 
sought to determine whether the interactions observed in vitro had impact on 
the inhibition of NF-B by MCPyV sT. A dual approach was undertaken 
consisting of sT mutants in reporter assays and siRNA depletion of 
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PP4C/PP4R1 to observe the impact on protein complex formation. 
Interestingly, knockdown of PP4C did not prevent the interaction between sT 
and NEMO, or the interaction with PP2A Aβ. This either means that in cells 
PP4C is not essential for the observed interaction with NEMO or that despite 
a significant reduction in PP4C levels, there was still sufficient protein 
present to function as a molecular bridge. A greater range of knock-down 
conditions either by using different siRNAs or by utilising CRISPR/Cas 
system will be needed to be tested to ascertain which of these is correct. In 
contrast, depletion of PP4R1 prevented the interaction with NEMO in cells 
whilst maintaining the interactions with PP4C and PP2A Aβ. These results 
indicate that PP4R1 is critical for the interaction with NEMO in cells but is not 
needed for sT binding to either PP4C or PP2A Aβ. Significant additional 
experiments would require an analysis of NF-B-driven gene expression in 
cells transfected with sT that have been depleted of either PP4C or PP4R1, 
to determine whether loss of either protein impairs the inhibitory abilities of 
sT. 
The luciferase data affirmed the importance of the sT-binding partners in 
down-regulating NF-B. Point mutations in sT that abrogated the interaction 
with PP4R1 and NEMO were less able to impair NF-B-driven transcription 
compared to wild-type and mutants that had no impact on binding. Whilst 
none of the mutants rescued luciferase levels to those of the GFP control, 
the differences were statistically significant. A more relevant experiment that 
would shed light on the true impact of these mutations would be to analyse 
levels of endogenous NF-B-driven gene expression in response to 
inflammatory stimuli, for example IL-8 or CCL20. These would be less prone 
to potential reporter associated artefacts.   
It is clear that MCPyV sT has a number of unique functions amongst the PyV 
encoded sT (Johnson, 2010, Shuda et al., 2011, Griffith et al., 2013, 
Spurgeon et al., 2015, Kwun et al., 2015). Given the number of novel binding 
partners identified during this work, we were interested to discover whether 
any were shared amongst the PyV or were unique to MCPyV. Towards this, 
we cloned sT from a limited number of human PyV (BPyVK and JCPyV) and 
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the paradigm PyV, SV40. Our results reinforce the notion that MCPyV sT 
performed unique functions, and utilises a novel set of host binding partners 
to accomplish this. JCPyV and BKPyV sT bound to PP2A A but failed to 
interact with any of the other host proteins identified in this study. 
Interestingly, SV40 sT also interacted with PP4C, and this was confirmed by 
a study published during this work (Kwun et al, 2015). Despite this 
interaction, SV40 sT failed to bind NEMO or PP4R1. Given that SV40 sT 
does not share sequence similarity with the region of MCPyV sT required to 
bind to PP4C, it is possible that a distinctive region of SV40 sT is necessary 
for mediating the interaction. Future work could focus on mapping the 
regions necessary for binding and using siRNA depletion of PP4C, or 
expressing a dominant active mutant of the enzyme, to test its requirement 
during the SV40 life cycle. It would also be worth expanding the range of sT 
tested to include other known human PyV (e.g. KIPyV and WUPyV) to see if 
binding is conserved. Given the recent expansion of phylogenetic knowledge 
of MCPyV-related PyV, these studies could even be expanded to some non-
human PyV to see if binding to these host proteins is associated with a sub-
group of PyV.  
In conclusion, work presented in this thesis demonstrates that MCPyV sT 
mediates NF-B inhibition by targeting NEMO with the involvement of PP4C 
and PP4R, which likely form a multi-protein complex with NEMO in cells. 
These studies shed light on the immune evasion mechanism utilised by 
MCPyV, and provide novel insights into the role of PP4C-PP4R1 in the 
control of NF-B during MCPyV expression.  
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